Genmab — Annual Report 2025

Feb 17, 2026

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT

OF 1934

OR

S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF

1934

For the fiscal year ended December 31 , 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF

1934

Date of event requiring this shell company report ____

For the transition period from _ to ___

Commission File number: 001-38976

Genmab A/S

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

The Kingdom of Denmark

(Jurisdiction of incorporation or organization)

Carl Jacobsens Vej 30

2500 Valby

Denmark

(Address of principal executive offices)

Anthony Pagano

Executive Vice President and Chief Financial Officer

Genmab A/S

Carl Jacobsens Vej 30

2500 Valby

Denmark

Tel: +45 7020 2728

Fax: +45 7020 2729

(Name, telephone, e-mail and/or facsimile number and address of Company contact person)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class	Trading symbol	Name of each exchange on which registered
American Depositary Shares, each representing one-tenth of one ordinary share	GMAB	The Nasdaq Stock Market LLC
Ordinary shares, nominal value DKK 1 per share	GMAB	The Nasdaq Stock Market LLC*

• Not for trading, but only in connection with the registration of the American Depositary Shares on The Nasdaq Stock Market LLC.

Securities registered or to be registered pursuant to Section 12(g) of the Act. None

Table of Contents

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered

by the annual report.

64,238,408 Ordinary Shares (including shares underlying American Depositary Shares)

64,377,450 American Depositary Shares

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act . Yes S No ☐

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13

or 15(d) of the Securities Exchange Act of 1934. Yes ☐ No S

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities

Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),

and (2) has been subject to such filing requirements for the past 90 days.

Yes S No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant

to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such

files). Yes S No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging

growth company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer S Accelerated filer ☐ Non-accelerated filer ☐ Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the

registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards †

provided pursuant to Section 13(a) of the Exchange Act. ☐

† The term new or revised financial accounting standard refers to any update issued by the Financial Accounting Standards Board to its Accounting

Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of

its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public

accounting firm that prepared or issued its audit report. S

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant

included in the filing reflect the correction of an error to previously issued financial statements ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based

compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

☐ US GAAP S International Financial Reporting Standards as issued by the International Accounting Standards Board ☐ Other

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant

has elected to follow ☐ Item 17 ☐ Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the

Exchange Act). Yes ☐ No S

3

Table of Contents

TABLE OF CONTENTS

INTRODUCTION		4
PART I		7
ITEM 1	IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS	7
ITEM 2	OFFER STATISTICS AND EXPECTED TIMETABLE	7
ITEM 3	KEY INFORMATION	7
ITEM 4	INFORMATION ON THE COMPANY	40
ITEM 4A	UNRESOLVED STAFF COMMENTS	75
ITEM 5	OPERATING AND FINANCIAL REVIEW AND PROSPECTS	75
ITEM 6	DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES	81
ITEM 7	MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS	93
ITEM 8	FINANCIAL INFORMATION	95
ITEM 9	THE OFFER AND LISTING	96
ITEM 10	ADDITIONAL INFORMATION	96
ITEM 11	QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISKS	108
ITEM 12	DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES	108
PART II		110
ITEM 13	DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES	110
ITEM 14	MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS	110
ITEM 15	CONTROLS AND PROCEDURES	110
ITEM 16A	AUDIT COMMITTEE FINANCIAL EXPERTS	111
ITEM 16B	CODE OF ETHICS	111
ITEM 16C	PRINCIPAL ACCOUNTANT FEES AND SERVICES	112
ITEM 16D	EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES	112
ITEM 16E	PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS	112
ITEM 16F	CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT	113
ITEM 16G	CORPORATE GOVERNANCE	113
ITEM 16H	MINE SAFETY DISCLOSURE	114
ITEM 16I	DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	114
ITEM 16J	INSIDER TRADING POLICIES	114
ITEM 16K	CYBERSECURITY	114
PART III		116
ITEM 17	FINANCIAL STATEMENTS	116
ITEM 18	FINANCIAL STATEMENTS	116
ITEM 19	EXHIBITS	116
SIGNATURES		119
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM		121

4

Table of Contents

INTRODUCTION

In this Annual Report on Form 20-F the terms the “Company”, “Genmab”, “we”, “us”, “our” and the “Group” refer to

the parent company Genmab A/S together with its consolidated subsidiaries. The term “Genmab A/S” is used when

addressing issues specifically related to this legal entity.

Pursuant to Rule 12b-23 of the Securities Exchange Act of 1934, as amended (the “Exchange Act” ), we incorporate

information for certain items of this Annual Report on Form 20-F by reference to certain pages of the Genmab A/S

statutory Annual Report 2025 (the “Annual Report 2025 ” ), filed together with this Form 20-F , as Exhibit 15.3. Therefore,

the information in this Annual Report on Form 20-F should be read in conjunction with the incorporated portions of the

Annual Report 2025. Items not contained or not specifically referenced within the Annual Report 2025 should not be

deemed to be part of this Annual Report on Form 20-F.

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 20-F contains forward-looking statements concerning our business, operations and

financial performance and condition, as well as our plans, objectives and expectations for our business operations and

financial performance and condition. Any statements contained herein that are not statements of historical facts may be

deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such

as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,”

“intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and

other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or

other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

• our expectations regarding sales and net sales, clinical development, regulatory approvals and commercialization

of our partnered and proprietary approved products;

• our expectations with regard to our ability to create and develop additional product candidates and to submit

investigational new drug (“ IND ”) applications and/or clinical trial applications (“ CTAs ”) for our preclinical

product candidates;

• our receipt of future milestone payments and royalties from our collaboration partners, and the expected amount

and timing of such payments;

• our estimates and expectations regarding the potential market size and the size of the patient populations for our

products and product candidates;

• our expectations regarding the potential advantages of our products and product candidates over existing therapies

or therapies currently in development;

• our expectations regarding the potential advantages of our proprietary technologies over existing antibody

technologies and the prospects for our ongoing and future technology collaborations;

• our plans to expand our translational research platform and the potential benefits of such platform;

• our expectations with regard to the willingness and ability of our current and future collaboration partners to

pursue the development, approval and commercialization of our products and product candidates;

• our and our collaboration partners’ product discovery, development and commercialization plans with respect to

our products and product candidates and our proprietary technologies;

• our potential to enter into new collaborations;

• our and our collaboration partners’ ability to develop, acquire and advance product candidates into, and

successfully complete, clinical trials;

5

Table of Contents

• the initiation, timing, progress and results of our preclinical trials and clinical trials, and our research and

development programs;

• the timing or likelihood of regulatory filings and approvals for our products and product candidates;

• our ability to identify, and to negotiate contracts with, suitable contract manufacturing organizations (“ CMOs ”)

and the ability of such CMOs to manufacture sufficient quantities of our products and product candidates for

clinical trials or commercialization in compliance with current Good Manufacturing Practices (“ cGMPs ”) (as

defined herein);

• our and our collaboration partners’ ability to identify, and to negotiate contracts with, suitable contract research

organizations (“ CROs ”) and the ability of such CROs to conduct clinical trials on our product candidates in

compliance with Good Clinical Practices (“ GCPs ”) (as defined herein);

• the commercialization and market acceptance of our products and product candidates;

• our plans to continue to develop our commercialization capabilities;

• the pricing of and reimbursement for our approved products in existing and additional key markets;

• the implementation of our business model and strategic plans for our business, products, product candidates and

technologies;

• our ability to operate our business without violating applicable laws and regulations;

• our and our collaboration partners’ ability to operate our businesses without infringing the intellectual property

rights and proprietary technology of third parties;

• the scope of protection we and our collaboration partners are able to establish and maintain for intellectual

property rights covering our products, product candidates and technologies;

• our analysis of potential patent infringement claims and our or our collaboration partners’ rights with respect to

such claims;

• estimates of our future expenses and revenue;

• our expectations regarding regulatory and geopolitical developments in the United States (“ US ”), the European

Union (“ EU ”), Japan and other jurisdictions;

• our ability to effectively manage our anticipated growth;

• our ability to attract and retain suitably qualified employees and key personnel, particularly for our

commercialization efforts;

• the anticipated benefits of the acquisition of Merus which may not be fully realized or may take longer to realize

than expected;

• our future financial performance; and

• developments and projections relating to our competitors and our industry, including competing therapies and

technologies.

The forward-looking statements contained herein involve a number of known and unknown risks and uncertainties that

could cause our future results, performance, or achievements to differ significantly from the results, performance or

achievements expressed or implied by such forward-looking statements.

6

Table of Contents

You should understand that many important factors, in addition to those discussed or incorporated by reference in this

report, could cause our results to differ materially from those expressed in the forward-looking statements. Potential factors

that could affect our results include, in addition to others not described in this report, those described under “Item 3.D—

Risk Factors.” These are factors that we think could cause our actual results to differ materially from expected results.

Forward looking statements speak only as of the date on which they are made, and we undertake no obligation to

update any forward-looking statements or other information contained in this report, whether as a result of new

information, future events or otherwise. You are advised, however, to consult any additional disclosures we make in our

reports on Form 6-K furnished or filed with the Securities and Exchange Commission (the " SEC "). Please also see the

cautionary discussion of risks and uncertainties under “Item 3.D—Risk Factors.” This discussion is provided as permitted

by the Private Securities Litigation Reform Act of 1995.

PRESENTATION OF FINANCIAL AND OTHER INFORMATION

We maintain our books and records in US Dollars and report under IFRS Accounting Standards as issued by the

International Accounting Standards Board (“ IASB ”) and as endorsed by the EU (“ IFRS Accounting Standards ”). Our

application of IFRS Accounting Standards results in no difference between IFRS as issued by the IASB and IFRS as

endorsed by the EU. None of the audited consolidated financial statements (the “ Audited Financial Statements ”) included

in our Annual Report 2025 and incorporated by reference into this Annual Report on Form 20-F were prepared in

accordance with accounting principles generally accepted in the US. We use the symbol “$” to refer to the US dollar,

“DKK” to refer to the Danish kroner and the symbol “€” to refer to the Euro herein. While our financial results disclosed

herein are presented in USD, certain amounts paid or payable to or by us under certain of our collaborations are presented

in the currencies in which payments under such collaborations are denominated.

All references to “shares” in this Annual Report on Form 20-F refer to ordinary shares of Genmab A/S with a nominal

value of DKK 1 per share.

This Annual Report on Form 20-F includes trademarks, trade names and service marks, certain of which belong to us

and others that are the property of other organizations. Solely for convenience, trademarks, trade names and service marks

referred to in this Annual Report on Form 20-F appear without the ®, ™ and SM symbols, but the absence of those

symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert

its rights to these trademarks, trade names and service marks to the fullest extent under applicable law. We do not intend

our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not

be construed to imply, a relationship with us, or endorsement or sponsorship of us, by these other parties.

This Annual Report on Form 20-F contains estimates, projections and other information concerning our industry, our

business and the markets for our products and product candidates. Information that is based on estimates, forecasts,

projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or

circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise

expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as

well as from reports, research surveys, trials and similar data prepared by market research firms and other third parties,

industry, medical and general publications, government data and similar sources. Management estimates are derived from

publicly available information, our knowledge of our industry and assumptions based on such information and knowledge,

which we believe to be reasonable.

In addition, assumptions and estimates of our and our industry’s future performance are necessarily subject to a high

degree of uncertainty and risk due to a variety of factors, including those described in “Item 3.D —Risk Factors.” These

and other factors could cause our future performance to differ materially from our assumptions and estimates. See

“Forward-Looking Statements” above.

ENFORCEABILITY OF CIVIL LIABILITIES

We are organized under the laws of Denmark, with a domicile in the district of Valby within the municipality of

Copenhagen, Denmark .

Several members of our Board of Directors and Executive Management are residents of Denmark or other jurisdictions

outside the US. A substantial portion of our and such persons’ assets are located in Denmark or other jurisdictions outside

7

Table of Contents

the US. As a result, it may not be possible for investors to effect service of process upon such persons or us with respect to

litigation that may arise under US law or to enforce against them or our company judgments obtained in US courts,

whether or not such judgments were made pursuant to civil liability provisions of the federal or state securities laws of the

US or any other laws of the US

The US and Denmark do not have a treaty providing for reciprocal recognition and enforceability of judgments

rendered in connection with civil and commercial disputes and, accordingly, a final judgment (other than an arbitration

award) rendered by a US court based on civil liability would not be enforceable in Denmark. However, if the party in

whose favor such final judgment is rendered brings the lawsuit in a competent court in Denmark, that party may submit to

the Danish court the final judgment that has been rendered in the US. A judgment by a federal or state court in the US

against the Company will neither be recognized nor enforced by a Danish court, but such judgment may serve as evidence

in a similar action in a Danish court.

PART I

ITEM 1 IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS

Not applicable.

ITEM 2 OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3 KEY INFORMATION

B. Capitalization and Indebtedness

Not applicable.

C. Reasons for the Offer and Use of Proceeds

Not applicable.

D. Risk Factors

Summary

Our business is subject to numerous risks and uncertainties. You should carefully consider these risks and uncertainties

when investing in our ordinary shares or American depositary shares (“ ADSs ”). The principal risks and uncertainties

affecting our business include the following:

• The substantial majority of our revenue comes from royalties on sales of DARZALEX, and our patents underlying

these royalties will start to expire in the late 2020s.

• Our launch of a new product or of an existing product in a new indication or territory is subject to a number of

risks and uncertainties and may not be successful.

• Our business and operations have experienced rapid growth that needs to be carefully managed.

• We may acquire businesses or products, form collaborations or enter into other strategic transactions in the future,

but we may not realize their benefits, and we may need to raise additional capital to fund these transactions.

• Sales of our products will depend on the degree of market acceptance by physicians, patients, healthcare payers

and others in the medical community.

• We rely on our collaboration partners in many aspects of our business.

8

Table of Contents

• We rely on third parties to conduct clinical trials.

• We rely on a limited number of third-party manufacturers for our product supply.

• Biopharmaceutical product development involves a substantial degree of uncertainty.

• Our product candidates will need to undergo clinical trials that are time-consuming and expensive, the outcomes

of which are unpredictable, and for which there is a high risk of failure.

• Any approval granted for our products or product candidates in the US does not assure approval of such products

in Japan and the EU or other foreign jurisdictions.

• We may be affected by reports of adverse events or safety concerns relating to our products or product candidates.

• We may face product liability claims related to the use or misuse of our products or technologies.

• Our business applications and information technology (“ IT ”) infrastructure, or those of our collaboration partners,

contractors or consultants, may fail or suffer cyber security breaches, and the use of novel technologies may

subject us to additional risks.

• Our ability to compete may decline if we or our collaboration partners are unable to or do not adequately protect

intellectual property rights or if our intellectual property rights are inadequate.

• Government restrictions on pricing and reimbursement, as well as other healthcare payer cost-containment

initiatives, may negatively impact our ability to generate revenue.

• Even if approved, our products will be subject to extensive post-approval regulation, which may result in

significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and

other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory

requirements or experience unanticipated problems with our products.

• Future laws and regulations and changes to existing ones may have an adverse impact on our business.

• We and our business arrangements with third parties are subject to fraud, abuse and other healthcare laws and

regulations.

• We may not realize the anticipated benefits from the acquisition of Merus.

• Our substantial indebtedness could adversely affect our financial condition .

Risks Related to Our Business and Financial Condition

The substantial majority of our revenue comes from royalties on sales of DARZALEX, and our patents underlying these

royalties will start to expire in the late 2020s.

In 2025 , royalties from Johnson & Johnson (“ J&J ”), legal entity Janssen Biotech, Inc., related to daratumumab

(marketed as DARZALEX for IV administration and as DARZALEX FASPRO in the US and as DARZALEX SC in

Europe for subcutaneous (“ SC ”) administration) for certain indications of multiple myeloma (“ MM ”) and light-chain

(“ AL ”) amyloidosis , accounted for 66% of our revenue. We anticipate that DARZALEX will continue to account for a

substantial portion of our revenue in the near term. J&J is currently fully responsible for developing and commercializing

daratumumab, and all costs associated therewith, and consequently, our revenue and resulting operating profit and near-

term prospects are substantially dependent on J&J’s efforts and the success of this collaboration.

The royalties payable to us by J&J are limited in time and subject to reduction on a country-by-country basis for

customary reduction events, including for lack of patent coverage or upon patent expiration or invalidation in the relevant

country and upon the first commercial sale of a biosimilar product in the relevant country (for as long as the biosimilar

product remains for sale in that country). Pursuant to the terms of the agreement, J&J’s obligation to pay royalties to us will

expire on a country-by-country basis on the later of the date that is 13 years after the first sale of daratumumab in such

country or upon the expiration or invalidation of the last-to-expire relevant Genmab patent covering daratumumab in such

country. The first US, European and Japanese sales of daratumumab occurred in 2015, 2016 and 2017, respectively.

9

Table of Contents

We have issued patents and pending patent applications covering daratumumab in numerous jurisdictions, including

patents issued in the US, Europe and Japan. J&J owns a separate patent portfolio related to the SC formulation of

daratumumab used in DARZALEX FASPRO/ DARZALEX SC, but a binding arbitration determined that we are not

entitled to royalties based on these separate patents.

Our issued US, European and Japanese patents covering daratumumab, after giving effect to issued US, European and

Japanese patent term extensions (“ PTEs ”) and supplementary protection certificates (“ SPCs ”), expire in 2029, 2031 and

begin to expire in 2030, respectively. Assuming constant underlying sales of DARZALEX, we expect that our royalties

from sales of DARZALEX will begin to decline materially in 2029 following expiration of our US patent rights on

daratumumab. There can be no assurance that we will be able to replace all or any portion of lost DARZALEX royalty

revenues through development and commercialization of other products or through acquisitions in a timely manner or at

all.

In addition, there can be no assurance that DARZALEX sales will remain at or near current levels or will continue to

grow while we remain entitled to royalties. In particular, DARZALEX is subject to intense competition in the MM therapy

market. In addition to numerous other US Food and Drug Administration (“ FDA ”) approved treatments for the same

indications, we are also aware of several additional investigational agents and technologies that are currently being studied

for the treatment of MM, any of which may compete with DARZALEX in the future. If DARZALEX is unable to

successfully compete with these or other agents and technologies, DARZALEX sales could decline materially.

Future prospects for daratumumab are subject to the risks outlined below with respect to our other product candidates,

including risks related to clinical trials, adverse events, regulatory requirements and approvals, intellectual property

matters, competition, manufacturing, pricing, reimbursement and marketing. In addition, future prospects for daratumumab

are also subject to the risk that we will be unable to successfully manage our relationship with J&J and other risks

described herein that are applicable to all our collaborations.

Our launch of a new product or of an existing product in a new indication or territory is subject to a number of risks

and uncertainties and may not be successful.

We are continuing to expand our commercialization capabilities, including sales, distribution and marketing, to allow

us to market our own products for the indications and in the geographies we determine would be most effective to create

value for patients and our shareholders. The continued commercialization of our existing products could be impaired, and

the launch and commercialization of any future products could be delayed or impaired, due to a variety of factors,

including supply constraints, delays or challenges in arranging a commercial infrastructure, delays in obtaining or failure to

obtain pricing and reimbursement approvals, or other factors, including those described elsewhere herein.

We continue to grow our market-based commercialization operations in existing and additional new markets. Building

comprehensive commercialization capabilities requires substantial investment of time and money and significant

management focus and resources. We are competing with pharmaceutical and biotechnology companies with established

commercialization and marketing capabilities. Without appropriate leveraging of our internal existing team or the support

of third parties, we may be unable to compete successfully against these more established companies as we expand into

new territories. In addition, we may be unable to develop productive relationships with local medical experts, patients and

other key stakeholders or may face barriers due to cultural or regulatory differences. We also compete for staffing with

transnational and local pharmaceutical and biotechnology firms and local medical, healthcare and research organizations.

Accordingly, there can be no assurance that our efforts to build and expand comprehensive commercialization capabilities

will be successful in an acceptable timeframe, without disproportionately substantial expenses or at all.

Even if more of our proprietary product candidates obtain regulatory approval, we may determine that

commercializing such product candidates ourselves would not be the most effective way to create value for our

shareholders. In addition, if we choose to commercialize any of our product candidates, our marketing efforts may be

unsuccessful as a result of unfavorable pricing or reimbursement limitations, delays, competition or other factors. We are

also subject to extensive and costly government regulation and are required to obtain and maintain governmental approvals

in order to successfully commercialize our products. Failure to successfully market one or more of our approved products,

or delays in our commercialization efforts, may diminish the commercial prospects for such products and may result in

financial losses or damage to our reputation, each of which may have a negative impact on our financial condition, results

of operations and future growth prospects.

10

Table of Contents

Our business and operations have experienced rapid growth that needs to be carefully managed.

We have experienced rapid growth over the last several years, and we anticipate further growth as our pipeline

advances and we further commercialize our products. Since 2019 Genmab has grown from 548 employees to 3,029 at the

end of 2025 . In 2019, there were 12 active industry sponsored clinical trials for Genmab proprietary products, which are

those owned at least 50% by Genmab. By the end of 2025 , this number had more than doubled to 30, including nine Phase

III trials, not including trials initiated by Merus . With the acquisition of Merus we added petosemtamab to our pipeline,

including two additional Phase III trials and two Phase II trials. Such growth has put significant demands on our

management and infrastructure, including new operational and financial systems, expanding commercial capabilities, as

well as extended manufacturing and commercial outsourcing arrangements. Our success will depend in part upon our

ability to manage this growth effectively, including by maintaining our collaborative culture. As we continue to grow, we

must continuously improve our operational, financial and management controls and our reporting systems and procedures.

We must ensure that our policies and procedures evolve to reflect our dynamic operating model and implementation of

financial systems. We must also continue to effectively retain existing employees and to attract, hire, train and retain new

employees. Any failure to expand these areas and implement appropriate procedures and controls in an efficient manner

and at a pace consistent with our business objectives could have a material adverse effect on our business, financial

condition, results of operations and cash flows.

We may acquire businesses or products, form collaborations or enter into other strategic transactions in the future, but

we may not realize their benefits, and we may need to raise additional capital to fund these transactions.

Should attractive opportunities arise, we may acquire companies or technologies, form collaborations or enter into

other strategic transactions that facilitate our access to new products, research projects or geographical areas, or that enable

us to achieve synergies with our existing operations. However, we may not be able to identify appropriate targets, make

acquisitions or form collaborations under satisfactory financial and other conditions. If we acquire or enter into

collaborations or other strategic transactions with businesses, we may not be able to realize the benefits of such acquisitions

or collaborations, including if we are unable to successfully integrate them with our existing operations and company

culture, or if we encounter difficulties in developing, receiving regulatory approval for, manufacturing and marketing any

new products resulting from such acquisitions, collaborations or transactions. The inability to achieve the expected benefits

of any such transaction, including if the products acquired as part of recent transactions, Rina-S and petosemtamab, should

be significantly delayed or fail, could have a material adverse effect on our business, financial condition, results of

operations, debt repayments and future growth prospects and our investors’ ability to realize on their investments.

In addition , we may need to seek additional funds to finance such transactions, and we may be unable to obtain

financing on favorable terms, in a timely manner or at all. Our ability to raise additional funds may be adversely impacted

by potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets

in the US and worldwide resulting from factors that include but are not limited to, actual or threatened trade restrictions and

tariffs, trade tensions, inflation, wars and geopolitical conflicts and tensions, including the conflict between Russia and

Ukraine and conflicts in the Middle East, diminished liquidity and credit availability, declines in consumer confidence,

declines in economic growth, increases in unemployment rates, uncertainty about economic stability, increases in interest

rates and potential for economic recession. If the equity and credit markets deteriorate, it may make any necessary debt or

equity financing more difficult, more costly and more dilutive. If we are unable to raise capital or if the cost is prohibitively

expensive, we may need to finance transactions using cash and cash equivalents and marketable securities that could

otherwise be allocated to other purposes in the context of our existing operations, and in hindsight our allocation decisions

may not be optimal.

Sales of our products will depend on the degree of market acceptance by physicians, patients, healthcare payers and

others in the medical community.

If any of our product candidates receive marketing approval or if any of our marketed products receive marketing

approval for additional indications, they may nonetheless fail to gain sufficient market acceptance by physicians, patients,

healthcare payers and others in the medical community, due to not being as well-established or known as conventional

therapies or otherwise. Accordingly, our commercial opportunity may be limited and/or our revenues from sales of these

products may be negatively impacted. The degree of market acceptance will depend on a number of factors, including: the

price, efficacy, safety, convenience and ease and safety of administration of such products, along with their competitive

advantages vis-à-vis other therapies, designation as a first-, second- or third-line treatment, changes in the relevant standard

of care or clinical guidelines and any labeling restrictions or warnings, the willingness of the target patient population to try

11

Table of Contents

and of physicians to prescribe our products, the availability and amount of coverage and reimbursement from government

payers, managed care plans and other third-party payers, and the strength of the sales, marketing and distribution support

provided by us or our collaboration partners.

We may not meet publicly announced product development objectives.

We sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical,

regulatory and other product development objectives. These milestones may include our expectations regarding the

commencement or completion of scientific trials or clinical trials, the submission of regulatory filings or the achievement

of commercialization objectives. From time to time, we may publicly announce the expected timing of some of these

milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of

marketing approval or a commercial launch of a product. The achievement of many of these milestones is outside of our

control. All of these milestones are based on a variety of assumptions, which may cause the timing of achievement of the

milestones to vary considerably from our estimates. If we fail to achieve announced milestones in the timeframes we

expect, or at all, it may have a material adverse effect on our business, financial condition and results of operations and the

price of our ADSs may be adversely affected.

Our target patient population may be lower than our estimates and we may be unable to recoup our development

investments.

Periodically, we and our collaboration partners make estimates regarding the incidence and prevalence of target patient

populations for particular diseases based on various sources and internally generated analysis and use such estimates in

making decisions regarding product development strategy, including determining indications on which to focus in

preclinical or clinical trials. These estimates may be inaccurate or based on imprecise data, or patient incidence and

prevalence for selected indications may evolve over time as treatments and patient outcomes change. The number of

patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to

treatment with our products, or new patients may become increasingly difficult to identify or gain access to.

Even if our product candidates obtain significant market share for their approved indications, because certain potential

target populations are small, we may never recoup our investment in such product candidates without obtaining regulatory

approval for additional indications for such product candidates. We expect that we or our collaboration partners will

initially seek approval of some of our product candidates as second- or third-line therapies for patients who have failed

other approved treatments, which further limits the size of the potential patient population for such indication. If we or our

collaboration partners are unable to obtain regulatory approval for such products for frontline or second-line therapy, we

may be unable to recoup our investment in such products.

We are exposed to foreign exch ange risk.

Most of our financial transactions are made in US dollars, DKK and Euro. As of January 1, 2025 we changed our

reporting currency to US dollars and, as a result, we currently experience exchange rate risk with respect to our holdings

and transactions denominated in currencies other than US dollars. Our currency exposure is mainly related to cash deposits,

marketable securities, and accounts payable denominated in currencies other than US dollars.

If we fail to manage our foreign exchange risk adequately, our business, financial condition, results of operations and

future growth prospects and the value of our ADSs may be adversely affected.

We are subject to risks as a result of our multinational operations.

We, our collaborators and third-party partners and suppliers operate in many jurisdictions around the world and as a

result could be adversely affected by risks and uncertainties associated with such multinational operations, including,

among others: capital and exchange controls; local and global economic conditions including inflation, recession, volatility

and/or lack of liquidity in capital markets; expropriation and other restrictive government actions; actual or threatened trade

restrictions or tariffs such as the sweeping tariffs announced by the US in 2025 and the trade tensions between US and

China; trade regulations; tax laws and regulations; and procedures and actions affecting approval, production, pricing, and

marketing of, reimbursement for and access to our products, as well as impacts of political or civil tensions, unrest or

military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and their economic

consequences; geopolitical instability; terrorist activity; unstable governments and legal systems; and inter-governmental

disputes and tensions. Some emerging market countries may be particularly vulnerable to periods of financial, economic or

12

Table of Contents

political instability, weakening of the rule of law, or significant currency fluctuations. Local economic and political

conditions may adversely affect our distributors, customers, suppliers, collaborators and service providers, and their ability

to perform their obligations under agreements with us.

Risks Related to Partners and Other Third Parties

We rely on our collaboration partners in many aspects of our business.

We rely on our collaboration partners in many aspects of our business, including to assist with, or to conduct, clinical

and regulatory development, manufacturing and/or commercialization of certain of our partnered and proprietary products

and product candidates or to provide access to antigens, technologies, skills and information that we do not possess.

If we are not able to maintain our existing material collaborations (or replace them if terminated), establish additional

collaborations on favorable terms or realize the anticipated benefits from our collaborations, our business, financial

condition and results of operations may be materially harmed. In particular, the termination of any of our key

collaborations could significantly delay the development and commercialization of our products and product candidates

and impact our financial results and future prospects. Our licensing collaboration partners generally have the right to

terminate our collaborations with notice at any time. Our ability to continue our current collaborations and to enter into

additional ones will depend in large part on whether we are able to successfully maintain, expand and demonstrate our

research, development and commercialization capabilities and the benefits of our technologies relative to those of our

competitors.

We also rely on our collaboration partners to periodically provide us with information about the status, progress and

results of clinical trials and regulatory processes that they are conducting, sponsoring, or pursuing with respect to products

that are the subject of the collaboration. For products and product candidates being developed by our collaboration

partners, we generally do not have direct access to the underlying data or direct communications with the relevant

regulators. As a result, our knowledge of material clinical events or data or material regulatory communications or

developments, and our corresponding ability to report these to our shareholders, may be limited or delayed.

In addition, our reliance on our collaboration partners subjects us to a number of additional risks, including the

following:

• our collaboration partners have significant discretion regarding whether and on what timeline to pursue planned

activities;

• we cannot control the quantity and nature of the resources our collaboration partners may devote to the

development, commercialization, marketing and distribution of products or product candidates;

• our collaboration partners may not develop products generated using our antibody technology as expected;

• disputes between us and our collaboration partners may delay or terminate the research, development or

commercialization of the applicable products and product candidates or result in costly litigation or arbitration that

diverts management’s attention and resources;

• with respect to collaborations under which we have an active role, we and our collaboration partners may have

differing opinions or priorities, or we may encounter challenges in joint decision making, which may delay or

terminate the research, development or commercialization of the applicable products and product candidates;

• we may not receive milestone payments from our collaboration partners, at the expected time or at all, if our

collaboration partners do not achieve future milestones or if we and our collaboration partners disagree about

whether a milestone has been reached;

• our collaboration partners may require, terminate or repeat clinical trials or require a new formulation of a product

candidate for clinical testing, or may abandon a product candidate;

• our relationships with our collaboration partners may divert significant time and effort of our scientific staff and

management team;

13

Table of Contents

• our collaboration partners may be subject to regulatory sanctions that could adversely affect the development,

approval or commercialization of the applicable products or product candidates;

• our collaboration partners may not properly maintain or defend relevant intellectual property rights, or may

infringe the intellectual property rights of third parties, or may use our or third parties’ proprietary information in

such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to

potential litigation;

• our collaboration partners may develop competing products, therapeutic approaches or technologies;

• business combinations, financial difficulties, strategic transactions, or significant changes in a collaboration

partner’s business strategy or as a result of changes in political or economic conditions, may adversely affect that

collaboration partner’s willingness or ability to continue to pursue our products or product candidates and make

payments under collaboration agreements to us when due; and

• our collaborations may be terminated, breached, or allowed to expire, or our collaboration partners may reduce the

scope of our agreements with them.

Any one or more of the foregoing risks, if realized, could have a material adverse effect on our business, financial

condition and results of operations.

We rely on third parties to conduct clinical trials.

We rely on third parties, such as CROs, to conduct clinical trials on product candidates we are developing. Our

collaboration partners may similarly rely on such parties. The third parties with whom we and our collaboration partners

contract for execution of our or their clinical trials play a significant role in the conduct of these trials and the subsequent

collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our

contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to

our programs. Although we rely on these third parties to conduct clinical trials, we remain responsible for ensuring that

each of our clinical trials is conducted in accordance with its investigational plan and protocol and in compliance with

applicable regulations and standards, commonly referred to as GCPs.

If the third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work

stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or

accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols or to

GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be

costly, and our clinical trials may need to be extended, delayed, terminated or repeated. We may not be able to obtain

regulatory approval in a timely fashion, or at all, for the applicable product candidate, or to commercialize such product

candidate being tested in such trials.

We rely on a limited number of third-party manufacturers for our product supply.

To ultimately be successful, our antibody products must be manufactured in commercial quantities in compliance with

regulatory requirements and at acceptable costs. J&J is responsible for the manufacture of daratumumab, amivantamab,

teclistamab and talquetamab. Novartis International AG (“ Novartis ”) is responsible for the manufacture of ofatumumab,

Amgen Inc. (“ Amgen ”) is responsible for the manufacture of teprotumumab, AbbVie is responsible for the manufacturing

of epcoritamab, and Pfizer Inc. (“ Pfizer ”) is responsible for the manufacturing of tisotumab vedotin.

For the product candidates we are entirely responsible for manufacturing, we currently rely on a limited number of

CMOs and specific sites at those CMOs to manufacture and supply our product candidates. We expect to negotiate

contracts for commercial production on a product-by-product basis for products that we choose to commercialize on terms

that make us responsible for manufacturing.

There are a number of companies on a worldwide basis that operate manufacturing facilities in which our product

candidates can be manufactured under GMP regulations. We cannot be certain that we will be able to contract with any of

these companies on acceptable terms, if at all. New suppliers would also need to have sufficient rights under applicable

intellectual property laws to the method of manufacturing such ingredients. In addition, significant cancellation penalties

14

Table of Contents

and the long lead times required for initial orders or to make any changes to existing orders, including changing the scale of

production, limit our flexibility in connection with product development, clinical trials or commercial sales. For example,

we may be required to order products for the second part of a clinical trial or for a proposed follow-on clinical trial before

we have initial results from the trial, which could result in a loss if we terminate the trial or need to make changes to the

product.

We could also encounter difficulties, delays or inefficiencies in our supply chain, product manufacturing and

distribution networks, as well as sales or marketing, due to regulatory actions, shut-downs, work stoppages or strikes,

approval delays, withdrawals, recalls, penalties, supply disruptions, shortages or stock-outs at our facilities or third-party

facilities that we rely on, reputational harm, the impact to our facilities due to health pandemics or natural or man-made

disasters.

Lastly, CMOs, especially those located in non-US countries, may be subject to or affected by various US legislation ,

executive orders, regulations, or investigations targeting certain development or economic activities involving those

countries. The CMO we use for the manufacturing of Rina-S is based in China, and there have been recent political and

economic tensions between China and the US. For example, the BIOSECURE Act enacted in December 2025 bans federal

procurement or funding associated with “biotechnology companies of concern” and restricts use of their equipment and

services in federal contracts, grants, and loans. The implementation of the act will be phased in over a period of years, and

could severely restrict the ability of companies to work with certain Chinese biotechnology companies of concern without

losing the ability to contract with, or otherwise receive funding from, the US government. If our CMO for Rina-S is

affected by this legislation or any other action against Chinese companies and we are unable to secure alternative

manufacturing capacity on a timely basis, this could delay our commercial launch of Rina-S. It could also increase costs,

reduce the supply of available materials, delay procurement or clinical trials, hinder our ability to secure significant

government commitments for potential therapies, and adversely affect our financial condition and business prospects.

We and our manufacturing partners must comply with applicable laws and regulations, including cGMPs.

In order to commercialize new pharmaceutical and biologic products, manufacturers must comply with the laws and

regulations, including drug and biologic cGMPs, of the applicable governmental authorities. Compliance with cGMP

regulations requires significant expertise and capital investment, including the development of advanced manufacturing

techniques and process controls. Manufacturing facilities are also subject to pre-approval and ongoing periodic inspection

by applicable governmental agencies, including unannounced inspections, and must be licensed before they can be used in

commercial manufacturing of products employing our technology. The FDA, the European Medicines Agency (“ EMA ”) or

similar regulatory agencies at any time may also implement new standards or change their interpretation and enforcement

of existing standards for manufacturing, packaging or testing of products.

Manufacturers of pharmaceutical and biologic products encounter difficulties in production, including difficulties with

production yields, stability of the product candidate, quality control and assurance, shortages of qualified personnel,

compliance with relevant regulations, production costs and development of advanced manufacturing techniques and

process controls. If our manufacturer were to encounter any of these difficulties or otherwise fail to comply with its

obligations to us or under applicable regulations, our ability to provide trial materials in our preclinical trials and clinical

trials would be jeopardized. Any delay or interruption in the supply of preclinical trial or clinical trial materials could delay

the completion of our preclinical trials and clinical trials, increase the costs associated with maintaining our preclinical trial

and clinical trial programs and, depending upon the period of delay, require us to commence new trials at significant

additional expense or terminate the trials completely.

In addition, we lack direct control over our manufacturers’ compliance with these regulations and standards and

manufacturers of our products and product candidates may be unable to comply with these cGMP requirements and with

other regulatory requirements. The discovery of manufacturing, quality control or regulatory documentation problems or

failure to maintain compliance with cGMP or other requirements after approval of a product may result in restrictions on

the marketing of a product, revocation of the license, withdrawal of the product from the market, seizures, injunctions,

fines or criminal sanctions. If the safety of any product supplied is compromised due to the manufacturers’ failure to adhere

to applicable laws or for other reasons, we or our collaboration partners may not be able to continue clinical trials for our

product candidates, obtain regulatory approval for or successfully commercialize our products, and we or our collaboration

partners may be held liable for any injuries sustained as a result. Any of these factors could cause a delay in clinical trials,

regulatory submissions, approvals or commercialization of our products and product candidates or entail higher costs or

15

Table of Contents

impair our reputation. No assurance is given that third-party manufacturers will be able to comply adequately with the

applicable regulations.

Our employees and collaboration partners may engage in misconduct or other improper activities.

We are exposed to the risk of fraud or other misconduct by our employees and collaboration partners. Misconduct by

our collaboration partners, vendors or suppliers could include intentional failures to comply with legal requirements or the

requirements of the FDA, the EMA and other comparable regulatory authorities; failure to provide accurate information to

applicable government authorities; failure to comply with fraud and abuse and other healthcare laws and regulations in the

US, the EU and other jurisdictions; failure to comply with the Foreign Corrupt Practices Act (“ FCPA ”) and other

applicable anti-bribery laws; failure to report financial information or data accurately; or failure to disclose unauthorized

activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive

laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, bribery and other abusive practices.

These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales

commission, customer incentive programs and other business arrangements. Our collaboration agreements include

provisions regarding regulatory compliance, but it is not always possible to identify and deter misconduct, and the

precautions we and our collaboration partners take to detect and prevent this activity may be ineffective in controlling

unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits

stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are

not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business,

including the imposition of significant fines or other sanctions.

Specifically, the FCPA prohibits companies and their intermediaries from making or offering improper payments to

non-US officials for the purpose of obtaining or retaining business, and requires companies listed on a US stock exchange

to maintain a system of adequate internal accounting controls and to make and keep books, records and accounts that

accurately and fairly reflect transactions and dispositions of assets. Because of the predominance of government-sponsored

health care systems around the world, many of our commercial relationships outside the US are with governmental entities,

and personnel of such entities may be considered non-US government officials for purposes of the FCPA. Violations of the

FCPA and other applicable anti-bribery laws are punishable by criminal fines and imprisonment, civil penalties,

disgorgement of profits, injunctions and debarment from government contracts as well as other remedial measures. We

have adopted a written code of business conduct, an anti-corruption, anti-bribery policy, and other policies and procedures

to assist us and our personnel in complying with the FCPA and other applicable anti-bribery laws, but there can be no

assurance that such policies will be effective in preventing or deterring violations of the FCPA, whether intentional or not.

Our personnel and others acting on our behalf could take actions that violate these requirements, which could adversely

affect our reputation, business, financial condition and results of operations.

Risks Related to Product Development

Biopharmaceutical product development involves a substantial degree of uncertainty.

Our product pipeline currently includes five proprietary products and product candidates in various stages of active

clinical development (early clinical development, late clinical development). There are also ongoing clinical trials for

daratumumab, amivantamab, teclistamab and talquetamab by J&J, ofatumumab by Novartis and teprotumumab by Amgen,

and additional product candidates being developed by our collaboration partners. Following the acquisition of Merus, we

expect to commence additional studies and continue current ongoing studies for petosemtamab. Many of our current

product candidates are in relatively early stages of development (preclinical proof of concept), and all of our product

candidates will require significant further development, financial resources and personnel to obtain regulatory approval and

develop them into commercially viable products, if at all.

Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, we or our

collaboration partners may not successfully develop any of our product candidates, or we or our collaboration partners may

choose to discontinue the development or co-development of product candidates for a variety of reasons, including due to

safety, risk versus benefit profile, exclusivity, competitive landscape, commercialization potential, production limitations

or prioritization of our or our collaboration partners’ resources. In addition, our research programs may initially show

promise in identifying potential product candidates yet fail to yield product candidates suitable for clinical development or

commercialization. Likewise, we and our collaboration partners have to make decisions about which clinical stage and

preclinical product candidates to develop and advance. We may not have the resources to invest in all of our current

16

Table of Contents

product candidates, or clinical data and other development considerations may not support the advancement of one or more

product candidates. Decision-making about which product candidates to prioritize involves inherent uncertainty, and our

and our collaboration partners’ development program decision-making and resource prioritization decisions may not

improve our results of operations or future growth prospects.

Many of our proprietary and partnered product candidates are created with, and dependent upon, our proprietary

technologies, and some of them also incorporate technologies of our partners or other third parties. Any failures or setbacks

with respect to our proprietary technologies or Pfizer’s anti-body drug conjugate (" ADC ") development programs,

including adverse effects resulting from the use of these technologies in human clinical trials and/or the imposition of

clinical holds on trials of any product candidates using our proprietary technologies, could have a detrimental impact on

our clinical pipeline.

Additionally, with the exception of acasunlimab, for which we discontinued clinical development in December 2025

and rinatabart sesutecan (“ Rina-S ”), we have not ourselves, or in collaboration, advanced any product candidates through

late-stage clinical development. If we are unable to continue to develop late-stage development capabilities, we will be

required to continue to contract with third parties via licensing and development agreements to complete the development

of our proprietary product candidates, which we may not be able to do on a timely basis, on terms favorable to us, or at all,

and the development of our proprietary product candidates could be delayed or terminated. Our failure to effectively

advance our development programs could have a material adverse effect on our business, financial condition, results of

operations and future growth prospects.

Furthermore, we may have to develop companion diagnostics to select the patient population that could benefit from

the relevant treatment, both during our clinical trials and in connection with the commercialization of our product

candidates, which are subject to regulation by the FDA, the EMA, and comparable foreign regulatory authorities as

companion diagnostic medical devices, and typically require separate regulatory approval prior to commercial use. Any

delay or failure by us or our collaboration partners to obtain regulatory approval of companion diagnostics could harm our

development strategy and/or delay or prevent approval of our product candidates, which may adversely affect our business,

financial condition and results of operations.

Our product candidates will need to undergo clinical trials that are time-consuming and expensive, the outcomes of

which are unpredictable, and for which there is a high risk of failure.

The FDA, EMA, and comparable regulatory authorities in other jurisdictions must approve new product candidates

before they can be marketed, promoted or sold in those territories. We or our collaboration partners must provide these

regulatory authorities with data from preclinical and clinical trials that demonstrate that our product candidates are safe and

effective for a specific indication before they can be approved for commercial distribution. We cannot be certain that our or

our collaboration partners’ preclinical or clinical trials for our product candidates will be successful or that any of our other

proprietary or partnered product candidates will receive approval from the FDA, the EMA or any other regulatory

authority. In addition, certain other third parties make decisions about products or product candidates based on results of

clinical trials, including determinations relating to pricing, access or reimbursement of approved products or validations or

endorsements of treatment options. Such third parties may require additional data or trials for their determinations.

Preclinical trials and clinical trials are long, expensive and unpredictable processes that can be subject to extensive

delays or failure.

We may be required to revise our development plans and extend dose exploration as a result of FDA’s Project

Optimus, which requires the implementation of strategies for dose finding and dose optimization that leverage preclinical

and clinical data in dose selection, including randomized evaluations of a range of doses in clinical trials. In support of this

initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-

approval.

It may take several years and require significant expenditures to complete the preclinical and clinical trials necessary to

commercialize a product candidate, and delays or failures are inherently unpredictable and can occur at any stage. Even if

we or our collaboration partners obtain positive results from preclinical or early clinical trials, we or they may not achieve

the same success in subsequent trials. In particular, the results of preclinical trials are based on animal, in vitro or other

laboratory testing and may not be predictive of the safety or efficacy of our product candidates in humans. Similarly,

topline or interim results of clinical trials do not necessarily predict final results. A number of companies in the

17

Table of Contents

pharmaceutical, biopharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical

trials even after obtaining promising results in earlier trials, and we cannot be certain that we or our collaboration partners

will not face similar setbacks. If topline or interim data that we or our collaboration partners report differ from final results,

or if others, including regulatory authorities, disagree with our assumptions, calculations, conclusions, or analyses or

interpret or weigh the data differently, or if subsequent trials are unsuccessful, we or our collaboration partners may be

unable to obtain marketing approval for product candidates on a timely basis or at all, which could impact our reputation,

business, financial condition, results of operations and future growth prospects.

Furthermore, the design of a clinical trial can determine whether its results will support approval of a product, and

flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed. The

failure of clinical trials to demonstrate safety and efficacy for our or our collaboration partners' desired indications could

harm the development of the relevant product candidate as well as other product candidates employing the same

technology, which could have a significant impact on our product pipeline and future growth prospects. An unfavorable

outcome in one or more trials would be a major setback for our product candidates and for us and may require us or our

collaboration partners to delay, reduce the scope of or eliminate one or more product development programs, which could

have a material adverse effect on our business, financial position, results of operations and future growth prospects. Any

delays in product development may allow our competitors to bring products to market before we or our collaboration

partners do or shorten any periods during which we or our collaboration partners have the exclusive right to commercialize

our product candidates. In addition, advancements or changes in the industry standards or techniques may impact the value

and recognition of our and our collaboration partners’ clinical data. Failure to adopt new industry standards may result in

less comparable or useful trial results. Alternately, early adoption of emerging protocols or endpoints may result in data

that is not recognized by certain regulatory bodies or industry professionals, or if such protocols are later found to be

ineffective, may require us or our collaboration partners to change the design of our clinical trials.

In connection with clinical trials of our product candidates, we face a number of risks, including risks that:

• we or our collaboration partners may be unable to manufacture or obtain sufficient quantities of qualified

materials for clinical trials or may be required to modify manufacturing processes;

• patient recruitment may be slower than expected and we may have difficulty accessing potential clinical trial

sites;

• a product candidate may be ineffective, inferior to existing approved products for the same indications,

unacceptably toxic or have unacceptable side effects;

• patients may die or suffer other adverse effects for reasons that may or may not be related to the product

candidate being tested;

• a clinical trial may be delayed, suspended or terminated by the Institutional Review Board (“ IRB ”) or ethics

committee responsible for overseeing the clinical trial, by regulatory authorities or by us or our collaboration

partners due to failure to meet clinical protocols, safety issues or adverse effects, failure to demonstrate

product efficacy, changes in clinical protocols, may require additional dose finding and/or dose optimization,

or applicable regulatory requirements, lack of funding or other factors;

• investigators or other third parties could conduct clinical trials on our products or product candidates that

could lead to adverse events or results that could negatively impact the development, regulatory approval or

marketability of such products;

• extension trials on long-term tolerance could invalidate the use of our product;

• clinical trials may not demonstrate statistically sufficient levels of safety and efficacy to obtain the requisite

regulatory approvals;

• even if data is sufficient for regulatory approval, it may not be sufficient to secure pricing reimbursement or

to secure validation of our products by key industry players, which could delay or prevent the commercial

launch of a product; and

• our collaboration partners or CROs may be unable or unwilling to perform under their contracts.

18

Table of Contents

The FDA may not accept data from trials we or our collaboration partners conduct outside the US or may require

additional US-based trials as a condition of regulatory approval.

We and our collaboration partners have conducted, currently are conducting and intend in the future to conduct clinical

trials outside the US, including in the EU where we are headquartered. Although the FDA may accept data from clinical

trials conducted outside the US, acceptance of this data is subject to certain conditions imposed by the FDA, including with

respect to compliance with GCPs and applicability of the data to the US population and US medical practice in ways that

the FDA deems clinically meaningful. If the FDA does not accept the data from any clinical trials that we or our

collaboration partners conduct outside the US, it would likely result in the need for additional clinical trials, which would

be costly and time-consuming and delay or permanently halt our ability to develop and market these product candidates for

the proposed indications in the US. In other jurisdictions, for instance, in Japan, there is a similar risk regarding the

acceptability of clinical trial data conducted outside of that jurisdiction.

We or our collaboration partners may encounter difficulties enrolling patients in our clinical trials.

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability

to enroll a sufficient number of patients who remain in the trial until its conclusion. We or our collaboration partners may

experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:

• the size and nature of the patient population;

• the patient eligibility criteria defined in the protocol;

• the size of the trial population required for analysis of the trial’s primary endpoints;

• the proximity of patients to trial sites;

• the design of the trial;

• our ability to recruit clinical trial investigators with the appropriate competencies and experience;

• competing clinical trials for similar therapies or other new therapeutics not involving our product candidates

and/or related technologies;

• clinicians’ and patients’ perceptions as to the potential advantages and side effects of the product candidate

being studied in relation to other available therapies, including any new drugs or treatments that may be

approved for the indications we are investigating;

• our ability to obtain and maintain patient consents; and

• the risk that patients enrolled in clinical trials will not complete a clinical trial.

In addition, our and our collaboration partners’ clinical trials will compete with other clinical trials for product

candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and

types of patients available for our and our collaboration partners’ clinical trials. We expect that we and our collaboration

partners will conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will

reduce the number of patients who are available for our and our collaboration partners’ clinical trials at such clinical trial

sites. Moreover, because our product candidates may represent a departure from more commonly used methods for cancer

treatment, potential patients and their doctors may be inclined to only use conventional therapies, such as chemotherapy

and radiation, rather than enroll patients in any future clinical trial.

Even if we and our collaboration partners are able to enroll a sufficient number of patients in our clinical trials, delays

in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which

could prevent completion of these trials and adversely affect our and our collaboration partners’ ability to advance the

development of our product candidates.

19

Table of Contents

Any approval granted for our products or product candidates in the US does not assure approval of such products in

Japan, the EU or other foreign jurisdictions.

In order to market and sell our drugs in Japan, the EU and other jurisdictions, we and our collaboration partners must

obtain separate marketing approvals, and comply with numerous and varying regulatory requirements. The approval

procedure varies among countries and can involve additional testing. The time required to obtain approval may differ

substantially from that required to obtain FDA approval. The marketing approval process outside the US generally includes

all of the risks associated with obtaining FDA approval. In addition, many countries outside the US require that the drug be

approved for reimbursement before the drug can be approved for sale in that country. We and our collaboration partners

may not obtain approvals from regulatory authorities outside the US on a timely basis, if at all. Approval by the FDA does

not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority

outside of the US does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.

We may fail to obtain designatio ns for expedited development or review or such designations may not lead to a faster

development or regulatory review. Acceptance into an expedited review program or receipt of accelerated approvals does

not assure ultimate full regulatory approval.

Fast Track Designation (“ FTD ”), Breakthrough Therapy Designation (“ BTD ”), and the accelerated approval programs

of the FDA and other regulatory authorities are intended to expedite the review and approval of drug candidates in certain

circumstances. These designations and programs do not, however, ensure that marketing approval will be granted in a

particular timeframe or at all. The FDA and other regulatory authorities have broad discretion regarding whether or not to

grant these designations or include product candidates within pilot programs, and, even if we or our collaboration partners

believe a particular product candidate is eligible for these designations or programs, we cannot assure that such authority

would agree. Even if we or our collaboration partners receive such designations or are eligible for inclusion in expedited

review pilot programs in the future, we may not experience a faster development, review or approval process compared to

conventional procedures. In addition, such designations or processing under such pilot programs may be withdrawn if the

FDA or the relevant regulatory body no longer believes such product candidate meets the criteria for the designation or

program. Furthermore, these designations and pilot programs do not change the scientific and medical standard for

approval or the quality of evidence necessary to support approval. As a result, applications for product candidates granted

expedited review or BTD or FTD designation may be ultimately denied based on trial data, trial design or other factors, and

even if our product candidates are accepted into such a program, this does not assure ultimate approval by the FDA or the

applicable regulatory body. Any accelerated approval received for our products, such as the approvals for EPKINLY, is

contingent on successful completion of diligently conducted post-marketing confirmatory trials, and accelerated approval

may be withdrawn if post-marketing trials do not verify the product’s benefit or demonstrate sufficient clinical benefit to

justify associated risks, other evidence demonstrates that the product is not safe or effective, or the FDA considers

promotional materials relating to the product to be false or misleading. The terms and conditions of expedited development

and review programs are subject to change as a result of regulatory developments, and any such changes may adversely

affect our ability to secure or maintain accelerated approvals or BTD, FTD or similar designations from the FDA or another

regulator. See “ Item 4 –Information on the Company —Government Regulation ” for more information about BTD, FTD

and accelerated approval programs for expedited review.

Risks Related to Our Products

We may be affected by reports of adverse events or safety concerns relating to our products or product candidates.

As with most biological drug products, use of our products and product candidates is associated with undesirable side

effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to

prevalent. In particular, many of our and our collaboration partners’ clinical trials are conducted in patients with serious

life-threatening diseases for whom conventional treatments have been unsuccessful or for whom no conventional treatment

exists, and in some cases, our product candidates are used in combination with approved therapies that themselves have

significant adverse event profiles. During the course of treatment, these patients may suffer adverse medical events or die

for reasons that may or may not be related to our product candidates. Reports of adverse events or safety concerns could

have negative impacts on our or our collaboration partners’ clinical trials, regulatory processes, reputation and results,

whether or not actually shown to be related to our product candidates.

Reports of adverse events or safety concerns involving our products or product candidates have sometimes resulted

and can in the future result in regulatory authorities interrupting, delaying or halting clinical trials (or otherwise negatively

20

Table of Contents

impacting patient enrollment in or completion of clinical trials), limiting, denying, withdrawing approval of or recalling

such product for any or all indications, including the use of such product in its previously approved indications, or may

require additional clinical trials, updates to the prescribing information, including boxed warnings, contraindications, or

other labeling statements, implementation of a Risk Evaluation and Mitigation Strategy (“ REMS ”) or the issuance of field

alerts, warnings or other communications to physicians, pharmacies or patients. In certain cases, regulatory authorities may

order us or our collaboration partners to conduct additional trials or to cease further development or commercialization of

the product or product candidate entirely. Furthermore, actual or potential drug-related side effects can affect patient

recruitment or the ability of enrolled patients to complete a trial for our products or product candidates. Reports of adverse

events or safety concerns, or changes to regulatory approvals or labeling, may also have a significant impact on market

acceptance of our products by patients and physicians or may trigger potential product liability claims, fines, injunctions or

the imposition of civil or criminal penalties. Any of these events has the potential to prevent us or our collaboration

partners from developing, commercializing or maintaining market acceptance of the relevant product or product candidate

or to substantially increase commercialization costs, which in turn could significantly harm our business, financial

condition, results of operations and future growth prospects.

Adverse events may also impact the sales of our products. We may be required to further update the prescribing

information for our products, including boxed warnings, limitations of use, contraindications, warnings and precautions,

and adverse reactions, based on reports of adverse events or safety concerns, or implement a REMS, which could adversely

affect the acceptance of our products in the market, make competition easier or make it more difficult or expensive for us

or our collaboration partners to distribute our products. In addition, the reporting of adverse safety events involving our

products or product candidates, or public rumors about such events, could cause the price of ADSs to decline or experience

periods of volatility.

Several of our products and product candidates are used or proposed to be used in combination with other therapeutic

products, which exposes us to risks related to those products.

Part of the clinical development strategy for certain of our product candidates, including daratumumab, is to seek to

identify patients or patient subsets within a disease category whose treatment may benefit from our products in

combination with other therapeutic products. Approval of a product for the treatment of a disease indication in combination

with other therapeutic products exposes us and our collaboration partners to certain risks related to those other therapeutic

products, including the risks that such products will become less competitive or obsolete or will be found to have safety

concerns, which could potentially result in removal of such products from the market. Furthermore, seeking to heighten

immune or other therapeutic responses through combination treatments carries an inherent risk that the combination may

cause unexpected side effects or safety issues not observed in treatment with the individual products alone.

We may face product liability claims related to the use or misuse of our products or technologies.

Our business exposes us to potential product liability risks which are inherent in research and development, preclinical

and clinical testing, manufacturing, marketing and use of antibody products. Product liability claims may be expensive to

defend and may result in judgments against us which are potentially punitive. It is generally necessary for us to secure

certain levels of insurance as a condition for the conduct of clinical trials. Although we believe that our current coverage

limits are appropriate, we cannot be certain that the insurance policies will be sufficient to cover all claims that may be

made against us. Product liability insurance is expensive, difficult to obtain and may not be available in the future on

acceptable terms. Any claims against us, regardless of their merit, could cause our business to suffer. Even a successful

defense would require significant financial and management resources. Regardless of the merits or eventual outcome,

product liability claims may result in decreased demand for our products, injury to our reputation, withdrawal of clinical

trial participants and inability to continue clinical trials, initiation of investigations by regulators, costs to defend the related

litigation, a diversion of management’s time and our resources, substantial monetary awards to trial participants or patients,

product recalls, withdrawals or labeling, marketing or promotional restrictions, exhaustion of any available insurance and

our capital resources, the inability to commercialize any product or product candidate, damage to our reputation, loss of

any potential future revenue and a decline in the market price of our ADSs.

21

Table of Contents

Risks Related to Our Business

We face intense competition and rapid technological change.

The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies and intense

competition. Many third parties, including pharmaceutical companies, biotechnology companies, academic institutions and

other research organizations, compete with us in developing various approaches to antibody therapy and other competing

therapies. Many of our competitors have significantly greater financial resources and expertise in research and

development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval and marketing

than we do, and earlier-stage companies may also prove to be significant competitors, especially through collaborative

arrangements with larger collaboration partners. In addition, many of these competitors are active in seeking patent

protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed.

These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in

acquiring technologies complementary to our programs. In addition, many other pharmaceutical and biotechnology

companies are developing and/or marketing therapies for the same indications that our products and product candidates are

designed for and being developed to treat. In addition, our DuoBody and other technology partners may develop

compounds utilizing our technologies that may compete with product candidates that we are developing. See “ Item 4B–

Business Overview—Competition ” below for more information about our competitors.

In the US, the Biologics Price Competition and Innovation Act of 2009 (“ BPCIA ”), created an abbreviated approval

pathway for biological products that are demonstrated to be “highly similar” or “biosimilar” to or “interchangeable” with

an FDA-approved biological product, which may be used by our competitors to receive approval for, and commercialize,

product candidates that compete with our products with less effort and expense than would otherwise be required, and any

period of exclusivity for which our products qualify may be reduced to a shorter period than we expect due to regulatory

action or otherwise. See “ Item 4B—Business Overview—Competition ” for more information on this regulatory pathway.

It is possible that our competitors will succeed in developing products and technologies that are more effective than

our products and product candidates or that would render our technology obsolete or noncompetitive. It is also possible that

our competitors will succeed in developing biosimilar or interchangeable products for our products or our product

candidates. Competition is increasing from companies that are utilizing artificial intelligence and other computational

approaches for drug discovery, including the development of antibody therapies and other competing therapies. These

competitors may incorporate AI into their businesses more quickly or more successfully than us, which could impair our

ability to compete effectively and adversely affect our results of operations. We anticipate that we will continue to face

increasing competition in the future as new companies enter our market and scientific developments surrounding

biosimilars and other cancer therapies continue to accelerate. We cannot predict the extent to which these developments

will impact potential future sales of our products or our product candidates.

In addition, the pricing of our products depends, and the pricing of our product candidates, if and when approved for

marketing, will depend, in part, on the pricing strategies adopted by our competitors. If we or our collaboration partners are

forced to reduce the prices of our products, or if sales of our products fall due to competitive pricing, our revenue from

milestone payments, sales or royalties related to such products will be negatively affected.

Any products we or our collaboration partners are able to commercialize in the US and the EU may be subject to

competition from lower-priced imports of those same products, as well as lower-priced imports of competing products

from Eastern Europe, Canada, Mexico and other countries with government price controls or other market dynamics that,

in each case, reduce prices of products leading to reduced revenues and lower sales margins. The ability of patients to

obtain these lower-priced imports has grown significantly. Some of these foreign imports are illegal under current US and

European law. However, the volume of imports is now significant, due in part to the limited enforcement resources and the

pressure in the current political environment to permit the imports as a mechanism for expanding access to lower-priced

medicines. Parallel importation or importation of foreign products could adversely affect our future profitability. This

impact potentially could become even greater if there is a further change in relevant protective legislation or if state or local

governments take further steps to import products from abroad.

22

Table of Contents

Our business applications and IT infrastructure, or those of our collaboration partners, contractors or consultants, may

fail or suffer cybersecurity breaches, and the use of n ovel technologies may subject us to additional risks.

Our business applications and IT infrastructure, including those hosted by third parties, and those of our collaboration

partners, contractors or consultants, may be vulnerable to cybersecurity risks, such as ransomware, malware, identify theft,

system or application failure,, and natural disasters, terrorism, war and telecommunication and electrical failures, which can

lead to damage, loss or leakage of business data or unavailability of computer systems. Our vulnerability to such events

may increase while employees work remotely which results in additional cybersecurity threat profiles and an increase in

the amount of traffic on secured remote corporate networks and preventing or detecting unauthorized access to internal

networks may be more challenging. These and other factors, including the increased use of artificial intelligence by threat

actors, can be exploited to facilitate phishing, malware, ransomware or other attacks on our systems. If such an event were

to occur, it could result in a critical or material disruption of our development programs and our business operations. In

addition, any loss or disclosure of trade secrets, clinical data, personal data, or other proprietary information as a result of

such disruption or breach could subject us to litigation, loss of intellectual property rights, or regulatory review and

sanctions and may impact our reputation and our collaboration partners’ ability to further develop and commercialize our

products and product candidates, any of which could have a material adverse effect on our business, financial condition,

results of operations and the market price of our ADSs.

Artificial intelligence-based software is increasingly being used in the biopharmaceutical and global healthcare

industries. We have expanded our scientific focus to use data science and artificial intelligence to aid in the discovery of

new targets and biomarkers and bolster our in-depth precision medicine and translational laboratory capabilities. As with

many developing technologies, artificial intelligence-based software presents risks and attack surfaces. If the analyses that

artificial intelligence-based applications assist in producing are deficient or inaccurate, we could be subjected to

competitive harm, potential legal liability and brand or reputational harm. Furthermore, use of artificial intelligence-based

software may lead to the release of confidential information which may impact our ability to realize the benefits of our

intellectual property. The integration of artificial technology into our and our vendors’ systems (potentially without the

vendor disclosing such use to us) subjects us to the risk that the providers of artificial technology may not meet existing or

rapidly evolving regulatory or industry standards with respect to privacy and data protection. Further, regulatory changes or

reinterpretations could introduce new compliance risks, including potential government enforcement actions or civil

lawsuits.

Climate change or legal, regulatory or market measures to address climate change may negatively affect

our financial condition and business operations.

Climate change may negatively affect our business, results, and value chain. Our primary exposure relates to physical

and transition risks such as natural or man-made disasters, extreme weather conditions such as hurricanes, tornadoes,

earthquakes, wildfires or flooding, or regulatory changes that could disrupt production or increase costs. Physical risks may

cause damage, delays, or reduced material availability across our limited number of third-party manufacturers for our

product supply, while evolving climate regulations and carbon-related requirements may lead to higher compliance and

energy costs across the value chain. These combined factors could negatively affect our operations, product development,

and long-term resilience.

Environmental, social and governance (“ESG”) matters may impact Genmab’s business, operations, and reputation.

Some investors, customers, and other stakeholders are increasingly focused on issues such as climate change, health

and safety, human rights and responsible supply chain practices. At the same time, sentiment that is critical of certain ESG

practices has gained momentum across the US, with several proposed or enacted “anti-ESG” policies, legislation, or

initiatives, and the US federal administration has issued an executive order opposing diversity, equity and inclusion

initiatives in the private sector. Evolving requirements—such as the EU Corporate Sustainability Reporting Directive and

emerging climate disclosure rules—may lead to higher compliance, reporting, and assurance costs. As Genmab’s

manufacturing is limited to a number of third-party manufacturers for our product supply, we also depend on third parties

to manage ESG risks in their own operations. Our ESG goals and commitments require investment and carry uncertainties.

Failure, or perceived failure, to meet these goals and commitments or to align with evolving, and sometimes conflicting,

laws, regulations, policies and administrative, investor and other stakeholder views could result in reputational harm,

increased scrutiny from investors or proxy advisors, reduced talent attraction and retention, and other adverse effects on our

business and results of operations.

23

Table of Contents

Our business depends on our ability to recruit and retain talented and highly skilled employees.

Our success depends on the ability to attract, develop, and retain highly skilled and diverse talent across scientific,

technical, and leadership roles. Competition for qualified professionals in the biotechnology industry is intense, as we

compete with global pharmaceutical and biotech companies, academic institutions, and other organizations for experienced

personnel. Our ability to achieve strategic objectives relies on maintaining a strong, purpose-driven culture, competitive

compensation, and opportunities for professional growth. Failure to attract or retain key talent could negatively affect

Genmab’s ability to advance its pipeline, meet operational goals, and deliver long-term value.

Risks Related to Our Intellectual Property

Our ability to compete may decline if we or our collaboration partners are unable to or do not adequately protect

intellectual property rights or if our intellectual property rights are inadequate.

Our commercial success and viability depend in part on our and our collaboration partners’ ability to obtain and

maintain adequate intellectual property protection in the US, Europe and other countries with respect to our existing

products, product candidates and processes and related technologies owned by us and to successfully defend these rights

against third-party challenges, successfully enforce these rights to prevent third-party infringement, as well as our ability to

maintain adequate intellectual property protection for any future technologies and products. If we or our collaboration

partners do not adequately protect our intellectual property, competitors may be able to use our technologies or products

and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect

our position in the marketplace, limit our ability to commercialize our products and product candidates and significantly

reduce our revenues and potential profits.

While we rely on a combination of patents, trademarks and trade secret protection, as well as nondisclosure,

confidentiality and other contractual agreements to protect the intellectual property related to our brands, products, product

candidates and proprietary technologies, our strategy and future prospects are based, in particular, on our patent portfolio.

The uncertainties with respect to the legal system in the US, Europe and other countries, including uncertainties regarding

the enforcement of laws, and sudden or unexpected changes in laws and regulations with little advance notice, or policies

and practices that weaken the intellectual property framework (such as laws or regulations that promote or provide broad

discretion to issue a compulsory license) could adversely affect us and limit the legal protections available to us. We and

our collaboration partners or licensees will best be able to protect our technologies, products and product candidates and

their uses from unauthorized use by third parties to the extent that valid and enforceable patents, effectively protected trade

secrets, or other regulatory exclusivities, cover them. However, the process of obtaining patent protection is expensive and

time-consuming, and we may not be able to prosecute all necessary or desirable patent applications at a reasonable cost or

in a timely manner.

The patent position and other intellectual property rights of biopharmaceutical companies involve complex legal,

administrative and factual questions, and the issuance, scope, validity and enforceability of patents cannot be predicted

with certainty. Also, intellectual property rights have limitations and do not necessarily address all potential threats to our

competitive advantage. Our and our collaboration partners’ ability to obtain patent protection for our or their technologies,

products and product candidates is uncertain, and the degree of future protection afforded by such intellectual property

rights is uncertain due to a number of factors, including, but not limited to:

• we or our collaboration partners may not have been the first to make or file patent applications for the

inventions covered by pending patent applications or issued patents;

• others may independently develop identical, similar or alternative technologies, products or compositions and

uses thereof;

• any or all of our or our collaboration partners’ pending, or any future patent applications may not result in

issued patents;

• any patents issued to us or our collaboration partners may not provide a basis for commercially viable

products, or may not provide any competitive advantages in countries of significant business opportunity;

24

Table of Contents

• third parties may initiate interference, re-examination, post-grant review, inter partes review, or derivation

actions in the US Patent and Trademark Office (“ USPTO ”), or oppositions in the European Patent Office

(“ EPO ”), or observations or protests, or any similar actions in other patent administrative or court

proceedings worldwide that challenge the validity, enforceability or scope of such patents, which may result

in our patent claims being narrowed or invalidated which could limit our ability to prevent competitors from

developing and marketing similar products;

• our or our collaboration partners’ technologies, compositions and methods may not be patentable;

• others may design around our or our collaboration partners’ patent claims to produce competitive products or

uses which fall outside of the scope of our patents;

• third parties may have blocking patents that could prevent us from marketing our products or practicing our

own patented technology;

• patent terms may be inadequate to protect our competitive position on our technologies, products and product

candidates for an adequate amount of time;

• the Supreme Court of the US, other US federal courts, Congress, the USPTO or similar foreign authorities

may change the standards of patentability and any such changes could narrow or invalidate, or change the

scope of, or change the patent lifetime of, our or our collaboration partners’ patents; and

• the USPTO and various foreign governmental patent agencies require compliance with a number of

procedural, documentary, fee payment, and other similar provisions during the patent application process. In

addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent

agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment

of a late fee or by other means in accordance with the applicable rules, there are situations in which

noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or

complete loss of patent rights in the relevant jurisdiction.

Patent applications may be denied or issued patents covering our products and product candidates could be found

invalid or unenforceable.

Even if patents do successfully issue and even if such patents cover our technologies, products, product candidates,

compositions and methods of use, third parties may initiate interference, re-examination, post-grant review, inter partes

review, or derivation actions in the USPTO, third-party oppositions at the EPO or observations or protests, or similar

actions challenging the validity, enforceability or scope of such patents in other patent administrative proceedings

worldwide, which may result in our or our collaboration partners’ patent claims being narrowed or invalidated. Such

proceedings could result in revocation or amendment of such patents in such a way that they no longer cover our

technologies, product candidates or competitive products. Further, if we or our collaboration partners initiate legal

proceedings against a third-party to enforce a patent covering our product, product candidate or technology, the defendant

could counterclaim that the patent covering our product, product candidate or technology is invalid or unenforceable. In

patent litigation in the US, certain European and other countries worldwide, it is commonplace for defendants to make

counterclaims alleging invalidity and unenforceability in the same proceeding, or to commence parallel defensive

proceedings such as patent nullity actions to challenge validity and enforceability of asserted patent claims. Such

proceedings could result in revocation or amendment of such patents in such a way that they no longer cover our

technologies, product candidates or competitive products.

We currently rely on proprietary technology licensed from third parties and may rely on other third-party licensors in

the future. If we lose our existing licenses or are unable to acquire or license additional proprietary rights from these

licensors or other third parties, we may not be able to continue developing and commercializing our products.

We currently in-license certain technology and intellectual property from third parties to be able to use such

technology and intellectual property in our products and product candidates and to aid in our research activities. In the

future we may in-license technology and intellectual property from additional licensors.

25

Table of Contents

We rely on certain of these licensors to file and prosecute patent applications and maintain patents and otherwise

protect the technology and intellectual property we license from them. We have limited control over these activities or any

other technology and intellectual property that may be related to our in-licensed intellectual property. For example, we

cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws

and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control

over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual

property rights or defend certain of the technology and intellectual property that is licensed to us.

The growth of our business may depend in part on our ability to acquire or in-license additional proprietary rights. We

may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or

important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable

terms, if at all, which would harm our business. We may need to proceed without making use of the technologies,

compositions or methods covered by such third-party intellectual property rights and may need to attempt to develop

alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and

development delays, even if we were able to develop such alternatives, which may not be feasible at a reasonable cost or at

all. The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that

may be more established, or have greater resources or greater clinical or commercialization capabilities than we do, may

also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or

attractive in order to commercialize our product candidates, products and related proprietary technologies. Furthermore,

companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to

obtain a license under third-party intellectual property rights, any such license may be non-exclusive, which may allow our

competitors to access the same technologies licensed to us. If we are unable to successfully obtain rights to additional

technologies or products, our business, financial condition, results of operations and prospects for growth could suffer.

Our existing in-licenses impose various diligence, milestone payment, royalty and other obligations on us. If we fail to

comply with these obligations or otherwise materially breach a license agreement, our licensors or collaboration partners

may have the right to terminate the license. Under the terms of some of the relevant agreements, our collaboration partners

also have the right to terminate the agreements at their discretion. In the event of termination of any of these agreements,

we may not be able to develop or market the products covered by such licensed intellectual property. In addition, any

claims asserted against us by our licensors may be costly and time-consuming, divert the attention of key personnel from

business operations or otherwise have a material adverse effect on our business.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property.

Competitors may infringe our patents, trademarks or other intellectual property. To counter infringement or

unauthorized use, we may be required to file infringement claims on a country-by-country basis, which can be expensive

and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert

against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their

patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent

infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or

in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that,

even if the validity of such patents is upheld, the court will construe the patent’s claims narrowly or decide that we do not

have the right to stop the other party from continuing its activities on the grounds that our patent claims do not cover these

activities. An adverse outcome in a litigation or proceeding involving one or more of our patents could limit our ability to

assert those patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties

from making and selling similar or competitive products, which could materially harm our business and negatively affect

sales of our products. Similarly, if we assert trademark or trade name infringement claims, a court may determine that the

trademarks or trade names we have asserted are invalid or unenforceable, or that the party against whom we have asserted

infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such

trademarks or trade names, which we may need in order to build name recognition with potential collaboration partners or

customers in our markets of interest, thus this could materially harm our business and negatively affect our position in the

marketplace.

Further, even if we prevail against an infringer in a US district court or foreign trial-level court, there is always the risk

that the infringer will file an appeal and the initial court judgment will be overturned at the appeals court and/or that an

adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse

26

Table of Contents

result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted in a

manner insufficient to achieve our business objectives.

Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity

and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the

substantial amount of discovery required in connection with intellectual property litigation in certain territories, there is a

risk that some of our confidential information could be compromised by disclosure during litigation. There could also be

public announcements of the results of hearings, motions or other interim proceedings or developments, which securities

analysts or investors could perceive to be negative. Moreover, there can be no assurance that we will have sufficient

financial or other resources to file and pursue such infringement claims, which typically last for years before they are

concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the

attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.

Claims that our products or product candidates or their uses infringe the intellectual property rights of third parties

could result in the need for third-party licenses with royalty payments or costly litigation with unfavorable outcomes.

Even if we or our collaboration partners have or obtain patents covering our technologies, products, product

candidates, compositions or uses, we or our collaboration partners may still be barred from making, using, importing or

selling or otherwise exploiting our products, product candidates or technologies because of the patent rights of others. Our

competitors have filed, and in the future may file, patent applications covering technology, compositions or products and

uses that are similar or identical to ours. There are many issued US, European and other worldwide patents relating to

therapeutic drugs, and some of these may relate to compounds we or our collaboration partners intend to commercialize.

Numerous worldwide patents and pending patent applications owned by others exist in the cancer field and may cover

products or product candidates which we or our collaboration partners are developing. It is difficult for industry

participants, including us, to identify all third-party patent rights relevant to our products, product candidates and

technologies. We cannot guarantee that our technologies, products, product candidates, compositions and their uses do not

or will not infringe third-party patents or other intellectual property rights. Because patent applications usually take

18 months to publish and many years to issue, there may be currently pending applications with patent claims unknown to

us or which will change over time and may later result in issued patents that purportedly cover our technologies, products,

product candidates or compositions and uses. These patent applications may have been filed earlier than or have priority

over patent applications filed by us or our collaboration partners. We may be required to develop or obtain alternative

technologies, review product design or, in the case of claims concerning registered trademarks, rename our products or

product candidates.

Claims that our or our collaboration part ners’ technologies, products, product candidates, compositions or their uses

infringe or interfere with the patent rights of third parties, or that we, our employees, our consultants or our collaboration

partners have misappropriated third-party trade secrets, are being brought from time to time and can result in costly

litigation and could require substantial time and money to resolve, even if litigation is avoided. When we, our employees,

our consultants or our collaboration partners face infringement claims or challenges by third parties, an adverse outcome

could subject us or our collaboration partners to significant liabilities to such third parties. Litigation or threatened litigation

could result in significant demands on the time and attention of our management team. A negative outcome could expose

us or our collaboration partners to payment of costs, damages and other financial remedies, including in some jurisdictions,

increased damages, such as treble damages and attorneys’ fees, if we were found to have willfully infringed a patent, and

equitable remedies such as restraining orders or injunctions. Litigation with third parties concerning alleged infringement

of their intellectual property rights could require us and our collaboration partners to bear substantial costs and impose

burdens on our and their management and personnel, even if we or our collaboration partners were to ultimately succeed in

such proceedings. Costs of patent litigation and awards of damages in patent infringement cases can be significant, and

equitable remedies such as temporary restraining orders and injunctions can negatively impact or prevent product

development and commercialization. A negative outcome could also lead us or our collaboration partners to delay, curtail

or cease the development and commercialization of some or all of our products and product candidates, or could cause us

or our collaboration partners to seek legal or administrative actions against third parties. We or our collaboration partners

may need to obtain licenses from third parties and such licenses may not be available on commercially reasonable terms, or

at all. Even if we are able to obtain licenses from a third-party to resolve a dispute, such settlement arrangements could

involve substantial costs including one-time and/or ongoing royalty payments.

27

Table of Contents

We may be unable to protect the confidentiality of our trade secrets and know-how.

In addition to seeking patent protection for our products and product candidates, we also rely on trade secrets,

including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We

seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who

have access to them, such as our employees, collaboration partners, consultants, advisors, vendors, university and/or

institutional researchers and other third parties. We also have entered or seek to enter into confidentiality and invention or

patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may

breach the agreements and disclose our proprietary information, including our trade secrets, and once disclosed we may

lose trade secret protection. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we

do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not

be able to obtain adequate remedies for such breaches. Our trade secrets may also be obtained by third parties by other

means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or

misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable and may be

inadequate. In addition, some courts inside and outside the US are less willing or unwilling to protect trade secrets.

Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would

have no right to prevent them, or those to whom they communicate it, from using that technology or information to

compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor, our

competitive position would be harmed.

We will not seek to protect our intellectual property rights or technologies in all jurisdictions throughout the world, and

we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek

protection.

Obtaining and maintaining a patent portfolio entails significant expense and resources. Filing, prosecuting and

defending patents on our technologies, products and product candidates in all countries and jurisdictions throughout the

world would be prohibitively expensive and, therefore, we typically elect to seek protections in certain jurisdictions only.

We may choose not to pursue or maintain protection for particular inventions, products or product candidates. In addition,

there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent

process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent

rights in the relevant jurisdiction. If we choose to forego patent protection or allow a patent application or patent to lapse

purposefully or inadvertently, our competitive position could suffer, and our contractual royalty rates on sales of wholly- or

partially-partnered products in the relevant jurisdictions may be reduced. Competitors may use our technologies in

jurisdictions where we do not pursue and obtain patent protection to develop their own products in a manner that exploits

our technologies and, further, may export otherwise infringing products to territories where we have patent protection, but

enforcement is not as strong as that in the US or in Europe, and thus such protection may not be sufficient to prevent or

stop infringing activities.

The requirements for patentability may differ from country to country, particularly in developing countries, and the

breadth of patent claims allowed can be inconsistent. In addition, the legal systems of some countries, particularly

developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those

relating to biopharmaceuticals or biotechnologies. This could make it difficult for us to stop the infringement of our patents

or the misappropriation of our other intellectual property rights. Also, many foreign countries have compulsory licensing

laws under which a patent owner must grant licenses to third parties if the patents are not being exploited within a certain

time period. In addition, many countries limit the enforceability of patents against third parties, including government

agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must

ultimately be sought on a country-by-country or region-by-region basis, which is an expensive and time-consuming process

with uncertain outcomes. If we fail to timely file a patent application in a specific country or major market, we may be

precluded from doing so at a later date.

In addition, changes in the law and legal decisions by courts in the US, Europe and foreign countries may affect our

ability to obtain or maintain adequate protection for our technologies, products, product candidates or compositions or uses

thereof and the enforcement of intellectual property, and may apply retroactively to affect the term and/or scope of our

patents. Additionally, the legal systems of certain countries, particularly China and certain other countries, may not protect

patents, trade secrets and other intellectual property to the same extent or in the same manner as the laws of the US,

particularly those relating to medical devices and biopharmaceutical and biotechnology products, which could make it

difficult for us to prevent or stop the infringement of our patents or other violations of our proprietary rights generally.

28

Table of Contents

Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. We

have written agreements with our collaboration partners that provide for the ownership of intellectual property arising from

our collaborations. In some instances, there may not be adequate written provisions to address clearly the resolution of

intellectual property rights that may arise from collaboration. Disputes may arise with respect to ownership of the

intellectual property developed pursuant to such collaborations. In addition, we may face claims by third parties that our

agreements with employees, contractors or consultants obligating them to assign intellectual property to us are ineffective,

or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes

regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial

value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we

may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property.

Either outcome could have an adverse impact on our business, financial condition, results of operations and future growth

prospects.

Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a

significant commercial advantage from the intellectual property that we develop or license.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition.

Our registered or unregistered trademarks and trade names may be challenged, infringed, circumvented or declared

generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and

trade names, which we need to build name recognition among potential collaboration partners or customers in our markets

of interest. If we do not own or control trademarks associated with our products, product candidates or technologies, we

may not be in control of defending against any claims brought against those trademarks. At times, competitors may adopt

trademarks and trade names similar to ours, thereby impeding our ability to build brand identity and possibly leading to

market confusion. In addition, there could be potential trademark infringement claims brought by owners of other

registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. Over the long

term, if we are unable to establish name recognition based on our trademarks, then we may not be able to compete

effectively, and our business may be adversely affected.

In addition, any proprietary name we propose to use with any of our product candidates in the US or other jurisdictions

must be approved by the FDA, the EMA or other governmental authorities, regardless of whether we have registered, or

applied to register, the proposed proprietary name as a trademark. The FDA typically conducts a review of proposed

product names, including an evaluation of potential confusion with other product names. If the FDA objects to any of our

proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify

a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of

third parties and be acceptable to the FDA.

Risks Related to Government Regulation

Government restrictions on pricing and reimbursement, as well as other healthcare payer cost-containment initiatives,

may negatively impact our ability to generate revenue.

Sales of certain of our products and our product candidates, if and when approved for marketing, have and will

depend, in part, on the extent to which our products will be covered by third-party payers, such as US government health

care programs like Medicare and Medicaid, commercial insurance and managed healthcare organizations. These third-party

payers play an important role in determining the extent to which new drugs, biologics and medical devices will be covered.

The Medicare and Medicaid programs increasingly are used as models for how private payers and other governmental

payers develop their coverage and reimbursement policies for drugs, biologics and medical devices. It is difficult to predict

at this time what third-party payers will decide with respect to coverage and reimbursement for our product candidates.

Further, the adoption and implementation of any future governmental cost containment or other health reform initiative

may result in additional downward pressure on the price that we may receive for any approved product. Outside the US,

international operations are generally subject to extensive governmental price controls and other market regulations.

Therefore, the reimbursement for our products may be reduced compared with the US and may be insufficient to generate

commercially reasonable revenue and profits. Adoption of price controls, cost containment measures, and adoption of more

restrictive policies in jurisdictions with existing controls and measures could limit our net revenue and results.

29

Table of Contents

Further, from time to time, typically on an annual basis, payment rates are updated and revised by third-party payers.

Such updates could impact the demand for our products, to the extent that patients who are prescribed our products, if

approved, are not separately reimbursed for the cost of the product.

In addition, in certain jurisdictions, marketing approval for a product, or the ability to launch an approved product, is

subject to determination of pricing and reimbursement levels. In such jurisdictions, even if we or our collaboration partners

are able to obtain marketing approval for our products, commercialization of our products may be significantly delayed or

prevented altogether if we are unable to secure reimbursement for our products, at competitive levels or at all.

Moreover, increasing efforts by governmental and third-party payers in the US and abroad to cap or reduce healthcare

costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and,

as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing

pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the

increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on

healthcare costs in general, particularly prescription drugs, medical devices and surgical procedures and other treatments,

has become very intense. As a result, increasingly high barriers are being erected to the successful commercialization of

new products.

In addition, any products we or our collaboration partners are able to commercialize may be subject to competition

from lower-priced imports of those same products, leading to reduced revenues and lower sales margins, as well as lower-

priced imports of competing products from countries with government price controls or other market dynamics that, in

each case, reduce prices of products.

Even if approved, our products will be subject to extensive post-approval regulation, which may result in significant

additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions

and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or

experience unanticipated problems with our products.

Once a product is approved, the manufacturing processes, labeling, packaging, distribution, adverse event reporting,

storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory

requirements. For US approvals, the holder of an approved Biologics License Application (“ BLA ”) is subject to periodic

and other FDA monitoring and reporting obligations, including obligations to monitor and report adverse events and

instances of the failure of a product to meet the specifications in the BLA. In addition, the FDA strictly regulates the

promotional claims that may be made about pharmaceutical products. In particular, a product may not be promoted for uses

that are not approved by the FDA as reflected in the product’s approved labeling. Application holders must also submit

advertising and other promotional material to the FDA and report on ongoing clinical trials.

Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal

and state laws. In addition, we or our collaboration partners may be subject to significant liability if physicians prescribe

any of our products to patients in a manner that is inconsistent with the approved label and if we are found to have

promoted off-label uses of such products. The FDA has also requested that companies enter into consent decrees or

permanent injunctions under which specified promotional conduct is changed or curtailed. Manufacturing facilities remain

subject to FDA inspection and must continue to adhere to the FDA’s cGMP requirements. Application holders must obtain

FDA approval for product and manufacturing changes, depending on the nature of the change. In addition, any regulatory

approvals that we or our collaboration partners receive for our product candidates may also be subject to limitations on the

approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements

for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and

efficacy of the product candidate.

Sales, marketing, patient support, and scientific/educational grant programs in the US must comply with the US

Medicare-Medicaid Anti-Fraud and Abuse Act, as amended, the False Claims Act, also as amended, the federal Anti-

Kickback Statute, the Federal Food, Drug and Cosmetic Act, and similar state laws. Pricing and rebate programs must

comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the

Veteran’s Health Care Act, as amended. If products are made available to authorized users of the Federal Supply Schedule

of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially

subject to federal and state consumer protection and unfair competition laws.

30

Table of Contents

Within the EU, once a marketing authorization is obtained, numerous post-approval requirements also apply. The

requirements are promulgated by both EU regulations (such as reporting of adverse events, etc.) as well as national

applicable regulations (related to, for example, prices and promotional material). In addition, as part of its marketing

authorization process, the EMA may grant marketing authorizations on the basis of less complete data than is normally

required, when, for certain categories of medicinal products, doing so may meet unmet medical needs of patients and serve

the interest of public health. In such cases, it is possible for the Committee for Medicinal Products for Human Use

(“ CHMP ”), to recommend the granting of a marketing authorization, subject to certain specific obligations to be reviewed

annually, which is referred to as a conditional marketing authorization. This may apply to medicinal products for human

use that fall under the jurisdiction of the EMA, including those that target the treatment, prevention, or medical diagnosis of

seriously debilitating diseases or life-threatening diseases and those designated as orphan medicinal products. The granting

of a conditional marketing authorization is restricted to situations in which only the clinical part of the application is not yet

fully complete. Incomplete non-clinical or quality data may only be accepted if duly justified and only in the case of a

product intended to be used in emergency situations in response to public-health threats. Conditional marketing

authorizations are valid for one year, on a renewable basis. The holder will be required to complete ongoing trials or to

conduct new trials with a view to confirming that the benefit-risk balance is positive. In addition, specific obligations may

be imposed in relation to the collection of pharmacovigilance data. Although we may seek a conditional marketing

authorization for one or more of our product candidates by the EMA, the EMA or CHMP may ultimately not agree that the

requirements for such conditional marketing authorization have been satisfied.

Other jurisdictions also impose certain post-approval requirements or may grant conditional marketing approvals.

Depending on the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines

or other penalties, injunctions, notices or warning letters, recall or seizure of products, total or partial suspension of

production or changes to manufacturing processes, denial or withdrawal of pre-marketing product approvals, import

controls, or refusal to allow us to enter into supply contracts, including government contracts, each of which could have a

significant impact on our business, financial condition, results of operations, future growth prospects and reputation. In

addition, even if we and our collaboration partners comply with FDA, EMA and other applicable requirements, new

information regarding the safety or effectiveness of a product could lead the FDA, the EMA or other regulatory authorities

to modify or withdraw a product approval. Any government investigation of alleged violations of law could also require us

or our collaboration partners to expend significant time and resources in response and could generate negative publicity.

Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our and our

collaboration partners’ ability to commercialize and generate revenue from our products. If regulatory sanctions are applied

or if regulatory approval is withdrawn, the value of our company and our operating results could be adversely affected.

A rapidly evolving legal, regulatory and policy landscape may have an adverse impact on our business.

Existing regulatory policies may change and additional government regulations may be enacted that could prevent,

limit or delay regulatory approval of our products and product candidates. We cannot predict the likelihood, nature or

extent of government regulation that may arise from future legislation or administrative action, either in the US, the EU or

in other countries. If we or our collaboration partners are slow or unable to adapt to changes in existing requirements or the

adoption of new requirements or policies, or if we and our collaboration partners are not able to maintain regulatory

compliance, we or they may lose any marketing approval that we or they may have obtained, which could adversely impact

our business and financial results.

The Inflation Reduction Act of 2022 (“ IRA ”) was signed into law on August 16, 2022. The IRA, among other things,

(i) allows the US Department of Health and Human Services (“ HHS ”) to negotiate prices for certain single-source drugs

and biologics covered under Medicare Part B and Part D, and subjects drug manufacturers to civil monetary penalties and a

potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the

negotiated “maximum fair price” under the law; and (ii) establishes rebates under Medicare to penalize drug price increases

that outpace inflation. Negotiations were conducted with ten high-cost drugs, none of which was DARZALEX, paid for by

Medicare Part D, and the negotiated prices will take effect in 2026. The effect of the IRA on the biopharmaceutical

industry is uncertain, and the IRA could have a material effect on our business and results of operations in the future.

In the US there is continued focus by the US federal and state governments on regulating or otherwise decreasing drug

prices. This includes efforts to establish international reference pricing, including Most-Favored-Nation ( “MFN” ) drug

pricing. On May 12, 2025, the US President issued an executive order “Delivering Most- Favored-Nation Prescription

Drug Pricing to American Patients,” directing executive agencies to take steps to facilitate MFN pricing for prescription

drugs in the US. The Secretary of HHS subsequently announced on May 20, 2025, that it communicated to manufacturers

31

Table of Contents

MFN pricing targets which apply to brand drugs and biologics without generic or biosimilar competition, using the lowest

prices observed in a set of economic peer countries (commonly described as OECD countries meeting a GDP-per-capita

threshold). Manufacturers are expected to make “significant progress” toward meeting these targets. If they fail to do so,

then other actions are to be pursued, including proposing rules to implement MFN pricing, working with Congress to allow

for expanded drug importation, exploring FDA drug approval reforms, increased antitrust enforcement and review of drug

export practices. The order also calls on the Secretary of Commerce and the US Trade Representative to address foreign

pricing practices that may harm US interests, including suppressing drug prices abroad and shifting the global research

burden to American consumers. Additionally, the order directs HHS to support direct-to-consumer sales at MFN prices,

seeking to bypass intermediaries in the current US drug supply chain. On July 31, 2025, the White House sent letters to 17

pharmaceutical manufacturers, which included Genmab collaboration partners AbbVie, J&J, Novartis and Pfizer, outlining

specific steps, including offering MFN prices to all Medicaid patients, committing not to offer better prices to other

developed nations for new drugs than prices offered in the US, and participating in direct-to-consumer or direct-to-business

models at MFN prices. The US administration recently announced voluntary MFN agreements with Pfizer and

AstraZeneca, signaling potential expectations for other manufacturers to follow. These actions demonstrate the growing

interest in aggressive policies to lower drug prices, which could adversely affect the prices of products that we or our

collaboration partners sell, and thereby our revenues and profits.

Our and our partners’ activities in certain non-US countries may also be subject to or affected by various US

legislation, executive orders, regulations, or investigations targeting certain development or economic activities involving

those countries. This includes, but is not limited to, the proposed BIOSECURE Act, which could increase costs, reduce the

supply of available materials, delay procurement or clinical trials, hinder our ability to secure significant government

commitments for potential therapies, and adversely affect our financial condition and business prospects.

In June 2024, the US Supreme Court overruled the Chevron doctrine, which gave deference to regulatory agencies’

statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous.

This landmark Supreme Court decision may invite more companies and other stakeholders to bring lawsuits against the

FDA to challenge longstanding decisions and policies of the FDA, including FDA’s statutory interpretations of market

exclusivities and the “substantial evidence” requirements for drug approvals, which could undermine the FDA’s authority,

lead to uncertainties in the industry, and disrupt the FDA’s normal operations, any of which could delay the FDA’s review

of our regulatory submissions. We cannot predict the full impact of this decision, future judicial challenges brought against

the FDA, or the nature or extent of government regulation that may arise from future legislation or administrative action.

Further, disruptions at the FDA and other government agencies may slow the time required for new drugs to be

reviewed and approved, which could adversely affect our business. For example, over the last several years the US

government has shut down several times, and certain regulatory agencies, including the FDA, have had to furlough

employees and suspend certain activities. The current administration’s freeze on hiring and new return-to-office policy may

disrupt normal operations of federal agencies, including the FDA. Future government shutdowns or other disruptions could

significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory

submissions, or to provide feedback on our clinical development plans, which could have a material adverse effect on our

business. Further, future government shutdowns or other disruptions to normal operations could impact our ability to

access the public markets and obtain the funding necessary to properly capitalize and continue our operations.

We are subject to various laws protecting the privacy, security and confidentiality of certain information and failure to

comply with these data ethics and privacy regulations could adversely affect our business and reputation.

We operate in an environment that relies on the collection, processing, analysis, and interpretation of large sets of

patients’ and other individuals’ personal data, including from our employees and third parties with whom we conduct

business. Numerous countries in which we, our collaboration partners and our third-party contractors, including CROs and

CMOs, operate, manufacture and sell our products have, or are developing, laws protecting personal data and the

individual’s right to privacy and security as well as the transparent and responsible processing of certain personal data and

patient health information.

The legal and regulatory environment of data privacy is diversified, with regional legislation such as the General Data

Protection Regulation in Europe, the Personal Information Protection Law enacted in 2021 and Regulations on the

Administration of Human Genetic Resources of the PRC in China, and other significant privacy legislation, including the

California Consumer Privacy Act and other similar comprehensive state data privacy laws in the US. As the framework

continues to evolve, uncertainty remains due to the absence of clear guidance or case law. This uncertainty, combined with

32

Table of Contents

limited global harmonization or simplification, makes it challenging for multinational companies to standardize their

approach to privacy and data protection compliance.

Increases in the volume of data processed and advances in technology have resulted in greater focus on data privacy

and the ethical use of personal data, over and above data privacy laws. Companies seeking to foster innovation in artificial

intelligence and other new technologies are faced with evolving decisions from global policymakers on how best to

promote trust in these systems and avoid unintended outcomes or harmful impacts. Failure in our data privacy and ethical

use of personal data could affect our business and reputation.

Additionally, there are several emerging laws concerning the localization of data, restrictions on international transfers,

and data security, which are changing the existing frameworks with which we previously complied. The increasing trend

for data sovereignty affects our ability to drive medical innovation and to effectively operate internationally. Regulatory

uncertainty could result in an operational risk limiting or preventing the transfer of personal data across borders, which may

have an impact on our activities (e.g. clinical trials). Breach of the regulations described above could also carry financial

sanctions, may cause us to become subject to audits, inquiries, whistleblower complaints, adverse media coverage,

investigations, criminal or civil sanctions, damage our reputation and adversely affect our business operations, including, in

particular, our activities that rely on personal data processing.

Our activities, and our business arrangements w ith third parties, are subject to fraud, abuse and oth er healthcare laws

and regulations.

Healthcare providers, such as physicians and others, play a primary role in the recommendation and prescription of our

products. Our or our collaboration partners’ arrangements with such persons and third-party payers and our general

business operations expose us or our collaboration partners to broadly applicable fraud and abuse regulations, as well as

other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through

which we research, market, sell and distribute our products. Restrictions under applicable US federal and state and non-US

healthcare laws and regulations include, but are not limited to, the Anti-Kickback Statute, the Beneficiary Inducement

Statute, the HIPAA federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False

Claims Act, the federal transparency requirements under the Physician Payments Sunshine Act and analogous US state

laws. Rules and regulations covering many of the same matters are found in numerous other countries, including in

Denmark, and may be more stringent or result in higher exposures than those in the US.

Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will

likely continue to be time-consuming and costly. It is possible that governmental authorities will conclude that our business

practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or

other healthcare laws and regulations, in which case we may be subject to significant civil, criminal and administrative

penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from government funded healthcare

programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings

and curtailment of our operations, any of which could substantially disrupt our business. For more information about these

and other applicable regulations, see ‘‘ Item 4 – Information on the Company —Government Regulation ’’ below.

Enhanced scrutiny of pharmaceutical manufacturer donations to and support of patient assistance programs offered by

charitable foundations may affect us or our collaboration partners.

To help patients afford our products, we and our collaboration partners have implemented, and may implement or

further expand in the future, patient assistance programs. We or our collaboration partners also occasionally make

donations to independent charitable foundations that help financially needy patients. These types of programs designed to

assist patients in affording pharmaceuticals have become the subject of scrutiny. In recent years, some pharmaceutical

manufacturers were named in class action lawsuits challenging the legality of their patient assistance programs and support

of independent charitable patient support foundations under a variety of US federal and state laws. At least one insurer also

has directed its network pharmacies to no longer accept manufacturer co-payment coupons for certain specialty drugs the

insurer identified. Our collaboration partners’ or own patient assistance programs and support of independent charitable

foundations could become the target of similar litigation.

In addition, there has been regulatory review and enhanced government scrutiny of donations by pharmaceutical

companies to patient assistance programs operated by charitable foundations. If we, our collaboration partners or our

vendors or donation recipients are deemed to fail to comply with laws or regulations in the operation of these programs, we

33

Table of Contents

or such collaboration partner could be subject to damages, fines, penalties or other criminal, civil or administrative

sanctions or enforcement actions. Further, numerous organizations, including pharmaceutical manufacturers, have received

subpoenas from government authorities seeking information related to their patient assistance programs and support. We

cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our

collaboration partners, employees, business partners or vendors that may violate the laws or regulations of the jurisdictions

in which we operate. Regardless of whether we have complied with the law, a government investigation could negatively

impact our business practices, harm our reputation, divert the attention of management and increase our expenses.

Our operations involve hazardous materials and we and third parties with whom we contract must comply with

environmental laws and regulations.

We are subject to environmental and safety laws and regulations, including those governing the use of hazardous

materials, and the cost of compliance is substantial. Our business activities involve the controlled storage, use and disposal

of hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at

our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of accidental

contamination or injury from these materials in our manufacturing process. We cannot guarantee that the safety procedures

utilized by our collaboration partners and by third-party manufacturers and suppliers with whom we may contract will

comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or

injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could

exceed our resources. In addition, European, US federal and state or other applicable authorities may curtail our use of

certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex,

change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be

certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. In the event

of an accident or environmental discharge, we may be held liable for any consequential damage and any resulting claims

for damages, face an interruption of our commercialization efforts, research and development efforts and business

operations, and cause environmental damage resulting in costly clean-up and liabilities under applicable laws and

regulations governing the use, storage, handling and disposal of these materials and specified waste products, which may

exceed our financial resources and may materially adversely affect our business, financial condition, results of operations

and future growth prospects and the value of our ADSs.

Risks Related to Our Ordinary Shares, ADSs and Foreign Private Issuer Status

If we lose our foreign private issuer status in the future, we would incur signific ant additional costs and expenses.

As a foreign private issuer, we are not required to comply with all the periodic disclosure and current reporting

requirements of the Exchange Act and related rules and regulations. We currently qualify as a foreign private issuer, and

will continue to qualify as a foreign private issuer until, as of June 30 of our most recent fiscal year, (i) more than 50% of

our shares are directly or indirectly owned of record by US residents, and (ii) either (x) the majority of our executive

officers or directors are US citizens or residents, (y) more than 50% of our assets are located in the US, or (z) our business

is administered principally in the US. We estimate that as of the latest determination date, approximately 36% of our

outstanding shares, or 23.0 million shares, were beneficially held by US residents.

Our foreign private issuer status will next be determined as of June 30, 2026 . There can be no assurance that we will

not lose our foreign private issuer status in the future.

The regulatory and compliance costs to us under US securities laws if we lose our foreign private issuer status would

be significantly more than the costs we incur as a foreign private issuer, and we would need to devote significantly more

financial, management and other resources to compliance with US securities laws than we currently do, particularly in the

year in which we lose our foreign private issuer status. If we lose our foreign private issuer status, we would be required to

report as a US domestic issuer and be subject to other US securities laws applicable to US domestic issuers. For example,

as a US domestic issuer, we would be required to file periodic reports and registration statements with the SEC on US

domestic issuer forms, which are more detailed and extensive in certain respects than the forms available to us as a foreign

private issuer. We would also be required to prepare our financial statements in accordance with US GAAP and modify

certain of our policies to comply with corporate governance practices applicable to US domestic issuers. In addition, we

may lose our ability to rely upon exemptions from certain corporate governance requirements on US stock exchanges that

are available to foreign private issuers, which could also increase our costs.

34

Table of Contents

ADS holders do not directly hold our shares, and may not be able to exercise their right to vote the shares underlying

their ADSs.

Holders of our ADSs are not treated as our shareholders and do not have shareholder rights. Our depositary, JPMorgan

Chase Bank, N.A., is the holder of the shares underlying our ADSs. The deposit agreement among us, the depositary, and

all other persons directly and indirectly holding ADSs, sets out ADS holder rights as well as the rights and obligations of

the depositary.

Accordingly, ADS holders may only exercise voting rights with respect to the shares underlying their respective ADSs

in accordance with the provisions of the deposit agreement and not as a direct shareholder of the Company. In order to vote

the shares underlying their ADSs, ADS holders may either withdraw the shares underlying their ADSs or instruct the

depositary to vote the shares underlying such ADSs. However, holders may not know about the meeting sufficiently far

enough in advance to withdraw the underlying shares and, even if they instruct the depositary to vote the shares underlying

their ADSs, Genmab cannot guarantee ADS holders that the depositary will vote in accordance with their instructions.

The depositary will try, as far as practicable, to vote the shares underlying the ADSs as instructed by the ADS holders.

In such an instance, if we ask for holders’ instructions, the depositary, upon timely notice from us, will notify holders of the

upcoming vote and arrange to deliver our voting materials to holders. We cannot guarantee that holders will receive the

voting materials in time to ensure that holders will be able to instruct the depositary to vote their shares or to withdraw their

shares so that they can vote such shares themselves. If the depositary does not receive timely voting instructions from

holders, it may give a proxy to a person designated by us to vote the shares underlying their ADSs. Voting instructions may

be given only in respect of a number of ADSs representing an integral number of shares or other deposited securities. In

addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of

carrying out voting instructions. This means that holders may not be able to exercise any right to vote that they may have

with respect to the underlying shares, and there may be nothing they can do if the shares underlying their ADSs are not

voted as they requested. In addition, the depositary is only required to notify holders of any particular vote if it receives

timely notice from us in advance of the scheduled meeting. Our articles of association permit, in the case of general

meetings, notice to be delivered within a relatively short time span, in which case the depositary would not be required to

provide holders with notice of and access to such vote.

ADS holders’ right to receive any dividends that Genmab declares on the shares are more limited than if they were

holding shares.

ADS holders’ right to receive any dividends that Genmab declares on its shares, whether in the form of cash or bonus

securities, are more limited than that of Genmab’s shareholders. For example, Genmab may elect to offer subscription

rights to its shareholders without offering such rights directly to ADS holders as such subscription rights will be offered to

the depositary as shareholder. The depositary has substantial discretion as to what will happen with any offered

subscription rights and may determine that it is not legal or practicable to make such rights available to ADS holders, in

which case it will make such a distribution as it deems permissible and practicable, or it may retain and hold some or all

property to be distributed as deposited securities, without liability for interest thereon or the investment thereof. In the case

of a distribution by Genmab of securities or property other than cash or subscription rights, the depositary may either (i)

distribute such securities or property in any manner it deems equitable and practicable or (ii) to the extent the depositary

deems distribution of such securities or property not to be equitable and practicable, sell such securities or property and

distribute any net proceeds in the same way it distributes cash. If the depositary is unable to distribute or sell any securities

or property distributed by Genmab on the shares, they will lapse, and ADS holders will receive no value. See Exhibit 2.3

“Description of Securities of the Registrant” to this Annual Report on Form 20-F.

ADS holders may be subject to limitations on their ability to cancel their ADSs and withdraw the underlying shares.

Holders’ ADSs, which will be evidenced by American depositary receipts (“ ADRs ”), are transferable on the books of

the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in

connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs

generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is

advisable to do so because of any requirement of law, government or governmental body, or under any provision of the

deposit agreement, or for any other reason subject to holders’ right to cancel their ADSs and withdraw the underlying

shares. Temporary delays in the cancellation of ADSs and withdrawal of the underlying shares may arise due to the

35

Table of Contents

depositary closing its transfer books or the closing of our share register. In addition, holders may not be able to cancel their

ADSs and withdraw the underlying shares when they owe money for fees, taxes and similar charges and when it is

necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to

the withdrawal of shares or other deposited securities. For more information, see the description of our securities registered

under Section 12 of the Exchange Act included as an exhibit to this Annual Report on Form 20-F.

By holding or owning an ADR or ADS or an interest therein, holders and beneficial owners each irrevocably agree that

any legal suit, action or proceeding against or involving the depositary and/or us brought by holders or beneficial owners,

arising out of or based upon the deposit agreement, the ADSs or the transactions contemplated therein or thereby,

including, without limitation, claims under the Securities Act, may be instituted only in the United States District Court for

the Southern District of New York (or in the state courts of New York County in New York if either (i) the United States

District Court for the Southern District of New York lacks subject matter jurisdiction over a particular dispute or (ii) the

designation of the United States District Court for the Southern District of New York as the exclusive forum for any

particular dispute is, or becomes, invalid, illegal or unenforceable).

Further, the federal or state courts in the City of New York have non-exclusive jurisdiction to hear and determine

claims brought by the depositary and/or us against or involving holders or beneficial owners arising out of or based upon

the deposit agreement.

ADS holders and beneficial owners, to the fullest extent permitted by the law, waive their right to a jury trial of any

claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit

agreement, including any claim under the US federal securities laws.

If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver

was enforceable based on the facts and circumstances of that case in accordance with the applicable US state and federal

law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising

under the US federal securities laws has not been finally adjudicated by the US Supreme Court. However, we believe that a

contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New

York, which govern the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver

provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury

trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that potential

holders consult legal counsel regarding the jury waiver provision before investing in the ADSs.

As a result of the jury trial waiver, if any holders or beneficial owners of ADSs bring a claim against us or the

depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under US federal

securities laws, a holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have

the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or

the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which

would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would

have had, including results that could be less favorable to the plaintiff(s) in any such action.

Nevertheless, if this jury trial waiver provision is not enforced, to the extent a court action proceeds, it would proceed

under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement

or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any

substantive provision of, or a disclaimer of liability under, the US federal securities laws and the rules and regulations

promulgated thereunder.

If securities or industry analysts publish inaccurate or unfavorable research about our business, the price of the ADSs

and their trading volume could decline.

The trading market for the ADSs and shares will depend in part on the research and reports that securities or industry

analysts publish about us or our business. If one or more of the analysts who covers us downgrades our equity securities,

publishes inaccurate or unfavorable research about our business or expresses a negative opinion regarding the performance

of our securities, or if our clinical trial results or operating performance fail to meet analyst expectations, the price of the

ADSs would likely decline. If one or more of these analysts fails to publish reports on us regularly, or downgrades our

securities, demand for ADSs could decrease, which could cause the price of the ADSs and their trading volume to decline.

36

Table of Contents

Claims of US civil liabilities may not be enforceable against us.

We are incorporated under the laws of Denmark. Although our wholly owned subsidiary, Genmab US, Inc., has an

office and laboratory space in the US, substantially all of our assets are located outside the US. Some of our directors and

Executive Management reside outside the US. As a result, it may not be possible to effect service of process within the US

upon such persons or to enforce judgments against them or us in US courts, including judgments predicated upon the civil

liability provisions of the US securities laws.

The US and Denmark currently do not have a treaty providing for the reciprocal recognition and enforcement of

judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment

given by a US court, whether or not predicated solely upon US securities laws, would not be enforceable in Denmark. In

order to obtain a judgment that is enforceable in Denmark, the party in whose favor a final and conclusive judgment of the

US court has been rendered will be required to file its claim again with a court of competent jurisdiction in Denmark. The

Danish court will not be bound by the judgment by the US court, but the judgment may be submitted as evidence. It is up

to the Danish court to assess the judgment by the US court and decide if and to what extent the judgment should be

followed. Danish courts are likely to deny claims for punitive damages and may grant a reduced amount of damages

compared to US courts.

Based on the lack of a treaty as described above, US investors may not be able to enforce any judgments obtained in

US courts in civil and commercial matters, including judgments under the US federal securities laws, against us or

members of our Board of Directors or our Executive Management, or certain experts named herein who are residents of

Denmark or countries other than the US.

We are a “foreign private issuer,” as defined in the SEC’s rules and regulations, and, consequently, we are not subject

to all of the disclosure and corporate governance requirements applicable to public companies organized within the US.

We are a “foreign private issuer,” as defined in the SEC’s rules and regulations, and, consequently, we are not subject

to all of the disclosure requirements applicable to public companies organized within the US. For example, we are exempt

from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the

solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the

US proxy rules under Section 14 of the Exchange Act. In addition, our directors and Executive Management are exempt

from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and related rules with

respect to their purchases and sales of our securities, although they may become subject to the reporting provisions in

March of 2026 absent a timely SEC exemption. Moreover, while we currently publish annual and quarterly reports on our

website pursuant to the rules of Nasdaq Copenhagen and expect to file such financial reports on an annual and quarterly

basis with the SEC, we are not required to file such reports with the SEC as frequently or as promptly as US public

companies and are not required to file quarterly reports on Form 10-Q or current reports on Form 8-K that a US domestic

company would be required to file under the Exchange Act. Accordingly, there may be less publicly available information

concerning our company than there would be if we were not a foreign private issuer. In addition, as a foreign private issuer

and as permitted by the listing requirements of the Nasdaq Stock Market LLC (“ Nasdaq ”), we will comply with certain

home country corporate governance practices rather than the corporate governance requirements of the Nasdaq Stock

Market.

Risks Related to Tax Matters

If we are a passive foreign investment company for US federal income tax purposes for any taxable year, US holders of

our ADSs could be subject to adverse US federal income tax consequences.

A non-US corporation will be a passi ve foreign investment company (“ PFIC ”) for US federal income tax purposes for

any taxable year if either (i) at least 75% of its gross income for such taxable year is “passive income” (as defined in the

relevant provisions of the US Internal Revenue Code of 1986, as amended (“ Code ”) or (ii) at least 50% of the value of its

assets (generally, based on an average of the quarterly values of the assets) during such year is attributable to assets that

produce or are held for the production of passive income. Based on the current and anticipated value of our assets and the

nature and composition of our income and assets, we do not expect to be a PFIC for US federal income tax purposes for

our current taxable year ending December 31, 2025, nor do we expect to be one in the foreseeable future. However, the

determination of whether we are a PFIC or not according to the PFIC rules is made on an annual basis and will depend on

the nature and composition of our income and assets and the value of our assets from time to time. Therefore, changes in

37

Table of Contents

the nature and composition of our income or assets or the value of our assets may cause us to become a PFIC. The

determination of the value of our assets (including goodwill not reflected on our balance sheet) may be based, in part, on

the total market value of our shares and ADSs, which is subject to change and may be volatile.

If we are a PFIC for any taxable year during which a US person holds ADSs, certain adverse US federal income tax

consequences could apply to such US person. See “Item 10.E—Taxation—Material US Federal Income Tax

Considerations—Passive Foreign Investment Company Considerations.”

Changes in Danish, Dutch, US or other foreign tax laws or compliance requirements, or the practical interpretation and

administration thereof, could have a material adverse effect on our business, financial condition and results of

operations.

We are affected by various Danish, Dutch, US, Chinese, Japanese and other foreign taxes, including direct and indirect

taxes imposed on our global activities, such as corporate income, withholding, customs, excise/energy, value added, sales,

environmental and other taxes. Significant judgment is required in determining our provisions for taxes and there are many

transactions and calculations where the ultimate tax determination is uncertain.

Changes in Danish or foreign direct or indirect tax laws or compliance requirements, including the practical

interpretation and administration thereof, including in respect to market practices, or otherwise, could have a material

adverse effect on our business, financial condition, results of operations and future growth prospects.

Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in

unanticipated costs, taxes or non-realization of expected benefits.

A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. As

the tax landscape is evolving and our business model is evolving, Danish, Dutch, US, Chinese, Japanese, or another tax

authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our subsidiaries

pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our

intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where

we believe we have not established a taxable connection, often referred to as a “permanent establishment” under

international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more

jurisdictions. A tax authority may take the position that material income tax liabilities, interest and penalties are payable by

us, in which case, we expect that we might contest such an assessment. Contesting such an assessment may be lengthy and

costly, and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective

tax rate.

Risks Related to the Acquisition of Merus

We may not realize the anticipated benefits from the acquisition of Merus.

The success of the acquisition of Merus will depend, in part, on our ability to realize the anticipated benefits from

successfully combining our and Merus' businesses. We plan on devoting substantial management attention and resources to

integrating our and Merus' businesses so that we can fully realize the anticipated benefits of the acquisition of Merus.

Nonetheless, the acquired Merus business, including petosemtamab, may not be successful, may require greater resources

and investments than originally anticipated or may result in the assumption of unknown or contingent liabilities, which

could have an adverse effect on us or our results of operations.

Potential difficulties we may encounter include the following:

• the inability to successfully combine our and Merus' businesses in a manner that permits us to realize the

anticipated benefits of the acquisition of Merus in the timeframe currently anticipated, or at all;

• the failure to integrate internal systems, programs and internal controls, or applying different accounting policies,

assumptions or judgments to Merus' operational results than Merus applied in the past;

• effectively and efficiently integrating IT and other systems;

38

Table of Contents

• issues not discovered as part of the transactional due diligence process or unanticipated liabilities or contingencies

of Merus, including employment or severance-related obligations under applicable law or other benefits

arrangements, claims by or amounts owed to vendors or other commercial disputes, cyber incidents and IT failures

or delays, matters related to data privacy, data localization and the handling of personally identifiable information,

and other unknown or contingent liabilities;

• preserving the important licensing, marketing, and other commercial relationships of Merus;

• the complexities associated with managing the combined company;

• the failure to retain key employees of either of the two companies who may be difficult to replace;

• the disruption of each company's ongoing businesses or inconsistencies in services, standards, controls,

procedures and policies;

• potential unknown liabilities associated with the acquisition of Merus; and

• performance shortfalls at one or both of the two companies as a result of the diversion of management's attention

caused by integrating our and Merus' operations.

Any of these risks could adversely affect our ability to maintain relationships with collaboration partners, vendors,

employees and other commercial relationships or adversely affect our or Merus' future operational results. As a result, the

anticipated benefits of the acquisition of Merus may not be realized or at all or may take longer to realize or cost more than

expected, which could adversely affect our business, financial condition, results of operations and growth prospects.

Genmab's ability to realize the anticipated benefits of the acquisition of Merus will depend on its ability to effectively

conduct clinical development of, obtain regulatory approvals for, and profitably commercialize, petosemtamab. We may

fail to realize the anticipated benefits of the acquisition of Merus if we are unable to successfully develop, obtain

regulatory approval for, and commercialize petosemtamab on the currently anticipated timeline, for all of the currently

anticipated therapeutic indications, or at all .

While petosemtamab delivered positive data in certain HNSCC indications in prior Phase I/II trials, there is no

assurance that the currently ongoing Phase III trials will ultimately demonstrate the efficacy of petosemtamab in those

indications at a level that will be sufficient to obtain regulatory approval. A number of companies in the pharmaceutical,

biopharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials even after

obtaining promising results in earlier trials, and we cannot be certain that we will not face similar setbacks with

petosemtamab.

In addition, while petosemtamab has received BTD from the FDA with respect to two HNSCC indications, this

designation does not assure ultimate approval by the FDA. BTD is a process designed to expedite the development and

review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may

demonstrate substantial improvement over available therapy on a clinically significant endpoint. Drugs that receive BTD

are eligible for certain procedural benefits as part of the FDA review process, including more frequent meetings with FDA

staff to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval,

more frequent written communication from FDA staff, rolling review of BLA or NDA submissions, intensive guidance on

an efficient drug development program, and organizational commitment involving senior managers. BTD does not,

however, change the scientific and medical standard for approval or the quality of evidence necessary to support approval.

As a result, applications for product candidates granted expedited review or BTD designation may be ultimately denied

based on trial data, trial design or other factors.

Furthermore, even though the available data from petosemtamab Phase I/II trials in certain HNSCC indications may

seem stronger in certain respects than data for certain alternative therapies, there is no completed head-to-head trial that

actually compared the safety and efficacy of petosemtamab with any alternative therapy as part of the same investigational

setting. Separate clinical trials for alternative therapies may differ in trial design and duration, patient population, treatment

protocols and investigators and other important factors, making it difficult to compare data across trials or to draw reliable

39

Table of Contents

conclusions from such cross-trial comparisons. It is possible that petosemtamab may turn out not to be superior to

alternative therapies in the currently ongoing Phase III trials in HNSCC.

Even if we can successfully progress the clinical development of petosemtamab and obtain the anticipated marketing

approvals, we may not be able to commercialize it on the currently anticipated timeline or at all, to realize its expected

revenue potential, or obtain additional financing, if needed, to fund the commercialization. For more information about the

risks involved in clinical development, regulatory approval and commercialization of new products generally, please see “

– Risks Related to Product Development.” Our ability to realize petosemtamab's potential is also subject to all of the other

risks affecting our business described in this “Risk Factors” section.

Risks Related to Our Indebtedness

Our substantial indebtedness could adversely affect our financial condition.

We have incurred substantial indebtedness which could have a negative impact on our financing options and liquidity

position. Our indebtedness requires us to dedicate a portion of our cash flow to service interest and principal payments and,

if interest rates rise, this amount may increase. The high degree of our debt leverage could have significant consequences,

including the following:

• making it more difficult for us to satisfy our debt obligations;

• limiting our ability to obtain additional financing in the future for working capital, capital expenditures,

acquisitions or other general corporate purposes;

• requiring a substantial portion of our cash flows to be dedicated to debt service payments, instead of other

purposes, thereby reducing the amount of cash flows available for working capital, capital expenditures,

acquisitions and other general corporate purposes;

• limiting our ability to refinance our indebtedness on terms acceptable to us or at all;

• imposing restrictive covenants on our operations;

• placing us at a competitive disadvantage to other, less leveraged competitors; and

• making us more vulnerable to economic downturns and limiting our ability to withstand competitive pressures.

Any of these risks could materially impact our ability to fund our operations or limit our ability to expand our

business, which could have a material adverse effect on our business, financial condition and results of operations.

The terms of the agreements governing our indebtedness may restrict our current and future operations, particularly

our ability to respond to changes or to pursue our business strategies, and could adversely affect our capital resources,

financial condition and liquidity .

The indentures governing our outstanding notes and our credit agreement contain a number of restrictive covenants

that impose significant operating and financial restrictions on us and may limit our ability to engage in acts that may be in

our long-term best interests, including, among other things, restrictions on our ability to:

• incur, assume or guarantee additional indebtedness;

• declare or pay dividends or make other distributions with respect to, or purchase or otherwise acquire or retire for

value, equity interests;

• make any principal payment on, or redeem or repurchase, subordinated debt;

• make loans, advances or other investments;

40

Table of Contents

• incur liens;

• sell or otherwise dispose of assets, including capital stock of subsidiaries;

• enter into sale and lease-back transactions;

• consolidate or merge with or into, or sell all or substantially all of the assets of the Issuers to, another person; and

• enter into transactions with affiliates.

In addition, our credit agreement requires us to comply with certain financial maintenance covenants. Our ability to

satisfy these financial maintenance covenants can be affected by events beyond our control and we cannot provide

assurance that we will meet them.

A breach of the covenants under the credit agreement and the indentures governing our outst anding notes could result

in an event of default under the applicable indebtedness, which, if not cured or waived, could result in us having to repay

our borrowings before their due dates. Any such default may allow the holders to accelerate the related debt and may result

in the acceleration of any other debt to which a cross-acceleration or cross-default provision applies. If we are forced to

refinance these borrowings on less favorable terms or if we experience difficulty refinancing the debt prior to maturity, our

results of operations or financial condition could be materially affected. In addition, an event of default under our credit

agreement may permit the lenders to terminate all commitments to extend further credit. Furthermore, if we are unable to

repay the amounts due and payable under our credit agreement or our outstanding notes, the lenders or holders of our

outstanding notes may be able to proceed against the collateral granted to them to secure that indebtedness . In the event

lenders or holders of our outstanding notes accelerate the repayment of such borro wings, we cannot assure you that we will

have sufficient assets to repay such indebtedness.

ITEM 4 INFORMATION ON THE COMPANY

A. History and Development of the Company

We were incorporated on June 11, 1998, as a private limited liability company (“ Anpartsselskab ”, or “ ApS ”) under

Danish law as a shelf company and are registered with the Danish Business Authority (Erhvervsstyrelsen) in Copenhagen,

Denmark under registration number (CVR) no. 21023884. Our name was changed to Genmab ApS on November 17, 1998,

and we commenced operations in February 1999. On May 31, 1999, we were converted into a public limited liability

company (“ Aktieselskab ”, or “ A/S ”) and changed our name to Genmab A/S.

Our shares are listed on Nasdaq Copenhagen under the symbol “GMAB.” Our ADSs are listed on the Nasdaq in the

US under the symbol “GMAB.”

Legal name:	Genmab A/S
Commercial name:	Genmab
Domicile:	Carl Jacobsens Vej 30, 2500 Valby, Denmark
Tel:	+45 70 20 27 28
Website:	www.genmab.com
	(The contents of this website are not incorporated by reference into this Annual Report on Form 20-F.)
Date of incorporation:	June 11, 1998
Legal form of the Company:	A Danish public limited liability company
Legislation under which the Company operates:	Danish law
Country of incorporation:	Denmark

41

Table of Contents

The SEC maintains an internet site at www.sec.gov that contains reports, proxy and information statements, and other

information regarding issuers that file electronically with the SEC.

For a description of our acquisition of Merus N.V. (" Merus ") please refer to “Item 5.A—Operating Results .”

B. Business Overview

Overview

We are an international biotechnology company with a pipeline of novel antibody-based products and product

candidates designed to address medical needs and improve treatment outcomes for patients with cancer and other serious

diseases. Our goal in building our pipeline is to bring medicines to market ourselves in geographic areas where we believe

we will be able to maximize their value and make a meaningful impact on the treatment landscape.

Our current priorities are the commercial or late-stage programs epcoritamab, Rina-S and petosemtamab. Epcoritamab,

marketed as EPKINLY in countries including the US and Japan and as TEPKINLY in the EU, is being developed and

commercialized in collaboration with AbbVie. Epcoritamab is the first and only bispecific antibody approved for the

treatment of multiple B-cell malignancies in various regions around the world . Rina-S and petosemtamab are wholly

owned by Genmab. Rina-S is in Phase III clinical development for platinum-resistant ovarian cancer (“ PROC ”), platinum-

sensitive ovarian cancer (" PSOC ") and endometrial cancer. Petosemtamab is in Phase III clinical development for newly

diagnosed and recurrent/metastatic (" r/m ") head and neck squamous cell carcinoma (" HNSCC ").

Our full pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function

enhanced antibodies and ADCs. We currently have five proprietary products or product candidates in active clinical

development, which comprise programs where we retain at least 50% of product rights in collaboration with partners. Our

first proprietary commercial product to be approved wastisotumab vedotin, marketed as Tivdak. Tivdak is being co-

developed globally and co-promoted in the US in collaboration with Pfizer and exclusively by Genmab outside of the US

and China. Tivdak is the first and only ADC approved for the treatment of adult patients with recurrent or metastatic

cervical cancer with disease progression on or after prior systemic therapy in territories including the US, Europe and

Japan. In addition to our marketed products and clinical product candidates, we have multiple proprietary and partnered

preclinical programs.

In addition to Genmab’s own pipeline of product candidates, our innovation and proprietary technology platforms are

applied in the pipelines of global pharmaceutical and biotechnology companies. These companies are running clinical

development programs with antibodies created by Genmab or created using Genmab’s proprietary DuoBody bispecific

antibody technology platform. The six approved medicines created by Genmab or that incorporate Genmab’s innovation or

technology platforms are daratumumab, marketed by J&J as DARZALEX (intravenous (“ IV ”) formulation) and

DARZALEX FASPRO or DARZALEX SC (SC formulation), approved in the US, Europe, Japan and other territories for

the treatment of certain indications of MM and light chain AL ; amivantamab, marketed in the US, Europe, Japan and

other territories by J&J as RYBREVANT for the treatment of certain adult patients with locally-advanced or metastatic

Non-Small Cell Lung Cancer (“ NSCLC ”) with epidermal growth factor receptor (“ EGFR ”) exon 20 insertion mutations

and also RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), an SC formulation approved in the US;

teclistamab, marketed in the US, Europe, Japan and other territories by J&J as TECVAYLI for certain indications of MM;

talquetamab, marketed in the US, Europe, Japan and other territories by J&J as TALVEY for certain indications of MM;

SC ofatumumab, marketed in the US, Europe, Japan and other territories as Kesimpta by Novartis for the treatment of

relapsing multiple sclerosis (“ RMS ”); and teprotumumab, marketed in the US, Europe and Japan as TEPEZZA by Amgen

for the treatment of thyroid eye disease (“ TED ”). In addition BIZENGRI (Z enocutuumab-zbco ) was added to our portfolio

of royalty medicines as part of our acquisition of Merus. Merus exclusively licensed to Partner Therapeutics Inc. (" P artner

Therapeutics ") the right to commercialize BIZENGRI for the treatment of Neuregulin 1 (" NRG1 ") fusion-positive cancer

in the US. Under the agreements for these products Genmab is entitled to certain potential milestones and royalties.

Our portfolio includes multiple proprietary antibody technology platforms: our DuoBody platform, which can be used

for the creation and development of bispecific antibodies; our HexaBody platform, which can be used to increase the

potential potency of antibodies through hexamerization; our DuoHexaBody platform, which enhances the potential potency

of bispecific antibodies through hexamerization; our HexElect platform, which combines two HexaBody molecules to

42

Table of Contents

maximize potential potency while minimizing potential toxicity by more selective binding to desired target cells; and our

ADC platforms, which we acquired through the purchase of ProfoundBio in May 2024. We gained additional proprietary

technology platforms as part of our acquisition of Merus. Antibody products created with these technologies may be used

in a wide variety of indications including cancer as well as autoimmune, central nervous system and infectious diseases.

These platforms play a key role in building our product pipeline, enhancing our collaborations and generating revenue. We

selectively enter into collaborations with other biotechnology and pharmaceutical companies that build our network in the

biotechnology space and give us access to complementary novel technologies or products that move us closer to achieving

our vision and fulfilling our core purpose.

Our Business Strategy

Key elements of our strategy to achieve our vision and fulfill our core purpose include:

• Actively advance and expand our proprietary product pipeline. We are actively advancing our promising

proprietary product candidates, and specifically our commercial or late-stage programs epcoritamab, Rina-S, and

petosemtamab through development and commercialization.

• Grow our commercialization capabilities. We are continuing to develop and expand our commercialization

capabilities to allow us to bring our own products to market for the indications and in the geographies we

determine would create value for patients and our shareholders. Our initial focus for commercialization is in the

US and in Japan, with the commercialization of Tivdak and EPKINLY. More recently, we have expanded our

commercial footprint to the EU.

• Strengthen our product portfolio with strategic collaborations and potential acquisitions. We enter into strategic

product and technology collaborations to build our network in the biotechnology space, to strengthen our portfolio

with complementary technologies or products and seek to expand our proprietary product pipeline by developing

new products in-house and through selective collaborations. We monitor for potential collaborations and

acquisitions that would advance our overall strategy, such as the 2025 acquisition of Merus.

• Leverage our proprietary technology platforms. Our leading proprietary antibody technology platforms play a

key role in building our product pipeline, enhancing our collaborations and generating revenue. Multiple new

product candidates are currently being developed by us and our collaboration partners using our technology

platforms, including proprietary product candidates created with our DuoBody, HexaBody and ADC technologies.

We actively seek collaboration partners interested in developing potential antibody therapeutics using our

technologies.

• Leverage recurring revenue streams from collaborations. There are six medicines on the market, developed and

commercialized by partners, that were created by Genmab or created using our DuoBody technology. Under the

agreements for these medicines, Genmab is entitled to certain royalties and potential milestone payments.

Originally, this strategy allowed us to bring our innovative products to the market and create a stable revenue

stream. Over time, it has allowed us to build and expand our own proprietary pipeline.

Our Products and Product Candidates

All late-stage ≥50% Genmab-owned medicines or product candidates in ongoing clinical development are discussed

below.

The following charts summarize the disease indications and most advanced development status of medicines or

product candidates in development by Genmab or by collaborators who are leveraging Genmab’s innovation and

technology as of December 31, 2025.

Approved Medicines

43

Table of Contents

Approved Product	Target	Developed By	Disease Indication 1
EPKINLY (epcoritamab-bysp, epcoritamab) TEPKINLY (epcoritamab)	CD3xCD20	Co-development Genmab/AbbVie	Approved in territories including the US and Europe for adult patients with relapsed/refractory (“ R/R ”) diffuse large B-cell lymphoma (" DLBCL ") after two or more lines of systemic therapy and in Japan for adult patients with certain types of R/R large B-cell lymphoma (" LBCL ") after two or more lines of systemic therapy
			Approved in territories including the US, Europe and Japan for adult patients with R/R follicular lymphoma (" FL ") after two or more lines of systemic therapy Approved in the US in combination with rituximab and lenalidomide (" R 2 ") for the treatment of adult patients with relapsed or refractory FL
Tivdak (tisotumab vedotin-tftv, tisotumab vedotin)	Tissue factor (“ TF ”)	Co-development Genmab/Pfizer	Approved in territories including the US, Europe and Japan for adult patients with recurrent/metastatic cervical cancer with disease progression on or after prior systemic therapy

1 Refer to relevant local prescribing information for precise indication and safety information.

44

Table of Contents

Pipeline in Active Clinical Development, Including Further Development for Approved Medicines

Product	Developed By	Target(s)	Technology	Disease Indications
				Pre- clinical	1	2	3
Epcoritamab	Co- development Genmab / AbbVie	CD3, CD20	DuoBody	Relapsed/refractory DLBCL
				Relapsed/refractory FL
				First line DLBCL
				First line FL
				B-cell non-Hodgkin lymphoma ( "NHL" )
				Relapsed/refractory chronic lymphocytic leukemia ( "CLL" ) & Richter's Syndrome
				Aggressive mature B-cell neoplasms in pediatric patients
Rinatabart Sesutecan (Rina-S, GEN1184)	Genmab	Folate receptor alpha (" FRα ")	ADC	PROC
				Endometrial cancer
				PSOC
				NSCLC
				Solid tumors
Petosemtamab	Genmab	EGFR, leucine-rich repeat- containing G- protein coupled receptor 5 (" LGR5 ")	Biclonics	r/m HNSCC
				Advanced solid tumors including metastatic colorectal cancer (" mCRC ")
				First line NSCLC with pembrolizumab
GEN1059 (BNT314)	Co- development Genmab / BioNTech	Epithelial cell adhesion molecule (" EpCAM "), 4-1BB	DuoBody	Solid tumors
GEN1057	Genmab	Fibroblast activation protein alpha (" FAPα "), death receptor 4 (" DR4 ")	DuoBody	Malignant solid tumors

In December 2025, f urther development of acasunlimab was discontinued as part of Genmab’s strategic focus on the

most value-creating opportunities in its late-stage portfolio and following a thorough assessment of the evolving

competitive landscape.

Epcoritamab

Epcoritamab is a proprietary bispecific antibody therapeutic created using our proprietary DuoBody technology

platform. Epcoritamab targets CD3, which is expressed on T-cells, and CD20, a clinically validated target on malignant B-

cells. We used technology licensed from Medarex, Inc. (“ Medarex ”) to generate the CD20 antibody forming part of

epcoritamab. We are co-developing, and co-commercializing in the US and Japan, epcoritamab in collaboration with

AbbVie. We and AbbVie have a broad clinical development program for epcoritamab across different treatment settings,

lines of therapy and in combination regimens across histologies, including five ongoing Phase III trials and additional trials

in development. Epcoritamab is marketed as EPKINLY in the US, Japan, and other regions, and as TEPKINLY in Europe

and other regions.

Epcoritamab for the Treatment of B-cell Malignancies

45

Table of Contents

DLBCL is the most common type of NHL worldwide, accounting for approximately 25% - 30% of all NHL cases.

DLBCL is a fast-growing type of NHL that can develop in the lymphatic system as well as in organs outside of the

lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men. [CC1] For many people

living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory,

meaning it does not respond to treatment. Although new therapies have become available, treatment management can

remain a challenge.

FL is typically an indolent or slow-growing form NHL that arises from B-cell lymphocytes and is the second most

common form of NHL, accounting for 20%-30% of all cases. About 15,000 people develop FL each year in the US and it

is considered incurable with current standard of care therapies. Patients often relapse and, with each relapse the remission

and time to next treatment is shorter. Over time, transformation to DLBCL, an aggressive form of NHL associated with

poor survival outcomes, can occur in more than 25% of FL patients. In March 2022, November 2023 and September 2024,

the FDA granted orphan-drug designation and BTDs respectively to epcoritamab for the treatment of FL.

Approvals and Results

3L+ R/R DLBCL . Epcoritamab received accelerated FDA approval in May 2023, as EPKINLY, for the treatment of

adult patients with R/R DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-

grade B-cell lymphoma ( “HGBCL ”), after two or more lines of systemic therapy. EPKINLY was approved under

accelerated approval based on response rate and durability of response. Continued approval for this indication is contingent

upon verification and description of clinical benefit in a confirmatory trial. In June 2023, epcoritamab-bysp was added to

the National Comprehensive Cancer Network (“ NCCN ”) Clinical Practice Guidelines in Oncology for “B-cell

Lymphomas” (Version 4.2023) for third-line and subsequent therapy for patients with DLBCL, including patients with

disease progression after transplant or chimeric antigen receptor (“ CAR-T ”) cell therapy and as a Category 2A, preferred

regimen for patients with histologic transformation of indolent lymphomas to DLBCL and no intention to proceed to

transplant, including patients with disease progression after transplant or CAR-T cell therapy. In February 2025,

epcoritamab-byp was added to the NCCN Clinical Practice Guidelines in Oncology for “B-cell Lymphomas” (Version

2.2025) for second-line patients with DLBCL who are ineligible for transplant as a Category 2A, preferred regimen.

In September 2023, epcoritamab was granted both conditional marketing authorization by the European Commission

and approval by the Japanese Ministry of Health, Labor and Welfare (“ MHLW” ). In Europe, epcoritamab, marketed as

TEPKINLY, was approved as a monotherapy for the treatment of adult patients with R/R DLBCL after two or more lines

of systemic therapy. Similar to the accelerated FDA approval in the US, this marketing authorization is contingent upon

verification and description of clinical benefit in a confirmatory trial. In Japan, epcoritamab, marketed as EPKINLY, was

approved for the treatment of adult patients with certain types of R/R LBCL, including DLBCL, HGBCL, primary

mediastinal LBCL and FLgrade 3B, after two or more lines of systemic therapy.

The approvals were supported by results from the LBCL cohort of the pivotal Phase II EPCORE NHL-1 open-label,

multi-center trial evaluating the safety and preliminary efficacy of epcoritamab in patients with relapsed, progressive or

refractory CD20+ mature NHL, including DLBCL. Approval in Japan was also based on the EPCORE NHL-3 clinical

trial.

In September 2025, updated results from the outpatient Phase II EPCORE NHL-6 trial were presented as a poster at

the 13th Society of Hematologic Oncology Annual Meeting. These results demonstrated the feasibility of treating and

monitoring patients in an outpatient setting following the first dose of epcoritamab and showed that the incidence and

severity of adverse events associated with epcoritamab were consistent with previous epcoritamab studies in patients with

R/R DLBCL.

In January 2026 we announced topline results from the EPCORE DLBCL-1 trial. These results demonstrated an

improvement in PFS (based on intent-to-treat principle) in patients treated with epcoritamab monotherapy. Additionally,

improvements were observed in the complete response rate, duration of response, and time to next treatment among

patients treated with epcoritamab monotherapy. EPCORE DLBCL-1 is the first Phase 3 study to demonstrate an

improvement in PFS in patients with R/R DLBCL who were treated with a CD3xCD20 T-cell engaging bispecific

monotherapy. The study demonstrated an overall survival that did not reach statistical significance.

R/R FL . Epcoritamab also received accelerated FDA approval in June 2024, as EPKINLY, for the treatment of adults

with R/R FL after two or more lines of systemic therapy. With this approval, EPKINLY became the first T-cell engaging

46

Table of Contents

bispecific antibody administered subcutaneously approved in the US to treat this patient population. This indication was

initially approved under accelerated approval based on response rate and was converted to a full approval in November

2025 based on results from a confirmatory clinical trial. In May 2024, epcoritamab-bysp was added to the NCCN Clinical

Practice Guidelines in Oncology for “B-cell Lymphomas” (Version 2.2024) for third-line and subsequent therapy for

patients with FL as a Category 2A preferred regimen. In December 2025, epcoritamab-bysp in combination with R 2 was

added to the NCCN Clinical Practice Guidelines in Oncology for “B-cell Lymphomas” (Version 1.2026) for second-line

therapy for patients with FL as a Category 1 preferred regimen.

In August 2024, epcoritamab was granted conditional marketing authorization by the European Commission as a

monotherapy for the treatment of adult patients with R/R FL after two or more lines of systemic therapy. In January 2025,

epcoritamab was approved in Japan for the same indication.

The approvals were supported by results from the FL cohort of the pivotal Phase II EPCORE NHL-1 trial. Aligned

with the FDA’s Project Optimus, the optimization part of the trial continued to evaluate alternative step-up dosing regimens

to mitigate the risk of CRS; preliminary data on the initial patients enrolled indicate a clinical improvement in CRS rate.

The results from this cohort, along with the results from the optimization part of the trial, were presented during the

American Society of Hematology Annual Meeting in December 2023. The approval in Japan was also supported by data

from the Japanese EPCORE NHL-3 study.

In November 2023, the FDA also granted BTD to epcoritamab in combination with R 2 for the treatment of adult

patients with R/R FL who have received at least two prior lines of therapy. In July 2025, the FDA accepted for priority

review the s upplemental Biologics License Application (“ sBLA ”) for epcoritamab plus R 2 following at least one prior

systemic therapy. The sBLA was approved on November 18, 2025. With this approval, epcoritamab plus R 2 became the

first bispecific antibody combination regimen available in the US as a second-line treatment option for patients with R/R

FL. The approval was based on data from the first interim analysis of the Phase III EPCORE FL-1 trial. Results from the

trial were presented at the American Society of Hematology Annual Meeting in December 2025 and will serve as the basis

for global regulatory submissions.

Ongoing Phase III Trials

Along with our collaboration partner, AbbVie, we are currently evaluating SC epcoritamab for the treatment of B-cell

malignancies including DLBCL and FL in multiple clinical trials . In October 2025, epcoritamab-bysp monotherapy was

added to the NCCN Clinical Practice Guidelines in Oncology for "CLL .Small Lymphcytic Lymphoma” (Version 1.2026)

for Richter's transformation as a Category 2A preferred regimen. More than 40 industry and investigator-sponsored clinical

trials are currently ongoing. In addition to the EPCORE FL-1 and EPCORE DLBCL-1 clinical trials noted above, the

following are the ongoing Phase III trials sponsored by Genmab and AbbVie:

EPCORE DLBCL-2 is a Phase III randomized, open-label trial to evaluate the safety and efficacy of epcoritamab in

combination with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (“ R-CHOP ”)

compared to R-CHOP in patients with newly diagnosed DLBCL. The trial is fully recruited.

EPCORE DLBCL-4 is a Phase III, open-label trial to evaluate the safety and efficacy of epcoritamab in combination

with lenalidomide compared to rituximab plus gemcitabine and oxaliplatin in patients with R/R DLBCL. The trial is fully

recruited.

EPCORE FL-2 is a Phase III, open-label trial to evaluate the safety and efficacy of epcoritamab in combination with

R2 compared to chemoimmunotherapy in patients with previously untreated FL. The trial is currently recruiting.

Tisotumab Vedotin

Tisotumab vedotin is an ADC composed of Genmab’s human monoclonal antibody directed to TF and Pfizer’s ADC

technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl

auristatin E to the antibody. Genmab used technology licensed from Medarex to generate the TF antibody forming part of

tisotumab vedotin. Tisotumab vedotin, marketed as Tivdak, is the first and only ADC approved for the treatment of adult

patients with recurrent or metastatic cervical cancer with disease progression on or after prior systemic therapy in territories

including the US, Europe and Japan. Tisotumab vedotin is being co-developed by Genmab and Pfizer. Under a joint

commercialization agreement, Genmab is co-promoting Tivdak in the US and is leading commercial operational activities

47

Table of Contents

in Japan, Europe and all other regions globally, excluding the US and China. Pfizer is leading commercial operational

activities in the US and will lead commercial operational activities in China once approved in connection with the

sublicense of its rights to develop and commercialize tisotumab vedotin in China to Zai Lab. Genmab will record sales for

Europe, Japan and rest of world markets (excluding the US and China), and will provide royalties in the low teens

percentage-wise to Pfizer on net sales. The companies have joint decision-making on the worldwide development and

commercialization strategy for Tivdak.

Tisotumab vedotin for the Treatment of Cervical Cancer

Cervical cancer remains a disease with high unmet need despite advances in effective vaccination and screening

practices to prevent and diagnose pre-/early-stage cancers for curative treatment. Recurrent and/or metastatic cervical

cancer is a particularly devastating and mostly incurable disease; up to 15% of adults with cervical cancer present with

metastatic disease at diagnosis and, for adults diagnosed at earlier stages who receive treatment, up to 61% will experience

disease recurrence. Cervical cancer is the fourth most common cause of cancer death among women globally.

Approvals and Results

In September 2021, the FDA granted Genmab and Pfizer accelerated approval for tisotumab vedotin-tftv as Tivdak,

the first and only ADC approved for the treatment of adult patients with recurrent or metastatic cervical cancer with disease

progression on or after chemotherapy. Tisotumab vedotin was approved under the FDA’s Accelerated Approval Program

based on tumor response, durability of the response and the safety profile. The initial approval was based on the Phase II

innovaTV 204 single arm trial in 101 patients with recurrent or metastatic cervical cancer who had received no more than

two prior systemic regimens in the recurrent or metastatic setting, including at least one prior platinum-based

chemotherapy regimen. In March 2024, tisotumab vedotin-tftv was added to the NCCN Clinical Practice Guidelines in

Oncology for Vaginal Cancer under ‘Other Recommended Regimens’ as second-line or subsequent systemic therapy for

patients with recurrent or metastatic squamous cell carcinoma/adenocarcinoma primary vaginal cancer.

In April 2024, the FDA granted approval to the sBLA for tisotumab vedotin-tftv for the treatment of patients with

recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the

September 2021 accelerated approval of tisotumab vedotin to a full approval. Tisotumab vedotin is the first ADC with

demonstrated overall survival data to be granted full FDA approval in this patient population. The approval was based on

the Phase III innovaTV 301 (ENGOT cx-12/GOG 3057) confirmatory trial in recurrent or metastatic cervical cancer

patients with disease progression on or after front-line therapy who received tisotumab vedotin, compared with

chemotherapy alone. Also based on these results, regulatory submissions were made in Europe and Japan in 2024. In

December 2024, the US NCCN updated its Clinical Practice Guidelines in Oncology for Cervical Cancer to recommend

tisotumab vedotin-tftv as the only Category 1 preferred option for second-line or subsequent therapy for recurrent or

metastatic cervical cancer. Tisotumab vedotin-tftv plus pembrolizumab was also added as an option for PD-L1 positive

tumors. In March 2025, tisotumab vedotin was granted approval in Japan by the MHLW and marketing authorization in

Europe by the European Commission. In September 2025, Tivdak became available for prescribing in Germany, the first

European country where the medicine is commercially available.

Rina-S

Rina-S, acquired as part of the acquisition of ProfoundBio, is a novel FRα-targeted topoisomerase 1 ADC being

evaluated for the potential treatment of ovarian cancer and other FRα-expressing cancers. Dose expansion data suggests

that Rina-S has robust single agent activity in various cancers across a broad range of FRα expression levels.

Ovarian Cancer . In January 2024, Rina-S was granted FTD by the FDA for the treatment of FRα-expressing high-

grade serous or endometrioid PROC.

In November 2025, development of Rina-S was expanded into PSOC with the initiation of the Phase III RAINFOL-04

trial. This trial will examine Rina-S with or without bevacizumab, versus bevacizumab or observation as maintenance

treatment after second line platinum-based doublet chemotherapy in patients with PSOC.

Endometrial Cancer . In June 2025, we presented initial data from the advanced or recurrent endometrial cancer

monotherapy dose expansion B2 cohort of the multi-part Phase I/II RAINFOL-01 trial evaluating Rina-S at the American

Society of Clinical Oncology annual meeting. In August 2025, the FDA granted BTD to Rina-S for the treatment of adult

48

Table of Contents

patients with recurrent or progressive endometrial cancer who have disease progression on or following prior treatment

with a platinum-containing regimen and a PD-(L)1 therapy.

Other Solid Tumors. The Phase I/II RAINFOL-01 trial of Rina-S in advanced solid tumors that are known to express

FRα is ongoing, and a Phase II Rina-S trial in NSCLC, RAINFOL-05, was initiated at the end of 2025.

Ongoing Phase III Trials

RAINFOL-02 is a randomized open-label trial is evaluating Rina-S versus treatment of investigator’s choice

chemotherapy in patients with PROC. The trial is currently recruiting.

RAINFOL-03 is a randomized, open-label trial is evaluating Rina-S versus treatment of investigator’s choice

chemotherapy in patients with endometrial cancer after platinum-based chemotherapy and PD(L)-1 therapy. The trial is

currently recruiting.

RAINFOL-04 is a randomized, open-label trial is evaluating Rina-S with or without bevacizumab, versus bevacizumab

or observation as maintenance treatment after second line platinum-based doublet chemotherapy in patients with PSOC.

The trial is currently recruiting.

Petosemtamab

Petosemtamab was added to Genmab's portfoli o with the acquisition of Merus. It is an investigational antibody-

dependent cell-mediated cytotoxicity (“ ADCC ”)-enhanced Biclonics for the potential treatment of solid tumors that is

designed to bind to cancer stem cells expressing EGFR and LGR5. EGFR is a member of the human epidermal growth

factor receptor (“ HER ”) family of receptor tyrosine kinases and is important for growth and survival of cancer stem cells,

including those with rat sarcoma mutations, while LGR5 is a wingless-related integration site (“ WNT ”) target gene

expressed in cancer cells with aberrations in the WNT signaling pathway and reported to be up-regulated in a variety of

cancers including HNSCC, gastric cancer, NSCLC, colorectal cancer and hepatocellular carcinoma. Petosemtamab is

designed to exhibit three independent mechanisms of action including inhibition of EGFR-associated signaling, LGR5

binding leading to EGFR internalization and degradation in cancer cells, and enhanced ADCC and antibody-dependent

cellular phagocytosis activity. In November 2025, Merus announced that they had entered a global collaboration and

license agreement with Halozyme to develop a SC formulation of petosemtamab.

In February 2025, the FDA granted BTD for petosemtamab in combination with pembrolizumab for the first-line

treatment of adult patients with r/m PD-L1 positive HNSCC with combined positive score (“ CPS ”) ≥ 1. In May 2024, the

FDA granted BTD for petosemtamab for the treatment of patients with r/m HNSCC whose disease has progressed

following treatment with platinum based chemotherapy and an anti-PD-1 or anti-PD-L1 antibody. This designation

followed receipt of FTD for petosemtamab for the treatment of patients with r/m HNSCC whose disease has progressed

following treatment with platinum-based chemotherapy and an antiprogrammed cell death protein 1 antibody announced in

August 2023.

Initial clinical data on petosemtamab in mCRC, from the Phase II study of other advanced solid tumors, including

mCRC, was presented in October 2025 at the at the AACR-NCI-EORTC International Conference on Molecular Targets

and Cancer Therapeutics. Petosemtamab in combination with chemotherapy regimens leucovorin, 5-Fluorouracil, and

oxaliplatin / leucovorin, 5-Fluorouracil, and irinotecan (“ FOLFIRI ”) and as monotherapy demonstrated promising efficacy

and a well tolerated safety profile in mCRC. In December 2025, a Phase II trial was initiated in adults with metastatic

NSCLC of petosemtamab in combination with pembrolizumab as first line treatment.

Ongoing Phase III Trials

Top line interim readout results are anticipated for LiGeR-HN1, LiGeR-HN2 or both in 2026.

LiGeR-HN1 is a Phase III, randomized, open-label trial to evaluate the safety and efficacy of petosemtamab in

combination with pembrolizumab compared to pembrolizumab in first-line treatment of r/m PD-L1 positive HNSCC. The

trial is currently recruiting.

49

Table of Contents

LiGeR-HN2 is a Phase III, randomized, open-label, controlled, multicenter trial to compare petosemtamab versus

investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable r/m disease. The

trial is currently recruiting.

Royalty Medicines Portfolio 1

Approved Medicines

Approved Product	Discovered and/or Developed & Marketed By	Disease Indication(s) 2
DARZALEX (daratumumab)/ DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)	J&J (Royalties to Genmab on global net sales)	MM
		AL Amyloidosis
RYBREVANT (amivantamab/amivantamab-vmjw)/ RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj)	J&J (Royalties to Genmab on global net sales)	Advanced NSCLC with certain EGFR mutations
TECVAYLI (teclistamab/teclistamab-cqyv)	J&J (Royalties to Genmab on global net sales)	R/R MM
TALVEY (talquetamab/talquetamab-tgvs)	J&J (Royalties to Genmab on global net sales)	R/R MM
Kesimpta (ofatumumab)	Novartis (Royalties to Genmab on global net sales)	Relapsing multiple sclerosis (RMS)
TEPEZZA (teprotumumab-trbw)	Amgen (Under sublicense from Roche, royalties to Genmab on global net sales)	TED
BIZENGRI (zenocutuzumab-zbco)	Partner Therapeutics (part of Genmab's acquisition of Merus, royalties to Genmab on US net sales)	Pancreatic adenocarcinoma and NSCLC that are advanced, unresectable or metastatic and harbor NRG1 gene fusions

1 Approved and investigational medicines under development and where relevant commercialized by a company other than

Genmab for which we receive royalties.

2 See local prescribing information for precise indication and safety information.

Pipeline, Including Further Development for Approved Medicines, ≥ Phase II Development

Product	Technology	Discovered and/or Developed By	Disease Indications — Preclinical
Daratumumab	UltiMAb 1	J&J	MM
			AL Amyloidosis
Teprotumumab	UltiMAb	Amgen	TED
Amivantamab	DuoBody	J&J	NSCLC
			Advanced or metastatic CRC
			r/m HNSCC
Teclistamab	DuoBody	J&J	MM
Talquetamab	DuoBody	J&J	MM
Amlenetug (Lu AF82422)	UltiMAb	Lundbeck	Multiple system atrophy
Mim8 (denecimig)	DuoBody	Novo Nordisk	Hemophilia A

1 UltiMAb transgenic mouse technology licensed from Medarex, a wholly owned subsidiary of Bristol Myers Squibb

Corporation (“ BMS ”).

Daratumumab (DARZALEX)

Daratumumab (marketed as DARZALEX for IV administration and as DARZALEX FASPRO in the US and as

DARZALEX SC in Europe for SC administration) is a human monoclonal antibody that binds with high affinity to the

CD38 molecule, which is highly expressed on the surface of MM cells and is also expressed by AL amyloidosis plasma

cells. Genmab used technology licensed from Medarex to generate the CD38 antibody. Daratumumab is being developed

and commercialized by J&J under an exclusive worldwide license from Genmab to develop, manufacture and

50

Table of Contents

commercialize daratumumab. Daratumumab is approved in a large number of territories for the treatment of adult patients

with certain MM indications. SC daratumumab is the only approved therapy for the treatment of patients with high-risk

smoldering MM, approved in the US and Europe. It is also the only approved therapy in the US, Europe and Japan for the

treatment of adult patients with AL amyloidosis .

Amivantamab (RYBREVANT), Teclistamab (TECVAYLI), Talquetamab (TALVEY)

In July 2012, and as amended in December 2013, Genmab entered into a collaboration with J&J to create and develop

bispecific antibodies using Genmab’s DuoBody technology platform. Three approved therapies were generated from this

agreement, RYBREVANT (amivantamab), TECVAYLI (teclistamab) and TALVEY (talquetamab).

RYBREVANT is approved for the treatment of certain adult patients with NSCLC in certain territories including the

US, Europe, Japan and other territories. RYBREVANT FASPRO is approved in the US. TECVAYLI and TALVEY are

approved for the treatment of certain adult patients with relapsed or refractory MM in certain territories including the US,

Europe, Japan and other territories. J&J is responsible for the development and commercialization of these medicines.

Ofatumumab (Kesimpta)

Ofatumumab is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the

small and large extracellular loops. Genmab used technology licensed from Medarex to generate the CD20 antibody.

Ofatumumab, marketed as Kesimpta, is approved in territories including the US, Europe, Japan and other territories for the

treatment of certain adult patients with RMS. Ofatumumab is the first B-cell therapy that can be self-administered by

patients using the Sensoready autoinjector pen, once monthly after starting therapy. Ofatumumab is being marketed

worldwide by Novartis under a license agreement between Genmab and Novartis.

Teprotumumab (TEPEZZA)

Teprotumumab, marketed as TEPEZZA, is a human monoclonal antibody that targets the Insulin-like Growth Factor 1

Receptor (“ IGF-1R ”), a validated target. It is the first and only medicine approved for the treatment of TED in the US,

Europe and Japan. Genmab used technology licensed from Medarex to generate the IGF-1R antibody. The antibody was

created by Genmab under a collaboration with Roche and development and commercialization of the product is currently

being conducted by Amgen.

Partnered Candidates

Our collaboration partners currently have multiple product candidates in clinical development through collaboration

agreements with us. These include products that are being developed in collaboration with L undbeck, Novo Nordisk and

Partner Therapeutics. In September 2025, Novo Nordisk submitted a BLA to the FDA for Mim8 (denecimig) to prevent or

reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital FVIIIa deficiency),

with or without inhibitors. Denecimig is a bispecific antibody created using our DuoBody technology platform.

Our Technology Platforms

DuoBody Platform

Antibodies are Y-shaped proteins that play a central role in immunity against bacteria and viruses (also known as

pathogens). As we develop immunity, our bodies generate antibodies that bind to pathogen structures (known as antigens),

which are specific to the pathogen. Once bound, the antibodies attract other parts of the immune system to eliminate the

pathogen. In modern medicine, we have learned how to create and develop specific antibodies against antigens associated

with diseased human cells for use in the treatment of diseases such as cancer and autoimmune disease. Genmab uses

several types of technologies to create antibodies to treat disease and has developed proprietary antibody technologies

including the DuoBody, HexaBody, DuoHexaBody and HexElect technology platforms. With our acquisition of

ProfoundBio we gained their novel ADC technology platforms. We also gained a number of proprietary technology

platforms as part of our acquisition of Merus.

We also use or license several other technologies to generate diverse libraries of high-quality, functional antibodies. In

addition, we use or license technologies to increase the potency of some of our antibody therapeutics on a product-by-

51

Table of Contents

product basis. See “—Product and Technology Collaborations—Collaborations and Other Agreements for our Partnered

Products” for more information about our current licenses and collaborations.

Manufacturing

We do not currently manufacture the products that we need to conduct clinical trials, and we therefore rely on our

collaboration partners or CMOs to supply product for our IND-enabling trials, clinical trials and process validation batches

and related activities for BLA and other regulatory submissions, and we expect to rely on such collaboration partners or

CMOs for production of commercial supply of our products in the future. Manufacturing pharmaceutical products is

subject to extensive regulations that impose various procedural and documentation requirements, which govern record

keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our vendors are required

to comply with GMP regulations, which are regulatory requirements enforced by the FDA, the EMA and other regulatory

bodies to assure proper design, monitoring and control of manufacturing processes and facilities for human

pharmaceuticals.

We have no involvement with the manufacturing process for our approved products in development with collaboration

partners, DARZALEX, RYBREVANT, TECVAYLI, and TALVEY, which are handled by J&J; Kesimpta, handled by

Novartis; and TEPEZZA, handled by Amgen, under the applicable agreements. Our partners Pfizer and AbbVie are

responsible for the manufacturing processes for Tivdak and EPKINLY/ TEPKINLY, respectively, under the applicable

agreements.

Currently, the majority of the products required for our clinical trials and preclinical trials are manufactured by a

limited number of CMOs and specific sites at those CMOs. In addition, we rely on other third parties to perform additional

steps in the manufacturing process, as well as analysis, shipping and storage of drug products and our product candidates.

Although we rely on our GMP manufacturers and suppliers, we have personnel with substantial manufacturing and

production experience to oversee our relationships with such manufacturers and suppliers and provide the necessary

technical, quality and regulatory oversight of our CMOs. We have also adopted procedures to promote compliance by our

CMOs with relevant regulatory requirements and internal guidelines with respect to production qualifications, facilities and

processes.

We believe our CMOs are, and any future CMOs will be, capable of producing sufficient quantities of drug products to

support our currently planned commercialization, clinical trials and preclinical trials. We also believe that there are

alternative third-party manufacturers that have similar capabilities that would be capable of providing sufficient quantities

of commercial products and drug products for our planned clinical trials and preclinical trials. However, should our CMOs

not be able to provide sufficient quantities of commercial products or drug product for our planned commercialization,

clinical trials or preclinical trials, we would be required to seek other CMOs to provide this product, potentially resulting in

a delay in such trials or delivery of our commercialized products.

Raw Materials

We currently rely on third-party manufacturers for raw materials. Raw materials are currently available in quantities

adequate to meet the needs of our business. The prices of the raw materials are subject to various service agreements.

While we do not anticipate any significant price volatility, to the extent that we are exposed to price fluctuations, we expect

the fluctuations to occur within a limited range and not have a material impact on our business, financial condition,

liquidity, or operating results.

Commercialization Strategy

Our approved products in development with collaboration partners are DARZALEX, RYBREVANT, TECVAYLI,

and TALVEY marketed by J&J, Kesimpta marketed by Novartis, TEPEZZA marketed by Amgen, under worldwide

license agreements with us, or in the case of TEPEZZ A, under a sublicense from Roche and BIZENGRI, which is marketed

in the US by Partner Therapeutics . We receive royalties from J&J, Novartis, Roche and Partner Therapeutics based on net

sales of DARZALEX, RYBREVANT, TECVAYLI, TALVEY, Kesimpta, TEPEZZA and BIZENGRI , but we are not

involved with commercialization activities or strategy.

52

Table of Contents

We are continuing to expand our commercialization capabilities to market our own products for the indications and in

the geographies we determine would be most effective to create value for patients and our shareholders. Genmab became a

commercial-stage company with the launch of Tivdak for the treatment of 2L+ recurrent or metastatic cervical cancer in

1. Tivdak is developed and commercialized together with Pfizer. Effective January 1, 2025, Genmab and Pfizer agreed

to amend the Pfizer License and Collaboration Agreement and the Tivdak Joint Commercialization Agreement, assigning

Genmab sole responsibility for the development and commercialization of Tivdak for 2L+ recurrent or metastatic cervical

cancer in Europe and all other regions globally, excluding the US and China. With this amendment, Genmab continues to

co-promote Tivdak with Pfizer in the US and leads operational activities in Japan. Pfizer will continue to lead

commercialization activities in China if and when approved in connection with the sublicense of its right to develop and

commercialize Tivdak in China to Zai Lab. Following this amendment, Genmab launched Tivdak in Japan and Germany in

2025.

In 2023, we began commercializing EPKINLY together with AbbVie. We are the lead in co-commercializing

EPKINLY in the US and Japan with AbbVie. AbbVie is responsible for commercialization in Europe and other markets as

TEPKINLY .

Moving forward, we may commercialize new products from our portfolio independently through our own operations

or, in some markets, through distribution partners depending on our assessment of the most effective commercialization

plan to benefit patients and create value for our shareholders.

Competition

The biotechnology and pharmaceutical industries generally, and the cancer drug sector specifically, are characterized

by rapidly advancing technologies, evolving understanding of disease etiology, intense competition and a strong emphasis

on intellectual property. While we believe that our product candidates and our knowledge and experience provide us with

competitive advantages, we face substantial potential competition from many different sources, including large and

specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and

public and private research institutions. Many of our current or potential competitors, either alone or with their

collaboration partners, have significantly greater financial resources and expertise in research and development,

manufacturing, preclinical trials, conducting clinical trials and marketing approved products than we do. Mergers and

acquisitions (“ M&A ”) in the pharmaceutical and biotechnology industries may result in even more resources being

concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be

significant competitors, particularly through collaborative arrangements with large and established companies. These

competitors also compete with us in recruiting and retaining qualified scientific and management personnel and

establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary

to, or necessary for, our programs. Accordingly, our competitors may be more successful than we may be in developing,

commercializing and achieving widespread market acceptance of their products. In addition, our competitors’ products may

be more effective or more effectively marketed and sold than any treatment we or our development collaboration partners

may commercialize and may render our product candidates obsolete or noncompetitive before we can recover the expenses

related to developing and commercializing our product candidates.

Below is a description of competition in certain of our products and product candidates.

With respect to daratumumab, there are numerous other FDA-approved drugs for the treatment of MM, and the

competition daratumumab faces is increasing. Isatuximab, a CD38 antibody developed by Sanofi S.A. (“ Sanofi ”), was

approved as Sarclisa® by the FDA in March 2020 and the European Commission in June 2020 for the treatment of adult

patients with MM who have received at least two prior therapies including lenalidomide and a PI. Although an earlier

accelerated approval was withdrawn due to a failed confirmatory Phase III trial, a ne\wer Phase III trial with daratumumab

as part of the control was the basis for the October 2025 approval of GSK’s Blenrep®. CAR-Ts have also been approved

for use in MM including BMS’s and 2seventybio’s ABECMA® and J&J’s CARVYKTI®, and two bispecific antibodies

have been approved: J&J’s TECVAYLI® and TALVEY™, and Pfizer’s Elrexfio®. We are also aware of numerous

additional investigational agents that are currently being studied. If any of these investigational agents are successful, they

may compete with daratumumab in the future. Data has also been presented on several developing technologies and related

potential products, including other bispecific antibodies, ADCs and CAR-Ts that may compete with daratumumab in the

future.

53

Table of Contents

With respect to ofatumumab for the treatment of RMS in adults, c o mpetition in the multiple sclerosis (“ MS ”) market is

intense and there are numerous FDA-approved drugs for the treatment of the various forms of MS. A number of companies

are also working to develop potential treatments for MS that may in the future further intensify the competition in the MS

market, such as TG Therapeutics’ BRIUMVI™, approved in December 2022 and Genentech Inc.’s OCREVUS ® (a CD20

antibody), approved in 2017 . Potential future sales may also be negatively impacted by the introduction of generics,

prodrugs of existing therapeutics or biosimilars of existing products and other technologies.

With respect to tisotumab vedotin, we are aware of other companies that currently have products in development for

the treatment of cervical cancer, which could be competitive with tisotumab vedotin, including checkpoint inhibitors from

Agenus Inc., BMS, Merck & Co., I nc. (“ Merck ”), Roche, and Innovent Biologics, Inc. as well as other drugs in

development from other companies. In June 2018, the FDA granted Merck’s Keytruda, a PD-1 inhibitor, accelerated

approval as monotherapy for patients with recurrent or metastatic cervical cancer. The FDA granted full approval for this

indication in October 2021, at the same time approving Keytruda in combination with chemotherapy, with or without

bevacizumab, for patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS ³1), as

determined by an FDA-approved test. Keytruda was subsequently approved in this indication in Europe in April 2022.

Keytru da was approved in January 2024 in combination with concurrent chemoradiotherapy for locally-advanced cervical

cancer. Also, a bispecific antibody having one similar target with Keytruda, AstraZeneca’s volrustomig, recently entered

Phase III trials and could complete in this indication within the next several years. In addition, in April 2024 the FDA

granted accelerated, tumor-agnostic approval to AstraZeneca and Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-

nxki), a HER2-directed antibody-drug conjugate, for adult patients with unresectable or metastatic HER2-positive (IHC

3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

We are similarly aware, with respect to epcoritamab, of a number of other companies that have bispecific CD3xCD20-

targeted product candidates in development for the treatment of B-cell malignancies, which are competing with

epcoritamab. These include: Regeneron Pharmaceuticals’ odronextamab, which was approved by the EMA in August 2024

for third line plus LBCL and DLBCL and was filed in the US for third line plus FL; and from Roche: mosunetuzumab,

which has BTD and which received conditional marketing authorization as LUNSUMIO® in Europe in third line plus FL

in June 2022 and accelerated approval in the US in December 2022; and glofitamab, which received accelerated approval

(as COLUMVI®) in both the US and in Europe in June and July of 2023, respectively and was filed in 2024 for R/R

DLBCL in combination with GemOx. We are aware that odronextamab, LUNSUMIO and COLUMVI are also being

evaluated in other Phase III trials in multiple other B-cell malignancies. We are also aware that there are a variety of CD20

and CD19 antibodies, immunomodulators, ADCs, BTK inhibitors, tyrosine kinase inhibitors and CAR-T therapies that are

either approved or in development for non-Hodgkin’s lymphomas. Some of these include ADC Therapeutics’

ZYNLONTA®, approved by the FDA in April 2021 for R/R LBCL and approved in Europe in December 2022, INCYTE’s

MONJUVI®, approved by the FDA in combination with lenalidomide in July 2020 in R/R DLBCL, Beigene’s

BRUKINSA approved by the FDA in March 2024 for third line plus FL in combination with obinutuzumab, and several

CAR-T therapies, Novartis’s KYMRIAH®, approved in the US and EU in R/R FL in May 2022, BMS’s Breyanzi®,

approved in the US in June 2022 for R/R LBCL, Gilead Sciences’ YESCARTA®, approved in the US in R/R LBCL in

April 2022 and second line DLBCL in Europe in October 2022 and Tecartus, approved for R/R MCL in 2020 in both the

US and Europe. In addition, in June 2019 Roche received accelerated approval in the US for POLIVY®, a first-in-class

anti-CD79b ADC, in combination with bendamustine and rituximab for adults with R/R DLBCL who have received at

least two prior therapies. In August 2021 Roche announced that the Phase III POLARIX trial met its primary endpoint. The

positive readout of POLARIX met the post-marketing requirement to convert the accelerated approval into a full approval,

potentially raising the bar for other drugs, including epcoritamab, to enter the 1L DLBCL space. POLIVY was granted full

approval by the European Commission in May 2022 and by the FDA in April 2023.

With respect to Rina-S competitors, Abbvie’s ELAHERE® was the first folate receptor-alpha (FRa) targeting ADC

approved, initially in the US and recently in the EU. We are aware of several other FRa ADCs in development, including

AbbVie’s next-generation FRa ADC IMGN151; Eli Lilly’s LY4170156; AstraZeneca’s AZD5335; Eiasi’s farletuzumab;

and BioThera Solutions’ BAT8006.

With respect to petosemtamab competitors, Lilly's Erbitux ® remains the established EGFR-targeting antibody in

HNSCC. We are aware of several next-generation EGFR-targeted approaches that could compete directly or indirectly with

petosemtamab, including J& J’s RYBREVANT, Bicara Therapeutics’ BCA101, and EGFR-directed antibody–drug

conjugates such as Lepu Biopharma’s MRG003 and AbbVie’s serclutamab talirine (ABBV-321). In addition, emerging

LGR5-targeted modalities (e.g., LGR5-directed cellular therapies like Carina Biotech’s CNA3103 CAR-T) could create

longer-term competitive pressure on LGR5 biology and patient selection strategies.

54

Table of Contents

In addition, many other pharmaceutical and biotechnology companies are developing and/or marketing therapies for

the same types of cancer that our products and product candidates are designed and being developed to treat. We are also

aware of other companies that have or are developing technologies that may be competitive with ours, including bispecific

antibodies, CAR-T and RNA-based technologies. In addition, our DuoBody and other technology collaboration partners

may develop compounds utilizing our technology that may compete with product candidates that we are developing.

In addition, in the US, the BPCIA created an abbreviated approval pathway for biological products that are

demonstrated to be “highly similar” or “biosimilar” to or “interchangeable” with an FDA-approved biological product. This

pathway allows competitors to reference the FDA’s prior approvals regarding innovative biological products and data

submitted with a BLA to obtain approval of a biosimilar application 12 years after the time of approval of the innovative

biological product. The 12-year exclusivity period runs from the initial approval of the innovator product and not from

approval of a new indication. In addition, the 12-year exclusivity period does not prevent another company from

independently developing a product that is highly similar to the innovative product, generating all the data necessary for a

full BLA and seeking approval. Data exclusivity only assures that another company cannot rely on the FDA’s prior

approvals of a BLA for an innovator’s biological product to support the biosimilar product’s approval. Further, under the

FDA’s current interpretation, a biosimilar applicant can obtain approval for one or more of the indications approved for the

innovator product by extrapolating clinical data from one indication to support approval for other indications. In the EU,

the European Commission has granted marketing authorizations for several biosimilars pursuant to a set of general and

product class-specific guidelines for biosimilar approvals issued since 2005. We are aware of many pharmaceutical and

biotechnology companies, as well as other companies, that are actively engaged in research and development of biosimilars

or interchangeable products.

It is possible that our competitors will succeed in developing technologies that are more effective than our products or

our product candidates or that would render our technology obsolete or noncompetitive or will succeed in developing

biosimilar or interchangeable products for our products or our product candidates. We anticipate that we will continue to

face increasing competition in the future as new companies enter our market and scientific developments surrounding

biosimilars and other cancer therapies continue to accelerate. We cannot predict to what extent the entry of biosimilars or

other competing products will impact potential future sales of our products or our product candidates.

With respect to our current and potential future product candidates, we believe that our ability to compete effectively

and develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to:

• advance our prioritized products, product candidates and technology platforms;

• license or acquire additional technology or product candidates;

• complete clinical trials which position our products for regulatory and commercial success;

• maintain a proprietary position in our technologies and products;

• obtain required government and other public and private approvals on a timely basis;

• attract and retain key personnel;

• become more efficient through productivity initiatives;

• commercialize effectively;

• obtain reimbursement for our products in approved indications;

• establish efficient manufacturing processes and supply chain;

• comply with applicable laws, regulations and regulatory requirements and restrictions with respect to our business,

such as the commercialization of our products, including with respect to any changed or increased regulatory

restrictions; and

55

Table of Contents

• enter into additional collaborations to advance the development and commercialization of our product candidates.

Product and Technology Collaborations

Certain Collaborations for our Proprietary Products

AbbVie Epcoritamab and Discovery Research Collaborations

In June 2020, we entered into a Collaboration and License Agreement with AbbVie to jointly develop and

commercialize epcoritamab and additional investigational bispecific antibody product candidates. In addition, under the

agreement, we agreed with AbbVie to enter into a discovery research collaboration for future differentiated antibody

therapeutics for cancer.

Genmab shares commercial responsibilities with AbbVie in the US and Japan, while AbbVie is responsible for global

commercialization outside of the US and Japan. We are the principal for net sales of epcoritamab in the US and Japan and

receive tiered royalties on remaining global sales outside these territories. We are entitled to tiered royalties between 22%

and 26% on net sales for epcoritamab outside the US and Japan, subject to certain royalty reductions. Except for these

royalty-bearing sales, we share with AbbVie profits from the sale of licensed products on a 50:50 basis. We and AbbVie

split 50:50 the development costs related to epcoritamab, while we will be responsible for 100% of the costs for the

discovery research programs up to the opt-in decision point.

For any product candidates developed as a result of the discovery research collaboration, we will share responsibilities

with AbbVie for global development and commercialization in the US and Japan. Subject to certain requirements, we have

an option to co-commercialize these products, along with AbbVie, outside of the US and Japan.

We and AbbVie grant to each other co-exclusive licenses to use certain intellectual property that is developed under

the agreement and the resulting licensed products, as further described in the agreement. The licenses can be sublicensed to

affiliates of the applicable licensee or to third-party sub-contractors meeting certain requirements or if otherwise approved.

Under the terms of the agreement, we received a $750 million upfront payment in June 2020 and we were initially

entitled to receive an aggregate of up to $3.15 billion in additional development, regulatory and sales milestone payments

for all programs. Included in these potential milestones were up to $1.15 billion in payments related to clinical

development and commercial success across the three bispecific antibody programs originally included in the agreement.

As a result of epcoritamab and one additional antibody product candidate being the remaining bispecific antibody

programs under the original Collaboration and License Agreement, we are instead contractually entitled to receive an

aggregate of up to $1.06 billion in additional development, regulatory and sales milestone payments. In addition, and also

included in these potential milestones, if the remaining next-generation antibody product candidate is developed as a result

of the discovery research collaboration and is successful, we are eligible to receive up to $510 million in option exercise

and success-based milestones.

The agreement expires when neither we nor AbbVie are developing or commercializing any licensed products.

AbbVie may terminate the agreement at AbbVie’s convenience at any time after a certain notice period, either in whole or

on a licensed product-by-licensed product basis or on a region-by-region basis. The US and Japan as a whole, Europe as a

whole, and the rest of the world each constitute one region for this purpose. If we or AbbVie terminate the agreement due

to a material breach, insolvency event or force majeure event with respect to the other party, the terminating party will have

the exclusive right (including the exclusive right to use the intellectual property licensed to it under the agreement) to

develop, manufacture and commercialize the terminated licensed product in the terminated region. The terminating party

will pay the other party a royalty on net sales of the terminated product in the terminated region up to certain thresholds

depending on which party terminated the agreement. A termination by AbbVie for convenience is treated the same way as

a termination by Genmab for a material breach by AbbVie for this purpose, which means that Genmab would have the

exclusive right to develop, manufacture and commercialize the terminated licensed product in the terminated region.

Pfizer Tisotumab Vedotin Collaboration

56

Table of Contents

In October 2011, we entered into a license and collaboration agreement with Seagen, Inc. (“ Seagen ”), now Pfizer per

Pfizer’s acquisition of Seagen in December 2023, that granted us rights to utilize Seagen ’s ADC technology with our TF

antibody in return for milestone payments and royalties (the “ Pfizer License and Collaboration Agreement ”). We also

granted Seagen a right to exercise a co-development and co-commercialization option at the end of Phase I clinical

development for tisotumab vedotin. In August 2017, Seagen exercised this option to co-develop and co-commercialize

tisotumab vedotin with us. In October 2020, Genmab and Seagen entered into a Joint Commercialization Agreement where

Genmab would co-promote tisotumab vedotin, marketed as Tivdak, in the US, and lead commercial operational activities

and record sales in Japan, while Seagen would lead operational commercial activities in the US, Europe and China with a

50:50 profit split in those markets (the “ Tivdak Joint Commercialization Agreement ”). In all other markets, if any,

Pfizer would be responsible for commercializing tisotumab vedotin and Genmab would receive royalties based on a

percentage of aggregate net sales ranging from the mid-teens to the mid-twenties. Effective January 1, 2025, Genmab and

Pfizer agreed to amend the Pfizer License and Collaboration Agreement and the Tivdak Joint Commercialization

Agreement, assigning Genmab sole responsibility for the development and commercialization of Tivdak for second line

plus recurrent or metastatic cervical cancer in Europe and all other regions globally, excluding the US and the China

region. With this amendment, Genmab will continue to co-promote Tivdak with Pfizer in the US and will record sales for

Europe, Japan and rest of world markets (excluding the US and China), and will provide royalties in the low teens

percentage-wise to Pfizer on net sales. Pfizer is leading commercial operational activities in the US and will lead

commercialization activities in China if and when approved in connection with the sublicense of its rights to develop and

commercialize tisotumab vedotin in China to Zai Lab discussed below. The companies will continue the practice of joint

decision-making on the worldwide development and commercialization strategy for tisotumab vedotin. In September 2022

Seagen and Zai Lab announced an exclusive collaboration and license agreement for the development and

commercialization of Tivdak in mainland China, Hong Kong, Macau and Taiwan. Under the terms of the agreement,

Seagen received an upfront payment of $30 million and will receive development, regulatory and commercial milestone

payments, as well as tiered royalties on net sales of Tivdak in the Zai Lab territory. Based on our agreement with Pfizer, all

upfront, milestone payments and royalties have been and will continue to be shared 50:50 with Genmab.

BioNTech Collaboration

In May 2015, we entered into an agreement with BioNTech to jointly research, develop and commercialize bispecific

antibody products using our DuoBody technology platform and antibodies. Under the terms of the agreement, BioNTech

provides proprietary antibodies against key immunomodulatory targets, while we provide proprietary antibodies and access

to our DuoBody technology platform. We paid an upfront fee of $10 million to BioNTech and an additional fee as certain

BioNTech assets were selected for further development. If the companies jointly select any product candidates for clinical

development, development expenses and product ownership will be shared equally going forward. If one of the companies

does not wish to move a product candidate forward, the other company is entitled to continue developing the product on

predetermined licensing terms. The agreement also includes provisions which will allow the parties to opt out of joint

development at key points.

In July 2022, we expanded this collaboration. Under the expansion, the companies will jointly develop and

commercialize, subject to regulatory approval, monospecific antibodies leveraging Genmab’s proprietary HexaBody

technology platform.

Genmab and BioNTech have one product candidate currently in active clinical development: DuoBody-

EpCAMx4-1BB. In August 2024, BioNTech opted not to participate in the further development of the acasunlimab

program under the parties’ existing license and collaboration agreement for reasons related to BioNTech’s portfolio

strategy. Genmab assumed sole responsibility for the continued development and potential commercialization of

acasunlimab. In December 2025, Genmab announced the discontinuation of further clinical development for acasunlimab.

The decision was made as part of Genmab's strategic focus on the most value-creating opportunities in its late-stage

portfolio and following a thorough assessment of the evolving competitive landscape.

Collaborations for our Partnered Products

J&J Daratumumab License and Development Agreement

In 2012, we entered into a global license, development and commercialization agreement with J&J, granting J&J an

exclusive, sublicensable license to certain of our patents, know-how and materials, owned by or licensed to us, to research,

develop, make, offer and sell worldwide certain licensed products containing the human mAb denoted “daratumumab,”

57

Table of Contents

also known as HuMax-CD38 and DARZALEX. With respect to licensed technology, we have given up the ability to

develop or commercialize other products with affinity to the CD38 antigen target. We recorded an upfront license fee of

$55.0 million and J&J Development Corporation invested DKK 475.2 million (approximately $80.0 million at the date of

the agreement) to subscribe for 5.4 million newly issued shares of Genmab at a price of DKK 88 per share. J&J is fully

responsible for developing and commercializing the licensed products and all costs associated therewith.

Under this agreement, we were entitled to up to approximately $1,015 million in development, regulatory and sales

milestones, in addition to tiered royalties between 12% and 20%. As of December 31, 2025, Genmab has recorded $920

million in milestone payments from J&J and could be entitled to receive up to $95 million in further payments if certain

additional milestones are met. The following royalty tiers apply for net sales in a calendar year: 12% on net sales up to and

including $750 million; 13% on net sales above $750 million and up to and including $1.5 billion; 16% on net sales above

$1.5 billion and up to and including $2.0 billion; 18% on net sales above $2.0 billion and up to and including $3.0 billion;

and 20% on net sales exceeding $3.0 billion.

The royalties payable to us by J&J are limited in time and subject to reduction on a country-by-country basis for

customary reduction events, including for lack of patent coverage or upon patent expiration or invalidation in the relevant

country and upon the first commercial sale of a biosimilar product in the relevant country (for as long as the biosimilar

product remains for sale in that country). Royalties are also reduced for licensing payments made by J&J to Halozyme in

connection with SC DARZALEX net sales. Pursuant to the terms of the agreement, J&J’s obligation to pay royalties to us

will expire on a country-by-country basis on the later of the date that is 13 years after the first sale of daratumumab in such

country or upon the expiration or invalidation of the last-to-expire relevant Genmab patent covering daratumumab in such

country. The first US, European and Japanese sales of daratumumab occurred in 2015, 2016 and 2017, respectively. We

have issued patents and pending patent applications covering daratumumab in numerous jurisdictions, including patents

issued in the US, Europe and Japan. Our issued US, European and Japanese patents covering daratumumab, after giving

effect to issued US, European and Japanese PTEs and SPCs, expire in 2029, 2031, and 2030, respectively. J&J owns a

separate patent portfolio related to the SC formulation of daratumumab used in DARZALEX FASPRO/ DARZALEX SC,

but a binding arbitration determined that we are not entitled to royalties based on these separate patents.

J&J may fully or partially terminate the agreement at any time upon 150 days’ prior written notice to us. Upon J&J’s

termination of the agreement, we are granted an exclusive, perpetual, sublicensable license under any intellectual property

controlled by J&J or its affiliates to the extent necessary to make, have made, import, use, offer to sell or sell the terminated

licensed product in such territory where the license has been terminated. If certain milestones have been met by J&J prior

to the termination, then we must pay royalties to J&J for 10 years from our first commercial sale of a licensed product.

Novartis Ofatumumab Collaboration

Genmab and GlaxoSmithKline (GSK) entered a co-development and collaboration agreement for ofatumumab

(“Novartis Agreement”) in 2006. The full rights to ofatumumab were transferred from GSK to Novartis in 2015. Novartis

is now fully responsible for the development and commercialization of ofatumumab in all potential indications, including

autoimmune diseases. Genmab is entitled to a 10% royalty payment on net sales for non-cancer treatments. Genmab pays a

royalty to Medarex based on Kesimpta net sales. Novartis’s obligation to pay royalties to Genmab under the Novartis

Agreement expires on a country-by-country basis only in the event Novartis is no longer selling such product in a given

country. The royalties are on a country‑by‑country basis subject to reduction in case of significant competition by

competing products (as defined in the Novartis Agreement) or a joint committee determination that a license of intellectual

property owned by a third-party is necessary for commercialization. All potential regulatory and sales milestone payments

under this agreement have been achieved and no further milestone payments remain outstanding.

Roche / Amgen Teprotumumab Collaboration

In May 2001, Genmab entered a research collaboration with Roche to develop human antibodies to disease targets

identified by Roche. In 2002, this alliance was expanded. Under the agreement, Genmab will receive milestones as well as

royalty payments on successful products.

Teprotumumab was initially developed in collaboration between Genmab and Roche, and later investigated under

license from Roche by River Vision Development Corporation and Horizon Therapeutics for ophthalmic use. The product

was approved under the brand name TEPEZZA in 2020 by the FDA for the treatment of TED and in 2024 by Japan’s

MHLW for the treatment of active or high clinical activity score TED. In October 2023, Amgen completed its acquisition

58

Table of Contents

of Horizon Therapeutics, including all rights to the development and commercialization of teprotumumab. Under the terms

of Genmab’s agreement with Roche, Genmab receives a mid-single digit royalty on net sales of TEPEZZA, on a country-

by-country basis, for 10 years following the first commercial sale in such country.

J&J DuoBody Collaboration (Amivantamab, Teclistamab and Talquetamab)

In 2012, and as amended in 2013, Genmab entered into a collaboration with J&J to create and develop bispecific

antibodies using our DuoBody platform.

Genmab will receive milestones and royalties between 8% and 10% on net sales of amivantamab, with J&J reducing

such royalty payments for Genmab’s share of J&J’s royalty payments made to Halozyme, a mid-single digit royalty on net

sales of teclistamab, and a mid-single digit royalty on net sales of talquetamab. Pursuant to the terms of the DuoBody

agreement, J&J’s obligation to pay these royalties will expire on a country-by-country and licensed product-by-licensed

product basis on the later of the date that is 10 years after the first sale of each licensed product in such country or upon the

expiration of the last-to-expire relevant patent (as defined in the agreement) covering the licensed product in such country.

Royalties for amivantamab, teclistamab and talquetamab are subject to a reduction in countries and territories where there

are no relevant patents (as defined in the agreement), among other reductions. Genmab pays a royalty to Medarex based on

net sales of amivantamab. All research work is funded by J&J. Amivantamab, teclistamab and talquetamab have received

regulatory approval.

Partner Therapeutics Collaboration (Z enocutuzumab)

In November 2024, prior to its acquisition by Genmab, Merus entered into a license agreement (“Partner Therapeutics

License Agreement”) with Partner Therapeutics, Inc (“PTx”). Under the terms of the Partner Therapeutics License

Agreement, Merus granted PTx US commercialization rights for zenocutuzumab and PTx granted to Merus an exclusive,

fully paid, royalty-free, perpetual and irrevocable license, with the right to grant sublicenses, to certain intellectual property

of PTx to exploit zenocutuzumab for (1) the treatment of NRG1+ cancer in a country outside of the US and (2) for any

other uses of zenocutuzumab in any other territory.

In exchange for the rights granted under the Partner Therapeutics License Agreement, PTx paid an upfront, non-

refundable payment, and agreed to fund certain development, manufacturing and clinical trial expenses for zenocutuzumab.

Genmab is eligible to receive up to $130.0 million per year in commercialization milestone payments based on annual net

sales of zenocutuzumab. Genmab is also eligible to receive tiered royalties based on the level of aggregate annual net sales

ranging from 8.5% to 22% until the royalty term expires, subject to the terms of the agreement. The sales of

zenocutuzumab are subject to certain annual sales target requirements.

Gilead Collaboration

In March 2024, prior to its acquisition by Genmab, Merus entered into a collaboration, option and license agreement

with Gilead (Gilead Collaboration Agreement) to research and develop trispecific T-cell engaging antibody product

candidates using Merus’ technology platform. Under the terms of the agreement, the collaboration included two preclinical

research programs, with an option for Gilead to include a third program.

Under the Gilead Collaboration Agreement, Merus granted Gilead a non-exclusive license and agreed to perform

related research and collaboration activities during the research term. On a program-by-program basis, Gilead was granted

an exclusive option to obtain an exclusive license for further development and commercialization of products arising from

each program. At the acquisition date, no exclusive license options had been exercised by Gilead.

Under the Gilead Collaboration Agreement, Merus received a non-refundable upfront payment and Genmab is eligible

to receive additional consideration in the form of option exercise payments, development and commercialization milestone

payments, and tiered royalties between 5% and 11% on net sales of any products successfully commercialized under the

Gilead Collaboration Agreement.

Certain other Collaborations, Agreements and Enabling Technologies

Medarex UltiMAb® System License

59

Table of Contents

In 1999, we entered into a license agreement with Medarex, now a wholly owned subsidiary of BMS, pursuant to

which we received access to the UltiMAb technology, the KM Mouse technology and the right to obtain antibody-

exclusive licenses for an unlimited number of antigens and own the worldwide development and commercialization rights

to antibody products targeting such antigens. In addition, Medarex granted us antigen-exclusive licenses in exchange for

Genmab shares that are fully paid-up subject to, in case the products have been generated in the KM Mouse, pass-through

of milestones and royalties payable by Medarex under its own license of the KM Mouse technology. Our principal

obligation under this agreement is to make milestone and royalty payments in connection with any such antibody-exclusive

licenses or in connection with use of the KM Mouse technology under this agreement. We used technology licensed from

Medarex to generate daratumumab, ofatumumab, tisotumab forming part of tisotumab vedotin, the CD20 antibody forming

part of epcoritamab (DuoBody-CD3xCD20), and certain of our other product candidates. Based on the type of license and

technology used in their development, product candidates that are subject to future payment obligations under this license

agreement include ofatumumab, epcoritamab (DuoBody-CD3xCD20), amivantamab (DuoBody-cMetxEGFR) and

amlenetug (Lu AF82422), but do not include daratumumab and tisotumab vedotin. With respect to ofatumumab and

amlenetug, Novartis and Lundbeck, respectively, have agreed to bear the majority of our payments to Medarex under these

agreements. Milestones for the product candidates subject to payment obligations are payable by us or our collaboration

partners across all such product candidates currently in development. Royalties are in the low single digits percentage-wise

of net sales.

O ther Collaborations and Agreeme nts

We have other active collaborations and agreements with a number of companies to create, develop and/or

commercialize antibody candidates and/or license certain of our product candidates and use of our technology platforms.

Under certain collaborations and agreements, which we have entered into in the ordinary course of business, and where we

have licensed our product candidates or technology platforms, we typically receive or are entitled to receive upfront cash

payments, progress- and sales-dependent milestones for the achievement by our collaborators of certain events, and, where

applicable, research funding. We also are typically entitled to receive royalties on net sales of commercialized products

resulting from the collaborations. We also enter into certain agreements where Genmab is obligat ed to make upfront cash

payments and milestone payments to third parties upon the achievement of certain development, regulatory and

commercial events as well as obligated to pay royalties on net sales of commercialized products.

We also license technologies from a number of other companies that we use or have used to contribute to the antibody

products in our pipeline. Pursuant to certain of these licenses, we or our collaboration partners are or may be obligated to

pay small royalties for certain products generated or produced using these technologies upon commercialization of such

products or product candidates.

See Note 5.6 to our Audited Financial Statements included in our Annual Report 2025 for details on our collaborations

and technology licenses.

Intellectual Property

Patents

As of December 31, 2025, we held more than 4,715 patents and patent applications, including 178 issued US patents

and 235 US patent applications . All of our current issued patents and patent applications are projected to expire between

2026 and 2045.

Our owned and licensed patents and patent applications are directed to daratumumab, ofatumumab, tisotumab vedotin,

epcoritamab, our product candidates, antibodies, our proprietary technologies and other antibody based and/or enabling

technologies. We commonly seek patent claims directed to compositions of matter, including antibodies, bispecific

antibodies, and ADCs, as well as methods of using such compositions. When appropriate, we also seek claims to related

technologies, such as antibody format technologies and linker-payloads suitable for ADCs. For daratumumab,

ofatumumab, tisotumab vedotin, epcoritamab and each of our product candidates, we or our collaboration partners have

filed or expect to file multiple patent applications. We maintain patents and prosecute applications worldwide for

technologies that we have out licensed, such as our DuoBody technology. Similarly, for partnered products and product

candidates, such as daratumumab, ofatumumab, tisotumab vedotin and epcoritamab, we seek to work closely with our

development collaboration partners to coordinate patent efforts, including patent application filings, prosecution, PTE,

defense and enforcement. As our products and product candidates advance through research and development, we and/or

60

Table of Contents

our collaboration partners seek to diligently identify and protect new inventions, such as formulations, combination

therapies, and methods of treatment. We also work closely with our scientific personnel to identify and protect new

inventions that could eventually add to our development or technology pipeline.

With respect to daratumumab, we have issued patents and pending patent applications covering daratumumab in

numerous jurisdictions, including patents issued in the US, Europe and Japan. Our patents do not begin to expire until

March 2026. The issued US, European and Japanese PTEs and SPCs, expire in 2029, 2031 and begin to expire in 2030,

respectively.

With respect to ofatumumab, our issued patents covering ofatumumab began to expire in October 2023, with the US

composition of matter patent extended to May 2031. In addition, we have PTEs granted in Japan which expire in 2028.

With respect to tisotumab vedotin, we have issued patents and pending patent applications in numerous jurisdictions,

including the US, Europe and Japan. Our issued US, European and Japanese patents covering the composition of matter for

tisotumab vedotin do not begin to expire until June 2031. In the US we have obtained patent term adjustment and patent

term extension of the composition of matter patent until September 2035. In Europe we have filed SPC applications

broadly, of which some are granted. Granted SPCs will expire June 2036. In Japan we have filed PTE applications which,

if granted, would provide protection beyond June 2031. In addition to our key composition of matter patents for tisotumab

vedotin, we have issued patents and pending patent applications in numerous jurisdictions relating to specific formulations,

indications and combination therapies that may offer additional protection.

With respect to epcoritamab, we have issued patents and pending patent applications in numerous jurisdictions,

including the US, Europe and Japan. Our US, European and Japanese patent applications and issued patents covering the

composition of matter for epcoritamab do not begin to expire until January 2035. In addition, we have filed a request for

PTE in the US covering the composition of matter for epcoritamab which, if granted, would provide protection beyond

1. In Japan, we have filed requests for PTE some which have been granted, extending the patent terms for composition

of matter relating to epcoritamab beyond 2035. In Europe, we have filed SPC applications broadly and when granted SPCs

will expire September 2038. In addition to our key composition of matter patents for epcoritamab, we have issued patents

and pending patent applications in numerous jurisdictions relating to specific formulations, dosing regimens, indications

and combination therapies that may offer additional protection.

The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the

scope of its coverage as determined by the patent office or courts in the country, and the availability of legal remedies in

the country. This list above does not identify all patents that may be related to daratumumab, ofatumumab, tisotumab

vedotin, epcoritamab and our product candidates. For example, in addition to the listed patents, we have patents on

platform technologies (that relate to certain general classes of products or methods), as well as patents that relate to

methods of using, formulating or administering a product or product candidate, which may confer additional patent

protection. We also have pending patent applications that may give rise to new patents related to one or more of these

product candidates, technologies, formulations and uses.

The information in “Intellectual Property” is based on our current assessment of patents that we own or control or have

exclusively licensed. The information is subject to revision, for example, in the event of changes in the law or legal rulings

affecting our patents or if we become aware of new information. Significant legal issues remain unresolved as to the extent

and scope of available patent protection for biotechnology products and processes in the US and other important markets

outside the US We expect that litigation will likely be necessary to determine the term, validity, enforceability, and/or

scope of certain of our patents and other proprietary rights. An adverse decision or ruling with respect to one or more of our

patents could result in the loss of patent protection for a product and, in turn, the introduction of competitor products or

follow-on biologics to the market earlier than anticipated.

Patents expire, on a country-by-country basis, at various times depending on various factors, including the filing date

of the corresponding patent application(s), the availability of patent term adjustment, PTE and SPC and requirements for

terminal disclaimers. Although we believe our owned and licensed patents and patent applications provide us with a

competitive advantage, the patent positions of biotechnology and pharmaceutical companies can be uncertain and involve

complex legal and factual questions. We and our collaboration partners may not be able to develop patentable products or

processes or obtain patents from pending patent applications. Depending on the terms of the relevant collaboration

agreement, on how those terms are interpreted, and on other legal considerations, we may not b e entitled to royalties based

on sales by our collaboration partners that are protected only by patents owned by those partners. In the event of patent

61

Table of Contents

issuance, the patents may not be sufficient to protect the proprietary technology owned by or licensed to us or our

collaboration partners. Our or our collaboration partners’ current patents, or patents that issue on pending applications, may

be challenged, invalidated, infringed or circumvented. In addition, changes to patent laws in the US or in other countries

may limit our ability to defend or enforce our patents or may apply retroactively to affect the term and/or scope of our

patents. Our patents have been and may in the future be challenged by third parties in post-issuance administrative

proceedings or in litigation as invalid, not infringed or unenforceable under US or foreign laws, or they may be infringed

by third parties. As a result, we are or may be from time to time involved in the defense and enforcement of our patent or

other intellectual property rights in a court of law and administrative tribunals, such as in USPTO inter partes review or

reexamination proceedings, foreign opposition proceedings or related legal and administrative proceedings in the US and

elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative

proceedings or litigation may be substantial and the outcome can be uncertain. An adverse outcome may allow third parties

to use our proprietary technologies without a license from us or our collaboration partners. Our collaboration partners’

patents may also be circumvented, which may allow third parties to use similar technologies without a license from us or

our collaboration partners.

Our commercial success depends significantly on our ability to operate without infringing patents and proprietary

rights of third parties. Organizations such as pharmaceutical and biotechnology companies, universities and research

institutions may have filed patent applications or may have been granted patents that cover technologies similar to the

technologies owned or licensed to us or to our collaboration partners. In addition, we are monitoring the progress of several

pending patent applications of other organizations that, if granted in their broadest scope, may require us to license or

challenge their validity or enforceability in order to continue commercializing our products and product candidates directly

or through our collaboration partners. Our and our collaboration partners’ challenges to patents of other organizations may

not be successful, which may affect our and our collaboration partners’ ability to commercialize daratumumab,

ofatumumab, tisotumab vedotin, epcoritamab, amivantamab, teclistamab, talquetamab, or teprotumumab or our ability to

commercialize our product candidates. We cannot determine with certainty whether patents or patent applications of other

parties may materially affect our or our collaboration partners’ ability to make, use or sell daratumumab, ofatumumab,

tisotumab vedotin, epcoritamab, amivantamab, teclistamab, talquetamab, teprotumumab or any other products or product

candidates.

Trademarks

As of December 31, 2025, we and/or our subsidiaries own approximately 410 trademark registrations and applications,

46 of which are US trademark registrations and applications, including: Genmab®; the Y-shaped Genmab logo®; Genmab

in combination with the Y-shaped Genmab logo®; HexaBody®; HuMax®; DuoBody®; DuoHexaBody®; HexElect®;

KYSO®; ABBIL1TY®; RAINFOL™; and Rina-S®. Merus™, Merus logo®, BIZENGRI®, Multiclonics®, Biclonics®,

Triclonics® and ADClonics™ are trademarks of Merus. Tivdak® is a trademark of Seagen Inc. and Genmab A/S;

EPCORE®, EPKINLY® and TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd. and Genmab

A/S; Kesimpta® and Sensoready® are trademarks of Novartis AG. ARZERRA® is a trademark of Novartis Pharma AG;

DARZALEX®, DARZALEX FASPRO®, RYBREVANT®, RYBREVANT FASPRO™, TECVAYLI®, and TALVEY®

are trademarks of J&J and/or its affiliates. TEPEZZA® is a trademark of Horizon Therapeutics Ireland DAC. Other than

the registered trademarks listed above, we currently rely on our unregistered trademarks, trade names and service marks, as

well as our domain names and logos, as appropriate, to market our brands and to build and maintain brand recognition. We

are seeking to register and will continue to seek to register and renew, or secure by contract where appropriate, trademarks,

trade names and service marks as they are developed and used, and reserve, register and renew domain names as

appropriate. If we do not secure trademark registration successfully for our trademarks, we may encounter difficulty in

enforcing, or be unable to enforce, our rights in our trademarks, trade names and service marks against third parties.

Trade Secrets

We require our scientific personnel to maintain laboratory notebooks and other research records in accordance with

our practices which are also designed to strengthen and support our intellectual property protection. In addition to our

patented intellectual property, we also rely on trade secrets and other proprietary information, especially when we do not

believe that patent protection is appropriate or can be obtained. Our practice is to require each of our employees,

consultants and advisors to execute a proprietary information and inventions assignment agreement before beginning their

employment, consulting or advisory relationship with us. These agreements provide that the individual must keep

confidential and not disclose to other parties any confidential information developed or learned by the individual during the

course of their relationship with us except in limited circumstances. These agreements also provide that we will own all

62

Table of Contents

inventions conceived or reduced to practice by the individual in the course of rendering services to us except in limited

circumstances. Our agreements with collaboration partners require them to have similar agreements with their employees,

consultants and advisors to ensure the agreed upon allotment of intellectual property rights can be enforced. Our practices

and agreements and those of our collaboration partners may not sufficiently protect our confidential information, or third

parties may independently develop equivalent information.

Legal Proceedings

From time to time in the ordinary course of business we may become involved in various lawsuits, claims and

proceedings relating to the conduct of our business, including those pertaining to the defense and enforcement of our patent

or other intellectual property rights. These proceedings are costly and time consuming. Successful challenges to our patent

or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and

may allow third parties to use our proprietary products and technologies without a license from us or our partners.

In 2024, Chugai filed a lawsuit in the Tokyo District Court in Japan against AbbVie’s and Genmab’s Japanese

subsidiaries asserting that their activities related to EPKINLY (epcoritamab) in Japan infringe two Japanese patents held by

Chugai and claiming damages and injunctive relief. In September 2025, Chugai filed two further lawsuits in the same

court, against the same parties and with similar assertions, based on two newly granted Japanese patents held by Chugai

which are similar to the patents from the original lawsuit.

Genmab and AbbVie believe that all four of the patents are invalid and/or not infringed and intend to vigorously

defend the claims, and thus no provision has been recorded related to this matter.

During the first quarter of 2025, AbbVie filed a complaint in the US District Court for the Western District of

Washington (Seattle) naming Genmab A/S; ProfoundBio US Co.; ProfoundBio (Suzhou) Co., Ltd.; and former AbbVie

employees as defendants. AbbVie alleges that the defendants have misappropriated AbbVie’s alleged trade secrets relating

to the use of disaccharides to improve the hydrophilicity of drug-linkers in ADCs in connection with Rina-S and other

ADC pipeline products of ProfoundBio. AbbVie is seeking damages and broad injunctive relief. AbbVie is not asserting or

enforcing any patent rights against the defendants, and to Genmab’s knowledge, AbbVie has not pursued any development

of products incorporating their alleged trade secrets. During the fourth quarter of 2025, AbbVie filed a complaint with the

US International Trade Commission under Section 337 of the Tariff Act against ProfoundBio US Co.; ProfoundBio

(Suzhou) Co., Ltd.; Genmab A/S; Genmab B.V.; and Genmab US, Inc., seeking to exclude certain antibody drug conjugate

products from importation into the US. The district court action has since been stayed. The ITC complaint is based on

allegations that are substantially similar to those asserted in the district court action.

Genmab categorically refutes these allegations and will vigorously defend the company against AbbVie’s claims, and

thus no provision has been recorded related to this matter.

Government Regulation

The FDA, the EMA, the Japan Pharmaceuticals and Medical Devices Agency (“ PMDA ”) and other regulatory

authorities at US federal, state, and local levels, as well as in other countries, extensively regulate, among other things, the

research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,

storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring, and post-

approval reporting of biologics such as those we are developing. We, along with our collaboration partners and third-party

contractors, are required to navigate the various preclinical, clinical and commercial approval requirements of the

governing regulatory agencies of the countries in which we wish to conduct trials or seek approval or licensure of our

product candidates. The process of regulatory approvals and the subsequent compliance with appropriate statutes and

regulations require the expenditure of substantial time and financial resources. The following sections outline the approval

process and other rules and regulations applicable to biologics in the US, EU, Japan, and the U.K. (following Brexit).

While the regulatory process in many countries is similar to the US, EU, or the U.K., each jurisdiction has its own

regulations, and approval in one jurisdiction does not guarantee approval in any other jurisdiction.

Review and Approval of Biologic Products in the US

63

Table of Contents

Biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act and the Public Health

Service Act and other federal, state, local and foreign statutes and regulations. Our product candidates must be approved by

the FDA before they may be legally marketed in the US.

The process required by the FDA before biologic product candidates may be marketed in the US generally involves the

following:

• completion of preclinical laboratory tests and animal trials performed in accordance with the FDA’s current Good

Laboratory Practices (“ GLPs ”) regulation;

• submission to the FDA of an IND , which must become effective before clinical trials may begin and must be

updated annually or when significant changes are made;

• approval by an independent IRB, or ethics committee at each clinical site before the trial is begun;

• performance of adequate and well-controlled human clinical trials to establish the safety and potency of the

proposed biologic product candidate for its intended purpose;

• preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;

• a determination by the FDA within 60 days of its receipt of a BLA to accept the application for review;

• satisfactory completion of an FDA Advisory Committee review, if applicable;

• satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the

proposed product is produced to assess compliance with GMP and to assure that the facilities, methods and

controls are adequate to preserve the biological product’s continued safety, purity and potency, and of selected

clinical investigations to assess compliance with current GCPs; and

• FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for

use in the US, which must be updated when significant changes are made.

Prior to beginning the first clinical trial with a product candidate in the US, we or our collaboration partner must

submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational product to

humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials.

The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and

pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available

human data or literature to support the use of the investigational product. An IND must become effective before human

clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA,

within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may

be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the

clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical

trial.

A clinical trial involves the administration of the investigational product to human patients under the supervision of

qualified investigators in accordance with GCPs, which includes the requirement that all research patients provide their

informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among

other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be

evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during

product development and for any subsequent protocol amendments. Furthermore, an IRB for each site proposing to

conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the

clinical trial begins at that site and must monitor the trial until completed. Regulatory authorities, the IRB or the sponsor

may suspend a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an

unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some trials also include oversight by an

independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or

data monitoring committee, which provides authorization for whether or not a trial may move forward at designated check

64

Table of Contents

points based on access to certain data from the trial and may halt the clinical trial if it determines that there is an

unacceptable safety risk for patients or on other grounds, such as no demonstration of efficacy. There are also requirements

governing the reporting of ongoing clinical trials and clinical trial results to public registries.

For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may

overlap.

• Phase I -The investigational product is initially introduced into human patients with the target disease or condition.

These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the

investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early

evidence on effectiveness.

• Phase II -The investigational product is administered to a limited patient population with a specified disease or

condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible

adverse side effects and safety risks. Multiple Phase II clinical trials may be conducted to obtain information prior

to beginning larger and more expensive Phase III clinical trials and we often conduct multiple Phase I/II trials.

Some of the Phase II trials can potentially provide an adequate basis for regulatory approval.

• Phase III -The investigational product is administered to an expanded patient population to further evaluate

dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at

multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/

benefit ratio of the investigational product and to provide an adequate basis for product approval.

In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is

approved to gain more information about the product. These so-called Phase IV trials may be made a condition to approval

of the BLA.

Concurrently with clinical trials, companies may complete additional animal trials and develop additional information

about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in

commercial quantities in accordance with GMP requirements. The manufacturing process must be capable of consistently

producing quality batches of the product candidate and, among other things, must include methods for testing the identity,

strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate

packaging must be selected and tested, and stability trials must be conducted to demonstrate that the product candidate does

not undergo unacceptable deterioration over its shelf life.

BLA Submission and Review by the FDA

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the

results of product development, non-clinical trials and clinical trials are submitted to the FDA as part of a BLA requesting

approval to market the product for one or more indications. The BLA must include all relevant data available from

pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with

detailed information relating to the product’s chemistry, manufacturing, controls, and proposed labeling, among other

things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of the

product, or from a number of alternative sources, including trials initiated by investigators. The submission of a BLA

requires payment of a substantial user fee to the FDA, and the sponsor of an approved BLA is also subject to annual

program fees. These fees are typically increased annually. A waiver of user fees may be obtained under certain limited

circumstances.

In addition, under the Pediatric Research Equity Act (“ PREA ”), a BLA or supplement to a BLA must contain data to

assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric

subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and

effective. A sponsor who is planning to submit a marketing application for a drug or biological product that includes a new

active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an

initial Pediatric Study Plan within sixty days after an end-of-Phase II meeting or as may be agreed between the sponsor and

FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which

orphan designation has been granted.

65

Table of Contents

Once a BLA has been submitted, the FDA’s goal is to review the application within 10 months after it accepts the

application for filing, or, if the application relates to an unmet medical need in a serious or life-threatening indication

granted Priority Review by FDA, six months after the FDA accepts the application for filing. If the submission is

incomplete or there are issues with its content or format, a Refusal to File notice is issued sixty days after submission,

rather than acceptance for filing by FDA. The review process may be extended by the FDA’s requests for additional

information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and

potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the

product’s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight

on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the

product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes

and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within

required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to

assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing

facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or

information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that

the application does not satisfy the regulatory criteria for approval.

The testing and approval process requires substantial time, effort and financial resources, and each may take several

years to complete. The FDA may not grant approval on a timely basis, or at all, and we may encounter difficulties or

unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us or our

collaboration partners from marketing our products. After the FDA evaluates a BLA and conducts inspections of

manufacturing facilities where the product will be produced, the FDA may issue an approval, which authorizes commercial

marketing of the product with specific prescribing information for specific indications or a complete response letter, which

indicates that the review cycle of the application is complete and the application is not ready for approval (a “Complete

Response Letter ”). A Complete Response Letter may request additional information or clarification. The FDA may delay

or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/

or require post-marketing testing and surveillance to monitor the safety or efficacy of a product.

If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which

such product may be marketed. For example, the FDA may approve the BLA with a REMS plan to mitigate risks, which

could include medication guides, physician communication plans, or elements to assure safe use, such as restricted

distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among

other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the

FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not

maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase IV

post-market trials and surveillance to further assess and monitor the product’s safety and effectiveness after

commercialization and may limit further marketing of the product based on the results of these post-marketing trials.

Expedited Develo pment and Review Programs

A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA’s review and

approval of new drugs and biological pr oducts that meet certain criteria. Specifically, new drugs and biological products

are eligible for FTD if they are intended to treat a serious or life-threatening condition and demonstrate the potential to

address an unmet medical need for the condition. For a fast-track product, the FDA may consider sections of the BLA for

review on a rolling basis before the complete application is submitted if relevant criteria are met. An FTD product

candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six

months after the FDA accepts the application for filing. Priority review is granted when there is evidence that the proposed

product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a

serious condition. Priority review designation does not change the scientific/medical standard for approval or the quality of

evidence necessary to support approval.

Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that

is reasonably likely to predict clinical benefit, or on a clinical objective that can be measured earlier than irreversible

morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical

benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative

treatments. Post-marketing trials or completion of ongoing trials, including the start of a confirmatory Phase III trial, after

marketing approval are generally required to verify the biologic’s clinical benefit in relationship to the surrogate endpoint

66

Table of Contents

or ultimate outcome in relationship to the clinical benefit. In addition, a sponsor may seek FDA BTD of its product

candidate if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a

serious or life threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate

substantial improvement over existing therapies on one or more clinically significant objectives, such as substantial

treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions

appropriate to expedite the development and review of the application, which may include holding meetings with the

sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive

communication with, the sponsor regarding the development of the drug to ensure that the development program to gather

the non-clinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and

experienced review staff, as appropriate, in a collaborative, cross disciplinary review; assigning a cross disciplinary project

lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific

liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically

appropriate. BTD also allows the sponsor to submit sections of the BLA for review on a rolling basis.

FTD, priority review, BTD, and accelerated approval do not change the standards for approval but may expedite the

development or approval process. Even if a product qualifies for one or more of these programs, FDA may later decide that

the product no longer meets the conditions for the designation or decide that the time period for FDA review or approval

will not be shortened.

Review and Approval of Combination Products

Certain of our product candidates are subject to regulation in the US as combination products. If marketed

individually, each component would be subject to different regulatory pathways and would require FDA approval of

independent marketing applications. A combination product, however, is assigned to a center within the FDA that will have

primary jurisdiction over its regulation based on a determination of the combination product’s primary mode of action,

which is the single mode of action that provides the most important therapeutic action. Our ADC candidates are both drug

and biologic molecules. Such ADCs are regulated as therapeutic biologics and the FDA’s Center for Drug Evaluation and

Research (“ CDER ”), will have primary jurisdiction over pre-market development. We expect to seek approval of these

combination products through a single BLA reviewed by CDER, and we do not expect that the FDA will require a separate

marketing authorization for each of the drug and biologic constituents of such products.

Post-Approval Requirements

Any products manufactured or distributed by us or our collaboration partners pursuant to FDA approvals are subject to

pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping,

reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of

the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims,

are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any

marketed products, as well as new application fees for supplemental applications with clinical data. Biologic manufacturers

and their subcontractors are required to register their establishments with the FDA and certain state agencies and are

subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP, which

impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the

manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA

approval before being implemented. FDA regulations also require investigation and correction of any deviations from

GMP and impose reporting requirements upon us and any third-party manufacturers that we or our collaboration partners

may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production

and quality control to maintain compliance with GMP and other regulations. If our present or future suppliers are not able

to comply with these requirements, the FDA may, among other things, halt our clinical trials, require us or our

collaboration partners to recall a product from distribution, or withdraw approval of the BLA.

We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our

products and product candidates. Future FDA and state inspections may identify compliance issues at our facilities or at the

facilities of our CMOs that may disrupt production or distribution, or require substantial resources to correct. In addition,

discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result

in restrictions on a product, manufacturer or holder of an approved BLA, including the withdrawal or recall of the product

from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. The

FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems

67

Table of Contents

occur after the product reaches the market. Later discovery of previously unknown problems with a product, including

adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with

regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-

market trials or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under

a REMS program. Other potential consequences include, among other things:

• restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the

market or product recalls;

• fines, warning letters or holds on post-approval clinical trials;

• refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or

revocation of product license approvals;

• product seizure or detention, or refusal to permit the import or export of products; or

• injunctions or the imposition of civil or criminal penalties.

The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only

those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the

provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the

promotion of any off-label uses. Failure to comply with these requirements can result in, among other things, adverse

publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally

available products for uses that are not described in the product’s labeling and that differ from those tested by us and

approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-

label uses are the best treatment for patients in varied circumstances. The FDA does not regulate the behavior of physicians

in their choice of treatments. The FDA does, however, restrict marketing authorization holders’ communications on the

subject of off-label use of their products.

Regulation of Diagnostic Tests

Certain of our product candidates may require the use of a diagnostic to identify appropriate patient populations that

may benefit from our products. These companion diagnostics are medical devices, often in vitro devices, which provide

information that is essential for the safe and effective use of a corresponding drug. In the US, unless an exemption applies,

diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary

types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k)

clearance, and approval of a premarket approval application (“ PMA ”). We expect that any companion diagnostic

developed for our drug candidates will utilize the PMA pathway.

FDA’s “In Vitro Companion Diagnostic Devices” guidance states that, for novel drugs such as ours, a companion

diagnostic device and its corresponding drug should be approved or cleared contemporaneously by the FDA for the use

indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make

treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed

for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as

patient selection, the diagnostic device generally will be considered a significant risk device under the FDA’s

Investigational Device Exemption (“ IDE ”) regulations. Thus, the sponsor of the diagnostic device will be required to

comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to

support their respective approvals, both products can be studied in the same investigational trial, if the trial meets both the

requirements of the IDE regulations and the IND regulations.

In the EU, in vitro devices are subject to the In Vitro Device Regulation (“ IVDR ”), which is directly applicable in all

EEA member states. The IVDR, among other things, subjects the marketing and sale of applicable medical devices to

stricter requirements, including in the areas of clinical evaluation requirements, quality systems and post-market

surveillance; introduces a new classification system for companion diagnostics; and sets up a central database to provide

patients, healthcare professionals and the public with comprehensive information on products available in the EU. While

the IVDR became effective on May 26, 2022, many classes of devices do not need to be fully compliant with the regulation

until the end of the applicable transitional period, which ranges from 2025 to 2028, depending on device class.

Healthcare Laws and Compliance Requirements

68

Table of Contents

Healthcare providers and third-party payers play a primary role in the recommendation and prescription of drug

products that are granted regulatory approval. Arrangements with providers, consultants, third-party payers and customers

are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain our business

and/or financial arrangements. Such restrictions under applicable federal and state healthcare laws and regulations include

the following:

• the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and

willfully soliciting, offering, receiving or providing remuneration (including any kickback, bribe or rebate),

directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the

purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under a

federal healthcare program such as Medicare and Medicaid. The term “remuneration” has been broadly interpreted

to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors

protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly.

Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or

recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person or

entity does not need to have actual knowledge of the federal Anti-Kickback Statute or a specific intent to violate it

to have committed a violation; in addition, the government may assert that a claim including items or services

resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes

of the False Claims Act. Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up

to $100,000 for each violation, plus up to three times the remuneration involved. Civil penalties for such conduct

can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties,

including criminal fines and imprisonment of up to 10 years. Similarly, violations can result in exclusion from

participation in government healthcare programs, including Medicare and Medicaid;

• the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties

laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be

presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to

avoid, decrease or conceal an obligation to pay money to the federal government. When an entity is determined to

have violated the federal civil False Claims Act, the government may impose civil fines and penalties and exclude

the entity from participation in Medicare, Medicaid and other federal healthcare programs;

• HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willingly

executing, or attempting to execute, a scheme or making false statements in connection with the delivery of or

payment for health care benefits, items, or services;

• HIPAA, as amended by the Health IT for Economic and Clinical Health Act and its implementing regulations,

which also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy,

security and transmission of individually identifiable health information on covered entities and their business

associates that perform certain functions or activities that involve the use or disclosure of protected health

information on their behalf. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have

actual knowledge of the statute or specific intent to violate it to have committed a violation;

• the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient

Protection and Affordable Care Act (the “ ACA ”), which requires certain manufacturers of drugs, devices,

biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health

Insurance Program, with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services

within the US Department of Health and Human Services, information related to payments and other transfers of

value to physicians, certain other healthcare providers, and teaching hospitals and information regarding

ownership and investment interests held by physicians and their immediate family members; and

• analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may

apply to healthcare items or services that are reimbursed by non-governmental third-party payers, including

private insurers.

Some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance

guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug

manufacturers to report information related to payments to physicians and other health care providers or marketing

69

Table of Contents

expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances,

many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating

compliance efforts.

Also, the US FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries

from making improper payments to foreign officials for the purpose of obtaining or retaining business. We cannot assure

you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our

employees, future distributors, partners or agents. Violations of these laws, or allegations of such violations, could result in

fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.

Healthcare Reform

A primary trend in the US healthcare industry and elsewhere is cost containment. There have been a number of federal

and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products,

limiting coverage and reimbursement for drugs and other medical products, introducing government control and other

changes to the healthcare system in the US.

In March 2010, the US Congress enacted the ACA, which, among other things, included changes to the coverage and

payment for drug products under government health care programs.

Other legislative changes have been proposed and adopted in the US since the ACA was enacted. The Budget Control

Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on

Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through

2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government

programs. This includes aggregate reductions of Medicare payments to providers of two percent (2%) per fiscal year,

which will remain in effect through 2031 unless additional Congressional action is taken.

Since its enactment, there have been numerous legal challenges and Congressional actions to repeal and replace

provisions of the ACA. Some of the provisions of the ACA have yet to be implemented. We continue to evaluate the effect

that the ACA and any repeal and replacement efforts may have on our business but expect that the ACA, as currently

enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future

could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our

existing products or to successfully commercialize our product candidates, if approved. In addition to the ACA, there will

continue to be proposals by legislators at both the federal and state levels, regulators and third-party payers to keep

healthcare costs down while expanding individual healthcare benefits.

Furthermore, the IRA was signed into law on August 16, 2022. The IRA, among other things, (i) allows the US

Department of HHS to negotiate prices for certain single-source drugs and biologics covered under Medicare Part B and

Part D, and subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the

legislation by offering a price that is n ot equal to or less than the negotiated “maximum fair price” under the law; and (ii)

establishes rebates under Medicare to penalize drug price increases that outpace inflation. Negotiations were conducted

with ten high-cost drugs paid for by Medicare Part D, and the negotiated prices will take effect in 2026.

Coverage and Reimbursement

Sales of pharmaceutical products depend significantly on the availability of third-party coverage and reimbursement.

Third-party payers include government health administrative authorities, managed care providers, private health insurers

and other organizations. Although we currently believe that third-party payers will provide coverage and reimbursement for

our products and product candidates, if approved, these third-party payers are increasingly challenging the price and

examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the

reimbursement status of newly approved healthcare products. We may need to conduct expensive clinical trials to

demonstrate the comparative cost-effectiveness of our products. The product candidates that we develop may not be

considered cost-effective. It is time-consuming and expensive for us to seek coverage and reimbursement from third-party

payers. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable

basis.

70

Table of Contents

The process for determining whether a payer will provide coverage for a product is typically separate from the process

for setting the reimbursement rate that the payer will pay for the product. A payer’s decision to provide coverage for a

product does not imply that an adequate reimbursement rate will be available. Additionally, in the US there is no uniform

policy among payers for coverage or reimbursement. Third-party payers often rely upon Medicare coverage policy and

payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and

approval processes. Therefore, coverage and reimbursement for products can differ significantly from payer to payer. One

third-party payer’s decision to cover a particular medical product or service does not ensure that other payers will also

provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. As a

result, the coverage determination process will require us to provide scientific and clinical support for the use of our

products to each payer separately and will likely be a time-consuming process. If coverage and adequate reimbursement are

not available, or are available only at limited levels, successful commercialization of, and obtaining a satisfactory financial

return on, any product we develop may not be possible.

Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness

of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for

any product that might be approved for marketing, we may need to conduct expensive trials in order to demonstrate the

medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain

regulatory approvals. Third-party payers may not consider our products or product candidates to be medically necessary or

cost-effective compared to other available therapies.

Additionally, the containment of healthcare costs (including drug prices) has become a priority of federal and state

governments. The US government, state legislatures, and foreign governments have shown significant interest in

implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for

substitution by generic products. Adoption of price controls and cost-containment measures, and adoption of more

restrictive policies in jurisdictions with existing controls and measures, could limit our net revenue and results. If these

third-party payers do not consider our products to be cost-effective compared to other therapies, they may not cover our

products or product candidates once approved as a benefit under their plans or, if they do, the level of reimbursement may

not be sufficient to allow us to sell our products on a profitable basis. Decreases in third-party reimbursement for our

products once approved or a decision by a third-party payer not to cover our products could reduce or eliminate utilization

of our products and have an adverse effect on our sales, results of operations, and financial condition. In addition, state and

federal healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that

federal and state governments will pay for healthcare products and services, which could result in additional pricing

pressures or reduced demand for our products or product candidates once approved.

Review and Approval of Medicinal Products in the EU

In order to market any product outside of the US, a company must also comply with numerous and varying regulatory

requirements of other countries and jurisdictions regarding quality, safety and efficacy, and governing, among other things,

clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA

approval for a product, an applicant will need to obtain the necessary approvals by the comparable non-US regulatory

authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions.

Specifically, the process governing approval of medicinal products in the EU generally follows the same structure as in the

US. It entails satisfactory completion of preclinical trials and adequate and well-controlled clinical trials to establish the

safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent

authorities of a marketing authorization application (an “ MAA ”) and granting of an MAA by these authorities before the

product can be marketed and sold in the EU.

The Clinical Trials Regulation (EU) No 536/2014 entered into application on January 31, 2022. The Regulation is

intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the

supervision of clinical trials and increase their transparency. Specifically, the new Regulation, which will be directly

applicable in all EU Member States, introduces a streamlined application procedure via a single entry point, the “EU

portal”, a single set of documents to be prepared and submitted for the application as well as simplified reporting

procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials will be

introduced and is divided into two parts. Part I is assessed by the competent authorities of a reference member state

proposed by the trial sponsor, based largely on the type of clinical trial, risk-benefit analysis, and compliance with technical

requirements. This assessment, which is valid for the entire EU, is then submitted to the competent authorities of all the

applicable member states in which the trial is to be conducted under Part II.

71

Table of Contents

In the EEA, which consists of the 27 Member States of the EU, as well as Norway, Iceland and Liechtenstein,

medicinal products can only be commercialized after a related marketing authorization has been granted. A company may

submit an MAA either on the basis of the centralized or decentralized procedure. Under the centralized procedure, MAAs

are submitted to the EMA for scientific review by the EMA’s CHMP. The CHMP issues an opinion concerning whether

the quality, safety and efficacy of the product has been demonstrated. The opinion is considered by the European

Commission which is responsible for granting a centralized marketing authorization in the form of a binding European

Commission decision. If the application is approved, the European Commission grants a single marketing authorization

that is valid throughout the EEA. The centralized procedure is mandatory for certain types of products, such as

biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic

cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the

treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and

viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in

the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the

interest of public health in the EU.

National marketing authorizations, which are issued by the competent authorities of EEA countries and only cover

their respective territory, are available for products not falling within the mandatory scope of the centralized procedure.

Where a product has already been authorized for marketing in an EEA country, this national marketing authorization can

be recognized in another EEA country through the mutual recognition procedure. The mutual recognition procedure

provides for the EEA countries selected by the applicant to mutually recognize a national marketing authorization that has

already been granted by the competent authority of another EEA country, referred to as the “ Reference Member State ”.

The decentralized procedure is used when the product in question has yet to be granted a marketing authorization in any

EEA country. Under this procedure the applicant can select the EEA country that will act as the Reference Member State.

In both the mutual recognition and decentralized procedures, the Reference Member State reviews the application and

submits its assessment of the application to the EEA countries for which marketing authorizations are being sought,

referred to as Concerned Member States. Within 90 days of receiving the application and assessment report, each

Concerned Member State must decide whether to recognize the Reference Member State assessment or reject it on the

basis of potential serious risk to public health. If the disputed points cannot be resolved, the matter is first referred to the

Heads of Medicines Agencies’ Coordination Group (the “ Group ”) for Mutual Recognition and Decentralised Procedures

for agreement. If the Group cannot reach an agreement, a referral is made to the EMA. The CHMP will provide an opinion

that will form the basis of a decision to be issued by the European Commission that is binding on all EEA countries. If the

application is successful during the decentralized or mutual recognition procedure, national marketing authorizations will

be granted by the competent authorities in each of the EEA countries chosen by the applicant.

In the EU, conditional marketing authorizations may be granted in the centralized procedure for a limited number of

medicinal products for human use in cases where the related clinical dataset is not yet complete. A conditional marketing

authorization may be granted for a medicinal product, if (1) the risk-benefit balance of the product is positive, (2) it is

likely that the applicant will be in a position to provide the required comprehensive data after the authorization, (3) the

medicinal product fulfills unmet medical needs and (4) the benefit to public health of the immediate availability on the

market of the medicinal product outweighs the risk inherent in the fact that additional data are still required. The

authorization is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any

pending trials are provided, the conditional marketing authorization can be converted into a traditional marketing

authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA, the marketing

authorization will cease to be renewed.

In the EU, innovative medicinal products that are subject to marketing authorization on the basis of a full dossier and

do not fall within the scope of the concept of global marketing authorization qualify for eight years of data exclusivity upon

marketing authorization and an additional two years of market exclusivity. The concept of global marketing authorization

prevents the same marketing authorization holder or members of the same group, or companies that have concluded tacit or

explicit agreements concerning the marketing of the same medicinal product, from obtaining separate data and market

exclusivity periods for medicinal products that contain the same active substance. Data exclusivity, if granted, prevents

regulatory authorities in the EU from referencing the innovator’s data to assess a generic application or biosimilar

application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar

MAA can be submitted, and the innovator’s data may be referenced. However, the generic product or biosimilar products

cannot be marketed in the EU for a further two years thereafter. The overall ten-year period may be extended for a further

year to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains

72

Table of Contents

an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their

authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference

medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of

appropriate preclinical or clinical trials must be provided in support of an application for marketing authorization.

Guidelines from the EMA detail the type and quantity of supplementary data to be provided for different types of

biological products.

A marketing authorization has an initial validity for five years in principle. The marketing authorization may be

renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent

authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent

authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced

since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid.

The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating

to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently

definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not

followed by the actual placing of the medicinal product on the EU market (in case of centralized procedure) or on the

market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset

clause).

Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a drug can be

designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the

diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five

in 10,000 persons in the EU when the application is made, or (2) a life-threatening, seriously debilitating or serious and

chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would

generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate

that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been

authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.

Once authorized, orphan medicinal products are entitled to 10 years of market exclusivity in all EU Member States and

in addition a range of other benefits during the development and regulatory review process including scientific assistance

for trial protocols, authorization through the centralized marketing authorization procedure covering all member countries

and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be

granted to a similar medicinal product with the same orphan indication during the 10-year period with the consent of the

marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan

medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar

medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically superior to

the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can

be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not

to justify maintenance of the 10 years of market exclusivity.

In case an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is

required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of

medicinal products. These include:

• Compliance with the EU’s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can

impose post-authorization trials and additional monitoring obligations.

• The manufacturing of authorized medicinal products, for which a separate manufacturer’s license is mandatory,

must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including

Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission

Guidelines for Good Manufacturing Practice (“ EU GMP ”). These requirements include compliance with EU

GMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the

manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active

pharmaceutical ingredients into the EU.

73

Table of Contents

• The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education

and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU

notably under Directive 2001/83EC, as amended, and EU Member State laws.

Regulation and Procedures Governing Approval of Medicinal Products in Japan

In order to market any medical product in Japan, a company must comply with numerous and varying regulatory

requirements regarding quality, safety and efficacy, obtaining marketing approval, distributing products and conducting

product sales. Japan is a member of the International Council for Harmonisation of Technical Requirements for

Pharmaceuticals for Human Use and has pharmaceutical law and regulations that are similar in many respects to those of

the US and the EU. These requirements are embodied in the Act on Securing Quality, Efficacy and Safety of Products

Including Pharmaceuticals and Medical Devices (“ Pharmaceuticals and Medical Devices Act ”) and related cabinet

orders, Ministerial ordinances, and guidelines. A pharmaceutical company that manufactures or markets medical products

in Japan is subject to the supervision of the MHLW and PMDA, primarily under the Pharmaceuticals and Medical Devices

Act.

A clinical trial notification needs to be submitted to the PMDA in advance of clinical trial initiation in Japan. The

marketing approval from MHLW needs to be obtained before the product can be marketed and sold in the Japanese market.

Obtaining marketing approval requires the satisfactory completion of pharmaceutical development, preclinical studies and

adequate and well-controlled clinical trials to establish the safety and efficacy of the medical product for each proposed

indication.

A company is required to obtain from the prefectural government a marketing license of the appropriate class to

conduct the business of marketing or providing medical products that are manufactured (or outsourced to a third party for

manufacturing) or imported by such person. Also, to conduct the business of manufacturing medical products which will be

marketed in Japan, a company is required to obtain from the prefectural government a manufacturing license for each

manufacturing site in Japan, and a manufacturing certification in the case of overseas manufacturing.

It is a requirement to obtain marketing approval from the MHLW for the marketing of each medical product. An

application for marketing approval must be made through the PMDA. The PMDA reviews the results of the quality and

nonclinical and clinical studies that show the efficacy and safety of the product candidate. A data compliance review, on-

site inspection for good clinical practice, audit and detailed data review for compliance with GMP are undertaken by the

PMDA. The application is then discussed by the committees of the Pharmaceutical Affairs Council. Based on the results of

these reviews, the final decision on approval is made by the MHLW.

If the product is designed for treating certain difficult diseases and those for which the patient population is limited, the

applicant may be able to obtain designation as an orphan drug product if it demonstrates unique therapeutic value. There

are also expedited programs.

The sponsor must complete a preclinical safety evaluation of the investigative product and submit a clinical trial

notification, including the clinical trial protocol, to the PMDA in advance of clinical trial initiation in Japan. If the

authorities raise an issue or comment on the notification application, those need to be resolved within 14 or 30 days, then

the sponsor may proceed to conclude a clinical trial agreement with the site and commence the clinical trial. Any changes

to the trial protocol or other information submitted must be cleared by the IRB and when protocol is changed substantially,

the clinical trial notification needs to be resubmitted.

The data from clinical trials and other pertinent data, which must be attached for an application for marketing

approval, must be obtained in compliance with the standards established by the MHLW, such as the ICH Good Clinical

Practice Guideline and GCP stipulated by the ministerial ordinances of the MHLW. Medicines used in clinical trials must

be manufactured in accordance with Japan’s GMP.

If the sponsor of the clinical trial is not an entity within Japan, it must appoint a domestic entity to act as its agent and

carry out obligations on the overseas sponsor’s behalf. The sponsor must hold a clinical trial insurance policy, and in

accordance with industry practice, should establish a compensation policy for the injuries from the trial.

Non-clinical studies performed to demonstrate the safety of new chemical or biological substance must be conducted

in compliance with the principles of Japanese GLP, which reflect the Organization for Economic Co-operation and

74

Table of Contents

Development (“ OECD ”) requirements. Currently, Japan, the EU and U.K. have a mutual recognition agreement for GLP,

and data generated compliant with EU requirements will be accepted by the Japanese authorities. There is no similar

agreement with the US, but this is not a significant issue because of the OECD arrangement.

A marketing license-holder that has obtained marketing approval for a new molecular entity, administration route,

combination drugs, indication, or posology must have that pharmaceutical re-examined by the PMDA for a specified

period after receiving marketing approval. Such re-examination period for EPKINLY and Tivdak is stated to be eight (8)

years after the marketing approval in September 2023 and March 2025 respectively. The purpose of this re-examination

process is to ensure the safety and efficacy of a newly approved pharmaceutical by imposing on the marketing license-

holder the obligation to gather clinical data for a certain period after the marketing approval was granted in order for the

PMDA to have the opportunity to re-examine the product. Results of use and other pertinent data must be attached for an

application for a re-examination. A marketing license holder that has obtained marketing approval is also required to

investigate, among other things, the results of use and to periodically report to the PMDA pursuant to the Pharmaceuticals

and Medical Devices Act. During the re-examination period, exclusivity on the market is granted regardless of effective

patent.

The MHLW may require additional post-approval studies (Phase IV) for some specific cases, to further evaluate safety

and/or to gather information on the use of the product under specified conditions.

In Japan, public medical insurance systems cover the entire Japanese population. The public medical insurance system,

however, does not cover any medical product which is not listed on the National Health Insurance (“ NHI ”) price list

published by the Minister of the MHLW. Accordingly, a marketing license-holder of medical products must first have a

new medical product listed on the NHI price list in order to obtain its coverage under the public medical insurance system.

New regulatory approved drugs are listed on the NHI price list within 60 or 90 days after its regulatory approval. The NHI

price list listed EPKINLY in November 2023 and Tivdak in May 2025.

The NHI price of a medical product is determined either by price comparison of comparable medical products with

necessary adjustments for innovativeness, usefulness or size of the market; or, in the absence of comparable medical

products, by the cost calculation method, determined after considering the opinion of the manufacturer. Prices on the NHI

price list are subject to revision, generally once every two years, on the basis of the actual prices at which the medical

products are purchased by medical institutions from wholesalers.

C. Organizational Structure

Genmab A/S holds investments either directly or indirectly in the following significant subsidiaries: Genmab B.V.

(Utrecht, the Netherlands), Genmab Holding B.V. (Utrecht, the Netherlands), Genmab Holding II B.V. (Utrecht, the

Netherlands), Merus B.V. (Utrecht, the Netherlands), Merus US Inc. (Massachusetts, USA), Genmab K.K (Tokyo, Japan),

and Genmab US, Inc. (New Jersey, USA). These subsidiaries perform certain research and development, selling,

general and administrative, and management activities on behalf of Genmab A/S.In addition, Genmab US, Inc. and

Genmab K.K conduct commercial activities in their respective markets.

D. Property And Equipment

The following table specifies our material leased facilities and their related activities:

75

Table of Contents

Location	Use of facility	Area (in square feet)	Lease expiry date
Valby, Denmark	Corporate headquarters	175,130	February, 2038
Ballerup, Denmark	Office and laboratory space	45,622	June, 2031
Utrecht, Netherlands	Office, laboratory, and pre- clinical development space	90,061	May, 2032
Utrecht, Netherlands	Office, laboratory, and pre- clinical development space	59,352	June, 2032
Utrecht, Netherlands	Office, laboratory, and pre- clinical development space	61,795	April, 2032
Plainsboro, NJ, USA	Office and laboratory space	135,136	August, 2031
Plainsboro, NJ, USA	Office and laboratory space	135,476	July, 2036
Tokyo, Japan	Office Space	28,744	June, 2029
Suzhou, China	Office and laboratory space	37,940	October, 2026
Utrecht, Netherlands	Office and laboratory space	54,015	July, 2029

We believe that our existing facilities are adequate to meet our current needs and that suitable additional or alternative

facilities will be available in the future on commercially reasonable terms to meet our future needs.

See Note 3.2 “Property and Equipment” in our Audited Financial Statements for additional details regarding our

property and equipment, and other capital expenditures.

ITEM 4A UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 5 OPERATING AND FINANCIAL REVIEW AND PROSPECTS

A. Operating Results

Overview

We are an international biotechnology company with a pipeline of novel antibody-based products and product

candidates designed to address unmet medical needs and improve treatment outcomes for patients with cancer and other

serious diseases. Our goal in building our pipeline is to bring medicines to market ourselves in geographic areas where we

believe we will be able to maximize their value and make a meaningful impact on the treatment landscape.

.

Our current priorities are the commercial or late-stage programs epcoritamab, Rina-S and petosemtamab. Epcoritamab,

marketed as EPKINLY in countries including the US and Japan and as TEPKINLY in the EU, is being developed and

commercialized in collaboration with AbbVie. Epcoritamab is the first and only bispecific antibody approved for the

treatment of multiple B-cell malignancies in various regions around the world . Rina-S and petosemtamab are wholly

owned by Genmab. Rina-S is in Phase III clinical development for PROC, PSOC and endometrial cancer. Petosemtamab is

in Phase III clinical development for newly diagnosed and recurrent/metastatic r/m HNSCC.

Our full pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function

enhanced antibodies and ADCs. We currently have five proprietary products or product candidates in active clinical

development, which comprise programs where we retain at least 50% of product rights in collaboration with partners. Our

first proprietary commercial product to be approved was tisotumab vedotin, marketed as Tivdak. Tivdak is being co-

developed globally and co-promoted in the US in collaboration with Pfizer and exclusively by Genmab outside of the US

and China. Tivdak is the first and only ADC a pproved for the treatment of adult patients with recurrent or metastatic

cervical cancer with disease progression on or after prior systemic therapy in territories including the US, Europe and

Japan. In addition to our marketed products and clinical product candidates, we have multiple proprietary and partnered

preclinical programs.

76

Table of Contents

To develop and deliver novel therapies to patients, we have formed strategic collaborations with biotechnology and

pharmaceutical companies. We selective ly enter into collaborations with other biotechnology and pharmaceutical

companies that build our network in the biotechnology space and give us access to complementary technologies or

products that move us closer to achieving our vision and fulfilling our core purpose. In addition to Genmab’s own pipeline

of product candidates, our innovation and proprietary technology platforms are applied in the pipelines of global

pharmaceutical and biotechnology companies. These companies are running clinical development programs with

antibodies created by Genmab or created using Genmab’s proprietary DuoBody bispecific antibody technology platform.

The six approved medicines created by Genmab or that incorporate Genmab’s innovation or technology platforms are

daratumumab, marketed by J&J as DARZALEX (IV formulation) and DARZALEX FASPRO or DARZALEX SC (SC

formulation), approved in the US, Europe, Japan and other territories for the treatment of certain indications of MM and

AL amyloidosis; amivantamab, marketed in the US, Europe, Japan and other territories by J&J as RYBREVANT for the

treatment of certain adult patients with locally-advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. A

SC formulation, RYBREVANT FASPRO , is also approved in the US; teclistamab, marketed in the US, Europe, Japan and

other territories by J&J as TECVAYLI for certain indications of MM; talquetamab, marketed in the US, Europe, Japan and

other territories by J&J as TALVEY for certain indications of MM; SC ofatumumab, marketed in the US, Europe, Japan

and other territories as Kesimpta by Novartis for the treatment of RMS; and teprotumumab, marketed in the US, Europe

and Japan as TEPEZZA by Amgen for the treatment of TED. In addition BIZENGRI (Z enocutuumab-zbco ) was added to

our portfolio of royalty medicines as part of our acquisition of Merus. Merus exclusively licensed to Partner Therapeutics

the right to commercialize BIZENGRI for the treatment of NRG1 fusion-positive cancer in the US. Under the agreements

for these products Genmab is entitled to certain potential milestones and royalties.

For our proprietary commercial products EPKINLY and Tivdak, our commercialization rights and related revenues

and expenses vary by jurisdiction as further described below:

• EPKINLY collaboration with AbbVie. Genmab shares commercial responsibilities for epcoritamab, marketed

as EPKINLY, with AbbVie in the US and Japan, while AbbVie is responsible for global commercialization

outside of the US and Japan. We are the principal for net sales of EPKINLY in the US and Japan and

therefore record such sales as net product sales. In the US and Japan, we share with AbbVie 50% of such

sales and related cost of product sales and these amounts are classified as cost of product sales. We and

AbbVie are each responsible for 50% of the aggregate research and development and sales and marketing

costs of EPKINLY in the US and Japan, and we classify our share of such costs in research and development

and selling, general and administrative expenses, respectively. We are entitled to tiered royalties between

22% and 26% on net sales for epcoritamab outside the US and Japan, subject to certain royalty reductions.

• Tivdak collaboration with Pfizer. Tisotumab vedotin, marketed as Tivdak, is being co-developed by Genmab

and Pfizer. Under a joint commercialization agreement, Genmab is co-promoting Tivdak in the US and is

leading commercial operational activities in Japan, Europe and all other regions globally, excluding the US

and China. Pfizer is leading commercial operational activities in the US and will lead commercial operational

activities in China once approved in connection with the sublicense of its rights to develop and commercialize

tisotumab vedotin in China to Zai Lab. Genmab will record sales for Europe, Japan and rest of world markets

(excluding the US and China), and will provide royalties in the low teens to Pfizer on net sales.

We are funding our operating requirements, including our research and development expenses and our planned

commercialization activities, primarily throu gh operating cash flow (including royalties and milestones from our

collaboration partners). We may also use additional debt financing, proceeds from equity financing or other forms of

financing to finance acquisitions or other forms of growth.

For a description of certain of our product and technology collaborations including relevant royalty tiers, milestones

and expense sharing provisions, please refer to “Item 4.B—Business Overview—Product and Technology Collaborations” .

77

Table of Contents

Acquisition of Merus

On December 12, 2025, we completed the Acquisition of Merus, resulting in Merus becoming a wholly owned

subsidiary of Genmab. It provided us with worldwide rights outside of the US to Merus' approved product, BIZENGRI

(zenocutuzumab-zbco), and its lead product candidate, petosemtamab. In addition, we acquired Merus' Biclonics and

Triclonics technology platforms. Petosemtamab is an investigational antibody-dependent cell-mediated cytotoxicity

(ADC)-enhanced Biclonics® for the potential treatment of solid tumors that is designed to bind to cancer stem cells

expressing EGFR and LGR5.

We intend to continue the clinical development of petosemtamab in the LiGeR-HN1 Phase III clinical trial for the

treatment of 1L PD-L1+ r/m HNSCC with pembrolizumab; the LiGeR-HN2 Phase III clinical trial for the treatment of

2/3L r/m HNSCC and the ongoing Phase I/II clinical trial in mCRC. We also intend to commence a Phase III clinical trial

of petosemtamab in locally advanced HNSCC.

The FDA granted petosemtamab BTD in combination with pembrolizumab for the first-line treatment of adult patients

with r/m PD-L1 positive HNSCC with CPS ≥ 1 in February 2025, and for the treatment of patients with r/m HNSCC whose

disease has progressed following treatment with platinum based chemotherapy and an anti-PD-1 or anti-PD-L1 antibody.

This designation followed receipt of FTD for petosemtamab for the treatment of patients with r/m HNSCC whose disease

has progressed following treatment with platinum-based chemotherapy and an anti-programmed cell death protein 1

antibody announced in August 2023.

See Note 5.5 in our Audited Financial Statements for additional details regarding our acquisition of Merus.

Key Compone nts of Our Results an d Related Trends

Impact of the Acquisition of Merus

We expect that the acquisition of Merus will increase our research and development expenses as well as our selling,

general and administrative expenses in the short to medium term as compared to our own recent historical level. We expect

an increase in these expenses primarily as a result of our planned development and commercialization activities for

petosemtamab. We intend to expand Merus' current development plan for petosemtamab in additional HNSCC settings and

other potential tumor types. Such expanded development will involve increased research and development and selling,

general and administrative expenses as we support related manufacturing, clinical trial activities, and commercialization

activities. See “—Liquidity and Capital Resources.”

While we expect to record additional royalty revenues because we acquired zenocutuzumab as a part of the Merus

acquisition, we do not expect such revenues to be material. Considering the costs of development of petosemtamab and

other Merus product candidates, we expect to maintain positive operating earnings and positive cash flow generation driven

by our royalty business and proprietary products.

In addition, we recorded acquisition-related costs and integration-related charges in the year ending December 31,

2025 related to the acquisition of Merus. We also expect to record integration-related charges related to the acquisition of

Merus in the year ending December 31, 2026. Such integration-related charges may be significant.

In December 2025, Genmab entered into two senior secured credit facilities, consisting of a a $1 billion Term Loan A

Facility and a $2 billion Term Loan B Facility (the loans thereunder, collectively the “Term Loans”), and a $500 million

revolving credit facility (together with the Term Loans, the "Loans"). Genmab also issued $1.5 billion principal amount of

Senior Secured Notes and $1.0 billion principal amount of Senior Unsecured Notes (together, the “Notes”). Genmab

incurred indebtedness under the Loans and Notes to contribute to the financing of the acquisition of Merus. The detailed

descriptions of the Term Loans and Notes in Note 4.8 to the Audited Financial Statements included in the Annual Report

for 2025 are incorporated herein by reference.

Revenues

Our revenues are currently comprised of royalties, net product sales, milestone revenue, reimbursement revenue,

collaboration revenue and license fees. Royalty revenue from licenses is based on third-party sales of licensed products.

Net product sales represent sales of products when Genmab is determined to be the principal in sales to the end customers.

Milestone revenue is typically related to reaching particular stages in product development, regulatory approval or a certain

78

Table of Contents

level of net sales. Reimbursement revenue is mainly comprised of the reimbursement of certain research and development

expenses related to the development work under our collaboration agreements. Collaboration revenue reflects profit sharing

arrangements for the sale of commercial products by our collaboration partners. License fees are non-refundable, upfront

fees for our intellectual property received from our collaboration partners.

The majority of our revenue is recognized from our collaboration partners under our collaboration agreements. In

particular, our ability to generate revenue significantly depends on the success of J&J’s continued ability to effectively

maintain and grow sales of DARZALEX for its approved indications, expand its indications, and successfully compete

with existing and potential new investigational agents and technologies that are currently being marketed or studied for the

same indications as DARZALEX. In addition, the royalties payable by J&J are limited in time. Pursuant to the terms of the

agreement, J&J’s obligation to pay royalties to us will expire on a country-by-country basis on the later of the date that is

13 years after the first sale of daratumumab in such country or upon the expiration or invalidation of the last-to-expire

relevant Genmab patent covering daratumumab in such country. The first US, European and Japanese sales of

daratumumab occurred in 2015, 2016 and 2017, respectively. We have issued patents and pending patent applications

covering daratumumab in numerous jurisdictions, including patents issued in the US, Europe and Japan. J&J owns a

separate patent portfolio related to the SC formulation of daratumumab used in DARZALEX FASPRO/DARZALEX SC,

but a binding arbitration determined that we are not entitled to royalties based on these separate patents. Our issued US,

European and Japanese patents covering daratumumab, after giving effect to issued US, European and Japanese PTEs and

SPCs, expire in 2029, 2031 and begin to expire in 2030, respectively. Assuming constant underlying sales of DARZALEX,

we expect that our royalties from sales of DARZALEX will begin to decline materially in 2029 following expiration of our

US patent rights on daratumumab. We have also received, and in the future may from time to time receive, revenues from

milestones and other payments relating to our collaborations.

In addition to revenue recognized from our collaboration partners, we also record revenue for sales of our proprietary

commercial products. Epcoritamab was approved by the FDA and Japan MHLW in May 2023 and September 2023,

respectively, and is marketed in the US and Japan under the tradename EPKINLY. O ur net product sales derive solely from

EPKINLY. Tisotumab vedotin was approved by the FDA in September 2021, and is currently marketed in the US as

Tivdak. Pfizer records net product sales in the US and shares 50% of the profit of such sales with us, and we record this

profit share as collaboration revenue. Our ability to generate revenue from our proprietary commercial products, including

EPKINLY and Tivdak, depends on the commercial potential of such products as well as our ability to successfully

commercialize them.

Our ability to generate revenue from our proprietary and partnered product candidates depends on our and our

collaboration partners’ ability to successfully complete clinical trials for our product candidates and receive regulatory

approvals, which could impact the commercial potential of such products and our potential to receive milestone payments,

royalties, net sales and other revenues for these products in the future.

Our reported revenue is affected by the translation of royalties and other revenues denominated in foreign currencies

into US dollars.

For more information on our revenues, including for the breakdown of our revenues by type, collaboration partner and

product, see Note 2.1 of our Audited Financial Statements included in this Annual Report.

Cost of Product Sales

Cost of product sales includes direct and indirect costs relating to the manufacturing of inventory mainly from third-

party providers of manufacturing as well as costs related to internal resources and distribution and logistics. Inventory

amounts written down as a result of excess or obsolescence are charged to cost of product sales. Also included in cost of

product sales are royalty payments on commercialized products.

Additionally, cost of product sales includes profit-sharing amounts owed to collaboration partners for the sale of

commercial products when Genmab is determined to be the principal in sales to end customers. The only profit-sharing

amounts owed to collaboration partners that are recorded as cost of product sales relate to sales of EPKINLY in the US and

Japan pursuant to the Collaboration Agreement with AbbVie.

Aside from these items, there are no other costs included within cost of product sales.

79

Table of Contents

Research and Development Expenses

We are currently advancing our proprietary product candidates through clinical development and are conducting

preclinical trials with respect to other programs. Developing product candidates is expensive, time-intensive and risky, and

we expect our research and development expenses to increase over the next few years, particularly as we seek to advance

our proprietary product candidates toward commercialization. Our research and development expenses include internal

costs relating to our research and development departments, as well as external costs relating to trials performed by

external suppliers and collaboration partners. Internal research and development expenses consist primarily of salaries and

benefits for our research and development staff and related expenses, including expenses related to cash bonuses, warrant

and restricted stock unit (“ RSU ”) programs as applicable to such personnel, costs of related facilities, equipment and other

overhead expenses that have been determined to be directly attributable to research and development, costs associated with

obtaining and maintaining patents for intellectual property, amortization of licenses and rights, amortization and

impairment of intangible assets and depreciation and impairment of property and capital assets used to develop our product

candidates.

Major components of the external costs are fees and other costs paid to CROs in conjunction with preclinical trials and

the performance of clinical trials, milestone payments for in-licensed technology, as well as fees paid to CMOs in

conjunction with the production of clinical compounds, drug substances and drugs. This includes (i) antibody clinical

material for use in clinical trials and (ii) preparation for production of process validation batches for potential future

regulatory submissions and related activities. These costs are expensed as incurred, because they do not qualify to be

capitalized as inventory under IFRS Accounting Standards since the technical feasibility of the materials is not proven and

no alternative use for them exists in the absence of marketing approval. Research and development expenses include

amortization of intangible assets only in connection with licenses and rights we have acquired and capitalized. We do not

capitalize intellectual property generated through our internal development activities. We expect to incur higher research

and development expenses in future periods, including increasing costs for clinical trials and manufacturing as our

proprietary product candidates advance in clinical development and we increase the number of product candidates under

active clinical development. Our research and development expenses may vary substantially from period to period based on

the timing of our research and development activities, including timing due to regulatory approvals and enrollment of

patients in clinical trials. See ‘‘Item 5.B—Liquidity and Capital Resources’’ below.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses consist primarily of wages and salaries for personnel other than

research and development staff. Also included are expenses related to pre-launch commercialization activities,

depreciation, amortization and impairment of property and equipment, to the extent such expenses are related to the

administrative functions, and co-promotion expenses related to commercial sales of Tivdak in the US in accordance with

our Joint Commercialization Agreement with Pfizer. Lastly, selling, general and administrative expenses include

our 50% share of the aggregate costs incurred by us and AbbVie in relation to sales and commercialization of EPKINLY in

the US and Japan. We expect our selling, general and administrative expenses to increase over the next few years as we

continue to expand our commercialization capabilities in a number of jurisdictions. Such expenses may also increase over

time as a result of inflation and other factors.

Overhead expenses are allocated to research and development expenses or selling, general and administrative expenses

based on the number of employees and their relevant functions. The Dutch Research and Development Act (“ WBSO ”)

provides compensation for a part of research and development wages and othe r costs at our Utrecht facility through a

reduction in payroll taxes in the Netherlands. WBSO grant amounts are offset against wages and salaries included in

research and development expenses.

Our ongoing research and development and, increasingly, commercialization activities will require substantial amounts

of capital and may not ultimately be successful. Over the next several years, we expect that we will continue to incur

substantial expenses, primarily as a result of activities related to the continued development of our proprietary pipeline and

developing our commercial capabilities. Our proprietary product candidates will require significant further development,

financial resources and personnel to pursue and obtain regulatory approval and develop them into commercially viable

products, if they are approved and commercialized at all. Our commitment of resources to the research and continued

development of our product candidates and expansion of our proprietary pipeline will likely result in our operating

expenses increasing and/or fluctuating as a result of such activities in future periods. We may also incur significant

80

Table of Contents

milestone payment obligations to certain of our licensors as our product candidates progress through clinical trials towards

potential commercialization.

Acquisition and Integration Related Charges

In the year ended December 31, 2025 , acquisition related charges comprise payments to holders of outstanding Merus

equity awards related to post-combination services. The remaining expenses are integration related charges, which

comprise professional fees incurred to assist with the integration of Merus into our operations post-acquisition.

See Note 5.5 in our Audited Financial Statements for additional details regarding our acquisition of Merus.

Results of Operations

Financial Results for the Year Ended December 31, 2025 Compared to the Year Ended December 31, 2024 and Financial

Results for the Year Ended December 31, 2024 Compared to the Year Ended December 31, 2023

The information on pages 38-46 in our Annual Report 2025 under the heading “Financial Review” is incorporated

herein by reference.

Significant Accounting Policies

The information in Note 1.1 to our Audited Financial Statements included in our Annual Report 2025 is incorporated

herein by reference.

Implementation of New and Revised Standards and Interpretations

The information in Note 1.2 to our Audited Financial Statements included in our Annual Report 2025 is incorporated

herein by reference.

Standards and Interpretations Not Yet in Effect

The information in Note 1.2 to our Audited Financial Statements included in our Annual Report 2025 is incorporated

herein by reference.

B. Liquidity and Capital Resources

The information on pages 43-44 in our Annual Report 2025 under the heading “Liquidity and Capital Resources” is

incorporated herein by reference.

The description of our internal and external sources of liquidity, including Genmab’s unsecured three-year revolving

credit facility and Genmab's five-year senior secured revolving credit facility, in Notes 4.1 and 4.8 to our Audited Financial

Statements included in our Annual Report 2025 is incorporated herein by reference.

The description of our lease obligations in Note 3.3 to our Audited Financial Statements included in our Annual

Report 2025 is incorporated herein by reference.

The description of our financial instruments in Notes 4.2 and 4.3 to our Audited Financial Statements included in our

Annual Report 2025 is incorporated herein by reference.

The description of our contractual obligations related to a number of agreements, primarily related to research and

development activities, in Note 5.3 to our Audited Financial Statements included in our Annual Report 2025 is

incorporated herein by reference.

The description of our contingent commitments under our license and collaboration agreements that may become due

for future payments in Note 5.3 to our Audited Financial Statements included in our Annual Report 2025 is incorporated

herein by reference. The contingent commitments entail uncertainties regarding the period in which payments are due

81

Table of Contents

because these obligations are dependent on milestone achievements, most of which are not expected to be incurred within

the next five years.

In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal

course of business. The terms generally allow us the option to cancel, reschedule and adjust our requirements based on our

business needs prior to the delivery of goods or performance of services. It is not possible to predict the maximum potential

amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and

circumstances involved in each particular agreement.

C. Research and Development, Patents and Licenses, etc.

See “Item 4.B—Business Overview” and “Item 5.A—Operating Results” .

D. Trend Information

See “Item 5.A—Operating Results—Key Components of Our Results and Related Trends” .

E. Critical Accounting Estimates

N ot applicab le.

ITEM 6 DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

A. Directors and Executive Management

The following table sets forth the name, age and position of each member of our Board of Directors (“ Board ”)

members as of the date of this Annual Report on Form 20-F. Our Board consists of six members elected by our

shareholders at the general meeting (“ Shareholder Elected Members ” and each, a “ Shareholder Elected Member ”), and

three members elected by our employees (“ Employee Elected Members ” and each, an “ Employee Elected Member ”).

Shareholder Elected Members are elected by our shareholders every year and Employee Elected Members are elected by

our employees every third year. The terms of office of the Shareholder Elected Members expire in 2026 and Employee

Elected Members expire in 2028. All members of the Board, however elected, are eligible for re-election.

The business address of our directors is our registered office address at c/o Genmab A/S, Carl Jacobsens Vej 30, 2500

Valby, Denmark.

Name of Board Member	Age	Position(s)
Deirdre P. Connelly	65	Chair (independent, Shareholder Elected)
Pernille Erenbjerg	58	Deputy Chair (independent, Shareholder Elected)
Anders Gersel Pedersen	74	Board member (non-independent, Shareholder Elected)
Paolo Paoletti	75	Board member (independent, Shareholder Elected)
Rolf Hoffmann	66	Board member (independent, Shareholder Elected)
Elizabeth O’Farrell	61	Board member (independent, Shareholder Elected)
Martin Schultz	50	Board member (non-independent, Employee Elected)
Mijke Zachariasse	52	Board member (non-independent, Employee Elected)
Michael Kavanagh	52	Board member (non-independent, Employee Elected)

The following is a brief summary of the business experience of our Board members:

Deirdre P. Connelly was elected to the Board in 2017 and currently acts as Chair of the Board. She is a member of the

Audit and Finance Committee, the Compensation Committee and the Nominating and Corporate Governance Committee.

Ms. Connelly has more than 30 years’ experience as a corporate leader and board member in publicly traded companies

with global operations. She has comprehensive knowledge and experience with business turnaround and product

development and has successfully directed the launch of more than 20 new pharmaceutical drugs. As a former HR

executive, Ms. Connelly also valuable insight in corporate culture transformation, talent development and managing large

82

Table of Contents

organizations. She furthermore has significant experience with the development of governance and ESG responsibilities

from various leadership roles and as a board member. Ms. Connelly was formerly the President of North America

Pharmaceuticals for GSK plc from 2009 to 2015 and currently serves on the Board of Directors of the Lincoln Financial

Corporation where she is Chair of the Compensation Committee and a member of the Audit Committee, Corporate

Governance Committee and Executive Committee. She also serves on the Board of Directors at Macy’s, Inc. where she is

Chair of the Nominating and Corporate Governance Committee and a member of the Compensation and Management

Development Committee. She furthermore serves on the Board of Directors of Sarepta Therapeutics, Inc. where she is

Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee. Prior to

her time at GSK plc, she spent 26 years with Eli Lilly and Company from 1984 to 2009, which included tenures as

President of US Operations, Vice President of Human Resources and President of Global Women’s Health. She holds a

bachelor’s degree in Economics and Marketing from Lycoming University and is a graduate of Harvard University’s

Advanced Management Program.

Pernille Erenbjerg was elected to the Board in 2015 and currently acts as Deputy Chair of the Board, as well as the

Chair of the Audit and Finance Committee and as a member of the Nominating and Corporate Governance Committee. Ms.

Erenbjerg has significant expertise in the operation and strategic transformation of large and complex companies, including

digital transformations and digitally-based innovations. She has been responsible for major transformation processes,

including M&A, within complex organizations. Furthermore, she has significant IT and cybersecurity expertise and ESG

experience from various executive and non-executive positions. Ms. Erenbjerg has a Certified Public Accountant

background (no longer practicing) and a comprehensive background within finance, including significant exposure to

public and private equity and debt investors. She is a former CEO and President of TDC Group A/S. Ms. Erenbjerg is an

audit committee financial expert based on her professional experience, including her background within accounting, her

service in senior finance leadership at TDC Group A/S and as an audit committee chair or member at other public

companies. Ms. Erenbjerg previously served as the Group CEO and President of TDC A/S, and, prior to that, served as the

Group CFO of the same Company. She currently serves as Chair of KK Wind Solutions. In addition, she is a member of

the Board of the RTL Group, where she serves as Chair of the Audit Committee, a member of the Board of GlobalConnect

and a member of the Board of Nokia, where she serves as a member of the Audit Committee and the Corporate Governance

and Nomination Committee. She is formerly a partner at Deloitte Touche Tohmatsu Limited and spent 14 years as a

Certified Public Accountant ( “CPA” ) at Arthur Anderson LLP from 1987 to 2002. Ms. Erenbjerg holds a B.S. and an

M.Sc. in Economics from Copenhagen Business School.

Anders Gersel Pedersen was elected to the Board in 2003 and currently serves as the Chair of the Nominating and

Corporate Governance Committee and as a member of the Compensation Committee and the Scientific Committee.

Dr. Pedersen currently has more than 30 years’ board and management experience in publicly traded, international

pharmaceutical and biotech companies. He has significant knowledge and expertise in discovery and development of the

product pipeline from preclinical activities to post-launch marketing studies as well as general business experience. Dr.

Pedersen furthermore has significant experience with the global pharmaceutical market, as well as knowledge of

governance and the development of ESG responsibilities from both various leadership roles and as a board member. He

serves as the Chair of the Board of Aelis Farma S.A.S., and as member of the Board of Bond 2 development 2 GP Limited.

Dr. Pedersen was formerly the Executive Vice President of Research & Development at H. Lundbeck A/S and holds a

medical degree and a doctoral degree in neuro-oncology from University of Copenhagen and a B.S. in Business

Administration from Copenhagen Business School. He is a member of the ESMO, the American Society of Clinical

Oncology, the Danish Society of Medical Oncology, the Danish Society of Internal Medicine and the International

Association for the Study of Lung Cancer.

Paolo Paoletti was elected to the Board in 2015 and currently serves as the Chair of the Scientific Committee and as a

member of the Compensation Committee. Dr. Paoletti has significant experience in research, development and

commercialization in the pharmaceutical industry, where he has been responsible of the development of several globally-

approved medicines and the related global commercial strategies. As an executive, he has led cross-functional teams in the

development and registration of medicines and has been responsible for all compliance aspects for the R&D organization.

Dr. Paoletti has successfully conducted submissions and approvals of new cancer drugs and new indications in the US and

in Europe. He furthermore has significant experience with governance from various leadership roles, including as a board

member. Dr. Paoletti served as President of Oncology at GSK plc and in various roles at Eli Lilly and Company, including

Vice President of Oncology Research. Prior to its acquisition by Takeda, Dr. Paoletti was the CEO of GammaDelta

Therapeutics Limited. He is currently a member of the Investment Committee for Apollo Therapeutics Limited and a

scientific advisor for both 3B Future Health Fund and Sun Pharmaceuticals . He was formerly the CEO of Kesios

83

Table of Contents

Therapeutics Ltd. from 2015 to 2017 and previously served as a member of the Board of NuCana BioMed Ltd and Psioxus

Therapeutics Ltd (renamed Akamis Bio). Dr. Paoletti holds a medical degree from the University of Pisa.

Rolf Hoffmann was elected to the Board in 2017 and is a member of the Audit and Finance Committee and the

Scientific Committee. Mr. Hoffmann has more than 30 years’ experience in senior management and as a board member in

the life science industry worldwide. He has significant expertise in creating and optimizing commercial opportunities in

global markets and has managed large, global companies. Mr. Hoffmann furthermore has knowledge and experience with

governance, compliance and organizational efficiency from various management positions as well as a board member.

Mr. Hoffmann has held a variety of sales and marketing and executive management positions at Eli Lilly and Company

from 1987 to 2004 and served at Amgen from 2004 to 2016 and is a former Senior Vice President, International

Commercial Operations and former Senior Vice President, US Commercial Operations with Amgen. Mr. Hoffmann is

currently an adjunct professor of Strategy and Entrepreneurship at the University of North Carolina Business School. He is

a member of the Boards of Semdor Pharma and Sun Pharmaceutical Industries Ltd where he is a member of the

Nomination and Remuneration Committee. He is also Deputy Chairman of the Supervisory Board of Priavoid GmbH. He

holds an M.A. in English from the University of Cologne, an MA in Kinesiology from Deutsche Sporthochschule Köln in

Cologne, Germany and an MBA from the University of North Carolina at Chapel Hill.

Elizabeth O’Farrell was elected to the Board in 2022 and currently serves as the Chair of the Compensation

Committee and as a member of the Audit and Finance Committee. Ms. O’Farrell has solid financial experience from her

25-year career in finance leadership roles and as a board member. During her career, she has led multiple strategy, planning

and resource allocation processes in multiple roles and in cross-functional teams. Ms. O’Farrell has significant knowledge

and expertise with enacting change in enterprises. In addition to experience at Price Waterhouse and Whipple & Company

Corporation, Ms. O’Farrell held various executive management positions at Eli Lilly and Company, including as former

Chief Procurement Officer. Ms. O’Farrell is an audit committee financial expert based on her professional experience,

including her service in senior finance leadership positions at Eli Lilly and as an audit committee chair or member at other

public companies. She has also completed the Nasdaq Center for Board Excellence Cyber Security Program. She is Chair

of the Board of PDL BioPharma and Chair of the Board of Geron Corporation where she is Chair of the Audit Committee.

She is also a member of the Boards of LENSAR, Karius and SpyGlass Pharma, where she is the Chair of the Audit

Committee for all three. Ms. O’Farrell holds a degree in accounting as well as an MBA in Management Information

Systems from Indiana University, Bloomington and has also served in roles at Price Waterhouse and Whipple & Company

Corporation.

Martin Schultz was elected to the Board in 2022. Mr. Schultz joined Genmab in 2005 and currently serves as Senior

Director, Head of Development Business Partnership & Strategy at Genmab. Mr. Schultz has broad experience within

clinical project management with a substantial understanding and knowledge of research and development. He furthermore

has specific expertise in project management, strategic sourcing, vendor collaboration, contract and budget governance. For

the past several years he has functioned as Clinical Project Leader and has overseen clinical trial budgets across Genmab’s

clinical trials. He has also been a member of Genmab’s employee representatives’ group for over 10 years.

Mijke Zachariasse was elected to the Board in 2019. Dr. Zachariasse joined us in 2017 and currently serves as our

Vice President, Head of Protein and Cell Supply. Dr. Zachariasse has broad experience in people and business management

and expertise in the research funding landscape, operational excellence and organizational strategy and change. Prior to

joining us, from 2010 to 2017, she was a Research Policy Advisor/Head of the Research Support Office at Utrecht

University. From 2008 to 2010, Dr. Zachariasse was Managing Director of the Leiden Institute of Physics. Dr. Zachariasse

served as a Programme Officer at the Foundation for Fundamental Research on Matter from 2002 to 2008. She received

her Doctorate in Physics from the Technical University of Eindhoven in 2002.

Michael Kavanagh was elected to the Board in 2025. Mr. Kavanagh joined Genmab in 2021 and currently serves as

Senior Director, Head of Strategic Engagement, Oncology Marketing at Genmab. He is a seasoned professional with over

25 years of experience in the pharmaceutical industry and has a track record of successful product launches in oncology

commercialization. His extensive expertise in building commercial teams and driving market expansion has been

demonstrated in the successful product launches at Genmab. Previously, he held senior leadership roles at Bristol Myers

Squibb, leading commercialization efforts for hematology and oncology brands in the US and globally.

84

Table of Contents

Executive Management

The following table sets forth information with respect to each of the members of our Executive Management,

including their respective ages and their positions as of the date of this Annual Report on Form 20-F. The business address

of these members of our Executive Management is our registered office address at c/o Genmab A/S, Carl Jacobsens Vej 30,

2500 Valby, Denmark. Only Jan G. J. van de Winkel and Anthony Pagano are registered with the Danish Business

Authority as members of executive management, or registered managers, within the meaning of the Danish Companies Act

(“ DCA ”).

Name of Member of Executive Management	Age	Position(s)
Jan G. J. van de Winkel	64	President and Chief Executive Officer (“CEO”)
Anthony Pagano	48	Executive Vice President and Chief Financial Officer
Judith Klimovsky	69	Executive Vice President and Chief Development Officer
Tahamtan Ahmadi	53	Executive Vice President and Chief Medical Officer, Head of Experimental Medicines
Christopher Cozic	48	Executive Vice President and Chief People Officer
Martine J. van Vugt	55	Executive Vice President and Chief Strategy Officer
Rayne Waller	58	Executive Vice President and Chief Technical Operations Officer
Brad Bailey	58	Executive Vice President and Chief Commercial Officer
Greg Mueller*	54	Executive Vice President, General Counsel & Chief Legal Officer

• – Greg Mueller was appointed Executive Vice President, General Counsel and Chief Legal Officer in July 2025.

The following is a brief summary of the business experience of our Executive Management.

Jan G. J. van de Winkel is our co-founder and served as President, Research & Development and Chief Scientific

Officer of the Company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel served as

Vice President and Scientific Director of Medarex Europe prior to founding Genmab. Dr. van de Winkel holds a

professorship of immunotherapy at Utrecht University. He holds an M.Sc. and a Ph.D. from the Radboud University of

Nijmegen in the Netherlands.

Anthony Pagano joined Genmab in 2007. His positions increased in seniority during his tenure with us and he

currently serves as our Executive Vice President and Chief Financial Officer. Prior to joining us, Mr. Pagano was

Corporate Controller and Senior Director of Business Planning at NovaDel Pharma, Inc. from 2005 to 2007, a publicly-

traded specialty pharmaceutical company. He previously worked as a Manager at KPMG LLP from 1999 to 2005. In

December 2025, Mr. Pagano was appointed to the Board of Directors of BillionToOne and as Audit Committee Chair,

effective January 2026. He is a CPA and received a B.S. in Accounting from The College of New Jersey, as well as an

MBA from the Stern School of Business at New York University.

Judith Klimovsky joined us in 2017 and currently serves as the Executive Vice President and Chief Development

Officer. She worked previously as a drug developer and has more than 20 years of experience in research and development

leadership roles at BMS and Novartis. Dr. Klimovsky is also a medical doctor who has worked as a clinician in hospital

environments. Prior to joining us, she held various positions at Novartis Pharma AG from 2009 to 2017, including Senior

Vice President, Head of Clinical Development. Dr. Klimovsky is a member of the Board of Bio-Techne. She holds a

medical degree from the Universidad de Buenos Aires in Argentina.

Tahamtan Ahmadi joined us in 2017 and became the Executive Vice President and Chief Medical Officer, Head of

Experimental Medicines effective March 1, 2021. Prior to that, Dr. Ahmadi was Head of Experimental Medicine and Early

Development Oncology at Janssen and a member of the Senior Leadership Team for Oncology from 2012 to 2017. During

his time at Janssen, he led the global development of daratumumab including clinical R&D and medical affairs strategy

across indications. Dr. Ahmadi was previously a faculty member of the Department of Hematology and Oncology at the

University of Pennsylvania. He holds an M.D. from the University of Cologne and a Ph.D. from the University of Freiburg,

both in Germany, and has experience in translational research, strategic product development, global regulatory

submissions and clinical development.

85

Table of Contents

Christopher Cozic joined Genmab in 2017 and was appointed Executive Vice President and Chief People Officer in

1. Prior to joining Genmab, Mr. Cozic was Vice President of Human Resources at Ipsen from 2014 to 2017. Previously,

he spent over eight years at Eisai, where he served as Director, Global Human Resources, after joining the company in

1. Mr. Cozic is a member of the Board of BioNJ and became Chair of the Board effective February 2026. He received

his B.A. in English and Communications from Quinnipiac University and also attained Professional in Human Resources,

Senior Professional in Human Resources, and Global Professional in Human Resources certifications.

Martine J. van Vugt started her professional career with us in 2001 and was appointed Executive Vice President and

Chief Strategy Officer in 2023. Dr. van Vugt is currently responsible for Corporate Strategy, Corporate Development,

Business Development and Licensing & Alliance Management. She has been active in business development operations

since 2011. From 1998 until joining us in 2001, she studied dendritic cell vaccination therapy as a post-doctoral fellow. Dr.

van Vugt holds an M.Sc. from the University of Wageningen and a Ph.D. from Utrecht University.

Rayne Waller joined Genmab in 2024 as Executive Vice President and Chief Technical Operations Officer. Mr.

Waller is responsible for all elements of technical operations from early-to-mid-stage product development through global

manufacturing of both clinical and commercial products. Prior to joining Genmab, Mr. Waller served as Chief Operating

Officer at Capsida Biotherapeutics, with responsibility for all aspects of technical operations as well as program

management, human resources, and IT. Prior to Capsida Biotherapeutics, Mr. Waller spent 27 years at Amgen in roles of

increasing responsibility across manufacturing and supply chain Management. These roles included Vice President and site

head of Amgen Manufacturing Limited in Puerto Rico, Vice President of European site operations, and Vice President of

Global Supply Chain Management with responsibility for contract manufacturing, global supply management, alliance

management, operations strategic planning, and risk management. Mr. Waller holds a Bachelor of Science degree in

Business Administration from the University of Arizona.

Brad Bailey joined Genmab in 2020 and became Executive Vice President and Chief Commercial Officer effective

August 19, 2024. Mr. Bailey leads Genmab’s commercial organization globally and is responsible for driving growth

across the company’s portfolio and delivering its antibody-based medicines to patients. In his prior role as Senior Vice

President and General Manager Genmab’s US operations, Mr. Bailey established the company’s commercial organization

in the US and led the launches of Genmab’s first two marketed medicines. With more than 25 years in the healthcare

industry, Mr. Bailey has extensive experience in strategic and operational commercial leadership roles across specialty

biopharma, oncology, immunology, and other serious diseases in the US and around the world. He holds a Bachelor of

Science in Business Administration from Clemson University.

Greg Mueller joined Genmab in July 2025 as Executive Vice President, General Counsel & Chief Legal Officer. Mr.

Mueller is responsible for leading and managing the global legal, intellectual property, corporate governance, and global

compliance and risk functions. Before joining Genmab, he spent more than 20 years at AstraZeneca, living and working in

North America, Europe and Asia. For the last 12 years, he was part of the Legal Senior Management Team, holding roles

as the Deputy General Counsel, International and then as the Deputy General Counsel, Corporate. Prior to AstraZeneca, he

worked as a corporate transactions lawyer at a large national Canadian law firm. He holds a Bachelor of Commerce

specialist degree from the University of Toronto and a Law Degree (LLB) from Queen’s University.

B. Compensation

Remuneration to the Board includes base board fees, committee fees, and share-based compensation. No member of

the Board is entitled to any kind of remuneration upon retirement from his or her position as a member of the Board. We

have not allocated funds for any pension benefits, severance schemes or similar measures, or undertaken any other

obligations to do so on behalf of the Board, and we have no obligation to do so. Remuneration to Executive Management

includes base salary, defined contribution plans, share-based compensation, annual cash bonuses, and other benefits.

See Note 5.1 to our Audited Financial Statements included in our Annual Report 2025 for details on compensation of

our directors in connection with their membership to the Board and our Executive Management in connection with their

employment with us.

86

Table of Contents

Certain Executive Management Agreements

Remuneration given to each member of Executive Management, in accordance with their service agreements consists

of a base salary, a cash bonus, and RSUs. The maximum bonus opportunity for Dr. van de Winkel is in accordance with the

Remuneration Policy and as recommended by the Compensation Committee and approved by the Board in a range of 0 to

150 percent of his annual base salary. The maximum bonus opportunity for other members of our Executive Management

is conditional upon the recommendation of the CEO, in an amount between 0 and 90 percent of the individual’s annual

base salary, in accordance with the Remuneration Policy and as recommended by the Compensation Committee and

approved by the Board; however, any bonus in excess of 100 percent of base salary for Dr. van de Winkel and 60 percent of

base salary for other members of our Executive Management will be deferred into RSUs subject to three years’ vesting in

accordance with Genmab’s Remuneration Policy. Each member of Executive Management qualifies for all of our benefit

programs, including retirement plans.

Each member of Executive Management can terminate their employment with us by giving a six-month notice. We

can terminate their employment with us by giving them a 12-month notice. In the event that we terminate the service

agreements without cause, we will be obliged to pay the then existing salary (including all benefits set forth in their

respective service agreements) to Dr. van de Winkel for two years, and to other members of Executive Management for

one year, after the end of the 12-month notice period.

In the event of a termination by us without cause in connection with a change in control (as defined in the individuals’

service agreements), the notice period will be extended up to 24 months in the first year after the change of control. In

addition, we will pay an additional two years of then current salary (including all benefits set forth in his service

agreement) to Dr. van de Winkel, and an additional year of then current salary (including all benefits set forth in their

respective service agreements) to each other member of Executive Management. Dr. van de Winkel will also receive an

amount equal to two times the highest total bonus awarded to him, and other members of Executive Management will each

receive an amount equal to the highest total bonus awarded to them, in any year during the term of their respective

employment, in each case payable in a lump sum payment on the individual’s last working day.

Other than as set out above, no member of Executive Management is entitled to any kind of remuneration upon

termination of employment. We have not granted any loans, issued any guarantees or undertaken any other obligations to

do so on behalf of any member of our Executive Management.

Other than as set out above, no exceptional or extraordinary agreements, including agreements regarding bonus

schemes, other than ordinary incentive schemes and remuneration of the Executive Management implying financial

obligations for us, have been concluded with members of our Executive Management.

Warrant Program

We have established a warrant program (“ Warrant Program ”) as an incentive for our employees. Warrants are

granted by the Board in accordance with authorizations given to it by our shareholders. Warrant grants are subject to the

relevant terms of our articles of association and, if applicable, the Remuneration Policy or any incentive guidelines or

remuneration principles adopted by the shareholders at the general meeting preceding the Remuneration Policy. Under the

terms of the Warrant Program, (i) warrants are granted at an exercise price equal to the share price on the grant date, (ii) the

exercise price cannot be fixed at a lower price than the market price at the grant date and (iii) in connection with exercise,

the warrants are to be settled with the delivery of our shares.

See Note 4.6 to our Audited Financial Statements included in our Annual Report 2025 for more details of our warrant

program, our outstanding warrants and a summary of the holders of such warrants as of December 31, 2025 .

Warrant Compensation

During 2025 , no members of Executive Management were granted warrants by our Board. Following an amendment to

the Remuneration Policy at our 2023 Annual General Meeting, members of Executive Management and members of the

Board may only be granted RSUs.

87

Table of Contents

Restricted Stock Unit Program

We have established an RSU program as an incentive for all our employees, members of Executive Management and

members of the Board. RSUs are granted and performance vesting criteria, if any, are decided by the Board in its sole

discretion. RSUs granted to members of Executive Management and members of the Board are subject to the

Remuneration Policy or any incentive guidelines or remuneration principles adopted by the shareholders at the general

meeting preceding the Remuneration Policy.

See Note 4.6 to our Audited Financial Statements included in our Annual Report 2025 for more details of our RSU

program, our outstanding RSUs and a summary of the holders of such RSUs as of December 31, 2025 .

Restricted Stock Unit Compensation

During 2025 , our Board granted the following RSUs to members of our Board and our Executive Management:

Name of Board Member or Executive Management, Position	Award Date	Granted	Share Price at Date of Grant (DKK)
Deirdre P. Connelly, Chair	March 12, 2025	1,311	1,373
Pernille Erenbjerg, Deputy Chair	March 12, 2025	1,092	1,373
Anders Gersel Pedersen, Board Member	March 12, 2025	1,092	1,373
Paolo Paoletti, Board Member	March 12, 2025	1,092	1,373
Rolf Hoffmann, Board Member	March 12, 2025	1,092	1,373
Elizabeth O'Farrell, Board Member	March 12, 2025	1,092	1,373
Mijke Zachariasse, Employee Elected Member	March 12, 2025	1,092	1,373
Martin Schultz, Employee Elected Member	March 12, 2025	1,092	1,373
Michael Kavanagh, Employee Elected Member	March 12, 2025	1,092	1,373
Jan van de Winkel, Chief Executive Officer	February 28, 2025	36,373	1,609
Anthony Pagano, Chief Financial Officer	February 28, 2025	18,270	1,609
Judith Klimovsky, Chief Development Officer	February 28, 2025	20,462	1,609
Tahamtan Ahmadi, Chief Medical Officer	February 28, 2025	19,332	1,609
Christopher Cozic, Chief People Officer	February 28, 2025	13,384	1,609
Martine J. van Vugt, Chief Strategy Officer	February 28, 2025	10,666	1,609
Rayne Waller, Chief Technical Operations Officer	February 28, 2025	6,406	1,609
Brad Bailey, Chief Commercial Officer	February 28, 2025	5,914	1,609
Greg Mueller, General Counsel & Chief Legal Officer*	September 25, 2025	5,398	1,853

• –Greg Mueller was appointed Executive Vice President, General Counsel, Chief Legal Officer, and a member of the Executive Management in July 2025.

Insurance and Discharge of Liability

According to the DCA , shareholders, at the general meeting, are permitted to discharge our Board members and

registered managers from liability for any particular financial year based on a resolution relating to the period covered by

the Audited Financial Statements for the previous financial year. This discharge means that the shareholders will relieve

88

Table of Contents

such Board members and registered managers from liability to us. However, shareholders cannot discharge any claims by

individual shareholders or other third parties. In addition, the discharge can be set aside in case the general meeting prior to

its decision to discharge was not presented with all reasonable information necessary for the general meeting to assess the

matter at hand.

In addition, we provide our Board members and registered managers with directors’ and officers’ liability insurance,

and have, similar to other Danish larger companies, implemented an indemnification scheme adopted during the 2025

Annual General Meeting that, in certain cases, covers the liability that Board members, registered managers and/or

managerial employees may incur while acting in their capacities as such.

We have not granted any loans, guarantees, or other commitments to or on behalf of any members of our Board of

Directors or Executive Management.

Employment Agreement and Warrant Grants

We have entered into employment agreements with, and issued RSUs and warrants to, our Executive Management.

See “—Compensation—Certain Executive Management Agreements” and “—Compensation—Warrant Program” and

“—Compensation—Restricted Stock Unit Program” for more information.

C. Board Practices

Board of Directors

The Board plays an active role in setting our strategies and goals and monitoring our operations and results. Board

duties include establishing policies for strategy, accounting, organization and finance and the appointment of the

Company’s registered managers. The Board also assesses our capital and share structure and is responsible for approving

share issues and the grant of warrants and RSUs. In addition, the Board ensures that our affairs are managed in accordance

with our articles of association and applicable law.

The Board performs its duties in accordance with the rules of procedure of the Board. The rules of procedure are

reviewed and updated by all members of the Board on a regular basis. The Board meets for at least eight scheduled face-to-

face, telephonic, videoconference or Teams meetings during the year. During 2025 , the Board held 15 meetings in addition

to the informal ongoing communication between Board members and our CEO. Our Board may consist of between three

and nine Shareholder Elected Members, elected for terms of one year, with the possibility of re-election. In addition, our

employees may, pursuant to Danish statutory rules regarding the representation of employees on the Board of Directors and

election regulations adopted by the Board, elect employee representatives to the Board, for terms of three years, with

possibility of re-election. The employees of the Company have adopted a voluntary program which allows for election of

employee representatives from the Company’s directly and indirectly owned subsidiaries. Currently, the Board has three

Employee Elected Members, Michael Kavanagh, Mijke Zachariasse, and Martin Schultz. In total, our Board currently

consists of nine Board members (including six Shareholder Elected Members and three Employee Elected Members). The

Board elects a chair and deputy chair from among its members. The majority of our Board members are considered to be

independent under the corporate governance standards of the Nasdaq Stock Market and Nasdaq Copenhagen.

Management Appointments

Registered managers are appointed by the Board, which sets out the terms and conditions of their employment and the

framework for their duties. Registered managers are responsible for our day-to-day management, including all assignments

that rest upon them according to the Board and under Danish law, in compliance with the guidelines and directions issued

by the Board. Management of our day-to-day operations does not include transactions of an unusual nature or of significant

importance, or transactions being outside our business plan, which must be authorized by the Board. Non-registered

managers are appointed by the CEO in consultation with the Board of Directors.

Committees of the Board of Directors

The Board has established and appointed a Compensation Committee, an Audit and Finance Committee, a Nominating

and Corporate Governance Committee and a Scientific Committee. These committees are charged with reviewing issues

pertaining to their respective fields that are due to be considered at Board meetings. Under Danish corporate law, it is not

89

Table of Contents

possible to delegate the decision-making authority of the entire Board to board committees. Written charters specifying the

tasks and responsibilities for each of the committees have been adopted by the Board.

Audit and Finance Committee

According to the Audit and Finance Committee charter, the Audit and Finance Committee must consist of at least three

non-executive Board members, all of whom must be independent. Furthermore, the Chair of the Board shall not be Chair of

the Audit and Finance Committee. As of the date of this Annual Report on Form 20-F, the Audit and Finance Committee

consists of members Rolf Hoffmann, Elizabeth O’Farrell and Deirdre P. Connelly and is chaired by Pernille Erenbjerg. The

Audit and Finance Committee assists the Board with the oversight of the financial and sustainability reporting process, the

effectiveness of internal controls over financial and sustainability reporting and risk management, the independent audit

process and compliance with legal and regulatory requirements, in accordance with the Audit and Finance Committee

charter. Each member of the Audit and Finance Committee satisfies the independence requirements of the corporate

governance standards of the Nasdaq Stock Market, and both Pernille Erenbjerg and Elizabeth O’Farrell qualify as “audit

committee financial experts,” as defined in Nasdaq Rule 5605(c)(2)(A) and Item 407(d)(5)(ii) of Regulation S-K of the

SEC and as determined by our Board.

Our Audit and Finance Committee oversees our accounting and financial reporting processes and the audits of our

consolidated financial statements. Our Audit and Finance Committee has the following principal responsibilities:

• overseeing the financial and sustainability reporting principles and process to ensure compliance with legal

and regulatory requirements and the quality, transparency and integrity of the published financial and

sustainability information;

• overseeing the appropriateness and effectiveness of our internal controls over financial and sustainability

reporting and risk management system and evaluating the need for an internal audit;

• overseeing our audits and assurances of the Company and the independent registered accounting firm and

assurances processes, including recommending the appointment of the independent financial and

sustainability auditors and overseeing the annual assessment of their performance and qualifications,

preapproving, and overseeing all audit and non-audit services and, to the extent permitted by applicable law,

being directly responsible for the appointment, retention and compensation of the independent auditors in

connection with audit, review or attestation services;

• overseeing the operation of the Company’s internal audit function, including approving the internal audit

charter, the staffing and organizational structure of the internal audit function, and monitoring management’s

responsiveness to the internal auditors’ findings and recommendations, including follow-ups;

• considering the independence of the independent financial and sustainability auditors and any potential

conflicts of interest, including by (a) ensuring receipt from the independent financial and sustainability

auditors of a formal written statement delineating all relationships between the independent financial and

sustainability auditors and the Company, (b) actively engaging in dialogue with the independent financial and

sustainability auditors with respect to factors that may impact the independent financial and sustainability

auditors’ objectivity and independence, and (c) taking, or recommending that the Board takes, appropriate

action to oversee auditor independence;

• ensuring that significant adjustments, unadjusted differences, disagreements between management and the

independent financial auditors and management responses thereto are discussed with the independent auditors

and resolving disagreements between management and the independent auditors;

• assessing transactions between the Company and the Company’s related parties and, in respect of material

related party transactions, submitting a recommendation for approval or non-approval of such transactions to

the Board prior to their completion;

• overseeing the integrity of the Company’s IT systems, processes and data and periodically (but no less than

annually), at its discretion, reviewing and assessing with Management (including the Head Internal Auditor

and Chief Information Officer), the adequacy of security for the Company’s IT systems, processes and data

90

Table of Contents

and the Company’s contingency plans in the event of a breakdown or security breach affecting the

Company’s IT systems, and data or the IT systems;

• overseeing compliance with legal and regulatory requirements in relation to financial and sustainability

reporting and auditing and assurance regulation;

• authority to obtain advice and assistance from independent counsel and other advisors;

• obtaining appropriate funding, as determined by the Audit and Finance Committee, for compensation to the

independent financial and sustainability auditors and to any advisors that the Audit and Finance Committee

chooses to engage;

• monitoring the whistleblower function, including establishment of procedures for the receipt, retention and

treatment of any complaints, including confidential anonymous submissions from our employees regarding

accounting, auditing and internal control issues received through a formalized complaint process, as well as

review of such complaints; and

• evaluating its own performance and the achievement of its duties on a regular basis, and annually reviewing

and updating the Audit and Finance Committee charter and discussing any required changes thereto with the

Board.

The Audit and Finance Committee also performs such other functions and exercises such other powers as may be

delegated to it by the Board from time to time.

Compensation Committee

According to its charter, our Compensation Committee must consist of at least three non-executive directors, appointed

by the Board. A majority of the members must be independent. As of the date of this Annual Report on Form 20-F, the

Compensation Committee consists of members Anders Gersel Pedersen, Paolo Paoletti and Deirdre P. Connelly and is

chaired by Elizabeth O’Farrell. Paolo Paoletti, Elizabeth O’Farrell, and Deirdre P. Connelly satisfy the independence

requirements of the corporate governance standards of the Nasdaq Stock Market. In accordance with the Danish corporate

governance recommendations, we consider Anders Gersel Pedersen non-independent solely by virtue of the length of his

tenure on our Board, following his election to the Board in 2003. The Compensation Committee assists the Board in the

areas of compensation of managers and the adoption of policies that concern our compensation programs, including equity-

based programs and benefit plans. The Compensation Committee also makes recommendations to the Board regarding

specific remuneration packages for each of the members of the Board as well as our registered managers, including pension

rights and any compensation payments. The proposed remuneration policy, if adopted by the Board, is subject to the

approval of our shareholders at the Annual General Meeting. The Compensation Committee’s primary responsibilities are

as follows:

• reviewing the trends in compensation and the competitiveness of our executive compensation programs to

ensure (a) the attraction and retention of registered managers, (b) the motivation of registered managers to

achieve our business objectives, and (c) the alignment of the interests of key leadership with the long-term

interests of our shareholders;

• making proposals for the approval of the Board prior to approval by shareholders at the general meeting, on

the remuneration policy for members of the Board and the registered managers, including the overall

principles of incentive pay schemes, compensation structure and long-term incentive compensation plans and

a remuneration policy applicable to the Company in general;

• reviewing the goals and objectives of our CEO and evaluating his performance to make recommendations

concerning CEO compensation; the CEO may not be present during deliberations or voting concerning the

CEO’s compensation;

• overseeing the evaluation of the performance of the Company’s registered managers, and discussing their

annual compensation, including salary, bonus, incentive and equity compensation, and the selection of

91

Table of Contents

performance measures, the setting of performance targets and the assessment of performance against those

targets;

• reviewing the Company’s policies relating to clawback of incentive awards and confirming that such policies

continue to be appropriate;

• reviewing plans for registered managers’ development and corporate succession plans for registered

management;

• reviewing termination and compensation packages for new registered managers as requested by management;

• in its sole discretion, retaining, terminating and receiving advice from outside counsel, compensation

consultants or other advisors, upon consideration of (i) whether such counsel, consultant or advisor provides

other services to the Company and the amount of fees they receive from the Company as a percentage of their

total revenue, (ii) the policies of such counsel, consultant or advisor designed to prevent conflicts of interest,

(iii) any business or personal relationship of the consultant, counsel or advisor with a member of the

Compensation Committee or a member of Executive Management of the Company, and (iv) any ownership of

shares in the Company by the consultant, legal counsel or advisor;

• approving the fees of outside counsel, compensation consultants or other advisors, to be appropriately funded

by the Company and directly overseeing the work of such counsel, consultants or advisors; and

• overseeing that the information in the annual report on the compensation of the Board and registered

managers is correct, true and sufficient.

The Compensation Committee also performs such other functions and exercises such other powers as may be

delegated to it by the Board from time to time.

Nominating and Corporate Governance Committee

According to its charter, our Nominating and Corporate Governance Committee must include at least two non-

executive directors, appointed by the Board. A majority of members must be independent. As of the date of this Annual

Report on Form 20-F, the Nominating and Corporate Governance Committee consists of members Deirdre P. Connelly and

Pernille Erenbjerg and is chaired by Anders Gersel Pedersen. Pernille Erenbjerg and Deirdre P. Connelly satisfy the

independence requirements of the corporate governance standards of the Nasdaq Global Select Market. In accordance with

the Danish corporate governance recommendations, we consider Anders Gersel Pedersen non-independent solely by virtue

of the length of his tenure on our Board, following his election to the Board in 2003. The Nominating and Corporate

Governance Committee identifies, reviews, evaluates and recommends to the full Board candidates to serve as directors of

the Company and makes recommendations to the Board regarding Board and committee members and corporate

governance issues. The Nominating and Corporate Governance Committee’s primary responsibilities include the

following:

• proposing to the full Board policies on the size and composition of the Board, including proposals for specific

changes to Board size, composition or internal rules of the Board;

• describing the qualifications required for the Board and the registered managers and for a given position and

identifying and recommending qualified candidates to the Board;

• evaluating at least annually the skills, knowledge and experience of the individual members of the Board and

the registered managers and evaluating, reviewing and considering whether to recommend existing directors

for re-election;

• annually ahead of providing a recommendation to the Board on election or reelection of members to the

Board, review and assess the board members’ current and planned time commitments outside the Company as

well as review the attendance rate and engagement of each board member in the board meetings and relevant

board committee meetings during their current term.

92

Table of Contents

• maintaining an orientation and continuing education program for directors;

• establishing a process for the periodic review and assessment of the performance of the Board and its

committees and conducting such review of the structure and performance of each board committee and

committee member, recommending any changes considered appropriate, as well as recommending the

establishment of new or special committees as desirable or necessary from time to time;

• periodically assessing the independence of directors and our corporate governance principles and their

application, and recommending any changes deemed appropriate to the Board, including in connection with

any proposals submitted by shareholders that relate to corporate governance, corporate social responsibility

and ESG matters;

• overseeing and reviewing the processes and procedures in place to ensure that the Board and its committees

timely receive accurate, relevant and appropriately detailed information;

• reviewing the adequacy of internal rules of the Board, management and any other codes of ethics with the

Board and management;

• overseeing the preparation and periodic review of a diversity policy for the Board’s approval;

• overseeing our policies and practices regarding philanthropic and political activities; and

• periodically reviewing, discussing and assessing the performance of the committee as well as the adequacy of

its charter, and recommending any proposed changes to the Board for approval.

Scientific Committee

According to its charter, the Scientific Committee must include at least three non-executive directors, the majority of

whom must be independent, with a broad scientific and medical understanding and experience, appointed by the Board. As

of the date of this Annual Report on Form 20-F, the Scientific Committee consists of members Anders Gersel Pedersen and

Rolf Hoffmann and is chaired by Paolo Paoletti. The Scientific Committee provides input and advises the Board in matters

relating to our research and development strategy, including reviewing our preclinical and clinical product pipeline in view

of our overall strategy and vision. The Scientific Committee’s primary responsibilities include the following:

• reviewing and discussing our preclinical and clinical product portfolio, including the commercial

attractiveness and the ranking thereof;

• reviewing and discussing our research and development strategy and reviewing scientific and technological

trends that we believe are of significant importance and providing strategic advice and making

recommendations with respect to our ongoing research and development programs;

• providing advice on external opportunities related to our research and development strategy and pipeline;

• discuss and provide advice on the research and development capacity and its organization, including the

product development process; and

• reviewing and discussing the Company’s intellectual property strategies.

D. Employees

As of December 31, 2025 , we had 3,029 employees; 556 in Denmark, 946 in the Netherlands, 1,158 in the US, 220 in

Japan, 132 in China, 12 in Germany, and 3 in France and the United Kingdom . Of these employees, 2,089 were engaged in

or supported research and development and 940 were in selling, administrative and business-related positions. Each of our

employees has signed confidentiality and inventions assignment agreements or has signed employment agreements

containing confidentiality and inventions assignment provisions, and none are covered by a collective bargaining

agreement. We have never experienced employment-related work stoppages and consider our employee relations to be

good.

93

Table of Contents

E. Share Ownership

For information regarding the share ownership of our directors and members of Executive Management, see “Item 6.B

—Compensation” and “Item 7.A—Major Shareholders.”

F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation

Not applicable.

ITEM 7 MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A. Major Shareholders

The following table sets forth information relating to the beneficial ownership of our shares as of February 17, 2026

by:

• each person, or group of affiliated persons, known by us to beneficially own equal to or more than 5% of our

outstanding shares;

• each of our directors; and

• each member of our Executive Management

Name of Beneficial Owner	Share Beneficial Ownership — Number of Shares Beneficially Owned	Number of Warrants Exercisable and RSUs to be Settled Within 60 days	Fully Diluted Number of Shares Beneficially Owned	Fully Diluted Percentage of Beneficial Ownership
5% Shareholders
BlackRock, Inc.(1)			3,707,346	5.80 %
Orbis Investment Management LTD. (2)			3,726,799	5.80 %
Board Members and Executive Management
Deirdre P. Connelly	6,582	—	6,582	0.01 %
Pernille Erenbjerg	5,470	—	5,470	0.01 %
Anders Gersel Pedersen	7,708	—	7,708	0.01 %
Paolo Paoletti	2,506	—	2,506	— %
Rolf Hoffmann	3,779	—	3,779	0.01 %
Elizabeth O’Farrell	1,885	—	1,885	— %
Mijke Zachariasse	787	595	1,382	— %
Martin Schultz	668	1,539	2,207	— %
Michael Kavanagh	221	1,711	1,932	— %
Jan van de Winkel	658,932	21,171	680,103	1.06 %
Anthony Pagano	9,546	9,859	19,405	0.03 %
Judith Klimovsky	*	*	*	*
Tahamtan Ahmadi	*	*	*	*
Christopher Cozic	*	*	*	*
Martine van Vugt	*	*	*	*
Brad Bailey	*	*	*	*
Rayne Waller	*	*	*	*
Greg Mueller	*	*	*	*
All Board Members and Executive Management as a group (18 persons)	726,756	90,935	817,691	1.27 %

94

Table of Contents

(1) This information is based solely on the Schedule 13G filed by BlackRock, Inc. on March 31, 2025 with the SEC. BlackRock, Inc. does not have different voting rights

from other shareholders.

(2) This information is based solely on the Schedule 13G filed by Orbis Investment Management LTD. on September 30, 2025 with the SEC. Orbis Investment Management

LTD does not have different voting rights from other shareholders. Orbis Investment Management Limited is an investment manager which has investment discretion and

voting control over the Genmab A/S shares and ADRs held by certain investment funds and portfolios.

The number of shares beneficially owned by each entity, person or member of our Board of Directors or Executive

Management is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of

beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the

individual has sole or shared voting power or investment power as well as any shares for which the individual has the right

to subscribe within 60 days of February 17, 2026 through the exercise of any options, warrants or other rights. There are

90,935 shares for which our board members and Executive Management as a group have the right to subscribe within

60 days of February 17, 2026 pursuant to the exercise of warrants or settlement of RSUs.

Subject to applicable community property laws, the persons named in the table have sole voting and investment power

with respect to all shares owned by that person. The percentage of shares beneficially owned is computed on the basis of

64,238,408 shares outstanding as of February 17, 2026 . Shares for which a person has the right to subscribe within 60 days

of February 5, 2026 are deemed outstanding for purposes of computing the percentage ownership of the person holding

such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person. We

conducted our last beneficial ownership analysis as of June 30, 2025 and we estimated that approximately 36%, or 23.0

million (including shares in the form of ADSs), of our outstanding shares as of such date were beneficially held by US

residents.

B. Related-Party Transactions

In the year ended December 31, 2025 , there were no material related party transactions. The Company has

employment agreements with, and has made equity compensation grants to, members of Executive Management in the

ordinary course of business. The Company also has remuneration packages for members of the Board of Directors. See

“Item 6.B—Compensation” , Note 5.1 and Note 5.2 to our Audited Financial Statements included in our Annual Report

2025 for details on related party transactions.

C. Interests of Experts and Counsel

Not applicable.

95

Table of Contents

ITEM 8 FINANCIAL INFORMATION

A. Consolidated Statements and Other Financial Information

Financial Statements

See “Item 18—Financial Statements” which contains our Audited Financial Statements prepared in accordance with

IFRS Accounting Standards .

Legal Proceedings

From time to time in the ordinary course of business we may become involved in various lawsuits, claims and

proceedings relating to the conduct of our business, including those pertaining to the defense and enforcement of our patent

or other intellectual property rights. These proceedings are costly and time consuming. Successful challenges to our patent

or other intellectual property rights through these proceedings could result in a loss of rights in the relevant jurisdiction and

may allow third parties to use our proprietary products and technologies without a license from us or our partners.

See note 5.7 to our Audited Financial Statements included in our Annual Report 2025 for details on legal matters.

Dividends

We do not currently pay out cash dividends on our shares and have not paid out any dividends within the last three

financial years. Any future determination related to our dividend policy and the declaration of any dividends will be made

at the discretion of our Board of Directors and will depend on a number of factors, including our results of operations,

financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our

Board of Directors deems relevant. In addition, the terms of our credit agreement and the indentures governing our

outstanding notes restrict our ability to make certain restricted payments, including dividends and other distributions by us,

as further described in Note 4.8 of our Annual Report 2025.

B. Significant Changes

No significant changes occurred since the date of the annual financial statements.

96

Table of Contents

ITEM 9 THE OFFER AND LISTING

A. Offer and Listing Details

Our shares are listed on Nasdaq Copenhagen in Denmark under the symbol “GMAB.” Our ADSs are listed on Nasdaq

Global Select Market in the US under the symbol “GMAB.”

B. Plan of Distribution

Not applicable.

C. Markets

Our shares have been publicly traded since October 2000 and have been listed on Nasdaq Copenhagen in Denmark

since that time.

ADSs representing the shares, as evidenced by ADRs issued by JPMorgan Chase Bank, N.A. as the Depository, have

been listed on the Nasdaq Global Select Market in the US since July 2019.

D. Selling Shareholders

Not applicable.

E. Dilution

Not applicable.

F. Expenses of the Issue

Not applicable.

ITEM 10 ADDITIONAL INFORMATION

A. Share Capital

Not applicable.

B. Memorandum and Articles of Association

The sections entitled “Description of Share Capital and Certain Corporate Matters—Shareholders’ Register,”

“Description of Share Capital and Certain Corporate Matters—Articles of Association and Danish Corporate Law” and

“Description of Share Capital and Certain Corporate Matters—Comparison of Danish Corporate Law and our Articles of

Association and Delaware Corporate Law” in the Company’s prospectus, filed with the SEC on July 19, 2019 are

incorporated herein by reference.

Under the Danish foreign direct investment (“ FDI ”) Rules, a screening mechanism applies to foreign direct or indirect

investments in certain sensitive sectors, if the foreign investor obtains at least 10% ownership or voting rights, or

equivalent control by other means. Among such sensitive sectors are companies and entities within critical infrastructure in

Denmark that are necessary to maintain or restore the production, registration, distribution, and monitoring of prescription

drugs. If a contemplated foreign direct or indirect investment in Genmab A/S is considered to fall within the scope of the

mandatory screening mechanism, the foreign investor is required to apply for prior authorization with the Danish Business

Authority. If a foreign investor fails to comply with the Danish FDI Rules, the Danish Business Authority may impose

restrictions, inter alia , ordering to reverse the investment or to suspend the foreign investor’s voting rights.

97

Table of Contents

C. Material Contracts

Except as otherwise disclosed in this Annual Report on Form 20-F (including the Exhibits), we are not currently party

to any material contract, other than contracts entered into in the ordinary course of business.

D. Exchange Controls

Other than the Danish rules on screening of certain foreign direct investments etc. in Denmark (the “Danish FDI

Rules”) and the applicable international trade and financial sanctions as outlined below, (i) there are no governmental laws,

decrees, or regulations in Denmark (including, but not limited to, foreign exchange controls) that restrict the export or

import of capital, or that affect the remittance of dividends, interest or other payments to non-resident holders of the shares

or the ADSs, and (ii) there are no limitations on the right of non-resident or foreign owners to hold or vote the shares or the

ADSs imposed by the laws of Denmark or the Articles of Association of the Company solely due to the fact that such

holders are non-residents or foreign owners.

Under the Danish FDI Rules, a screening mechanism applies to foreign direct investments in certain sensitive

sectors, if the foreign investor obtains at least 10% ownership or voting rights, or equivalent control by other means.

Among such sensitive sectors are companies and entities within critical infrastructure in Denmark that are necessary to

maintain or restore the production, registration, distribution, and monitoring of prescription drugs. If a contemplated FDI in

Genmab A/S is considered to fall within the scope of the mandatory screening mechanism, the foreign investor is required

to apply for prior authorization with the Danish Business Authority. If a foreign investor fails to comply with the Danish

FDI Rules, the Danish Business Authority may impose restrictions.

International trade and financial sanctions are continually evolving. If applicable, such international trade and financial

sanctions may under certain circumstances prevent the possibility of export and import of capital, and affect the remittance

of dividends, interest and other payments to non-resident holders of shares or ADSs. In addition, international trade and

financial sanctions may restrict the right of non-resident or foreign owners to acquire, transfer, hold or vote the shares and

ADSs. Failure to comply with international trade and financial sanctions can lead to criminal and civil liability.

E. Taxation

Payment of Taxes

Holders will be responsible for any taxes or other governmental charges payable, or which become payable, on their

ADSs or on the deposited securities represented by any of their ADSs. The depositary may refuse to register or transfer

their ADSs or allow holders to withdraw the deposited securities represented by their ADSs until such taxes or other

charges are paid. It may apply payments owed to holders or sell deposited securities represented by their ADSs to pay any

taxes owed and holders will remain liable for any deficiency. If the depositary sells deposited securities, it will, if

appropriate, reduce the number of ADSs to reflect the sale and pay to holders any net proceeds, or send to holders any

property, remaining after it has paid the taxes. Holders agree to indemnify us, the depositary, the custodian and each of our

and their respective agents, directors, employees and affiliates for, and hold each of them harmless from, any claims with

respect to taxes (including applicable interest and penalties thereon) arising from any refund of taxes, reduced rate of

withholding at source or other tax benefit obtained for holders. Holders’ obligations under this paragraph shall survive any

transfer of ADRs, any surrender of ADRs and withdrawal of deposited securities or the termination of the deposit

agreement.

Material US Federal Income Tax Considerations

General

The following discussion is a summary of the material US federal income tax consequences relating to the acquisition,

ownership and disposition of the ADSs. This summary does not purport to be a comprehensive description of all of the US

federal income tax considerations that may be relevant to a particular person’s decision to acquire the ADSs. This

discussion is based on the Code, and US Treasury regulations promulgated thereunder (“ Treasury Regulations ”), as well

as judicial and administrative interpretations thereof as in effect as of the date of this Annual Report on Form 20-F. All of

the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax

consequences described below, and there can be no assurance that the US Internal Revenue Service (“ IRS ”) or US courts

will agree with the tax consequences described in this summary. The Company undertakes no obligation to publicly update

98

Table of Contents

or otherwise revise this summary whether as a result of new Treasury Regulations, Code sections, judicial and

administrative interpretations or otherwise.

This summary applies only to US Holders (as defined below) that hold the ADSs as capital assets within the meaning

of Section 1221 of the Code (generally, property held for investment). This summary does not address any US federal

estate and gift tax, alternative minimum tax or Medicare tax on net investment income consequences, or any US state or

local or non-US tax consequences. This summary also does not address the tax considerations that may be relevant to

certain types of investors subject to special treatment under US federal income tax laws, such as:

• banks and other financial institutions;

• insurance companies;

• regulated investment companies or real estate investment trusts;

• dealers or traders in securities or currencies that use a mark-to-market method of accounting;

• broker-dealers;

• tax exempt organizations, retirement plans, individual retirement accounts and other tax deferred

accounts;

• persons holding the ADSs as part of a straddle, hedging, conversion or integrated transaction for US

federal income tax purposes;

• US expatriates;

• US Holders whose functional currency is not the US dollar;

• any entity or arrangement classified as a partnership for US federal income tax purposes or investors

therein;

• persons who own or are deemed to own, directly or constructively, 10% or more of the total combined

voting power of all classes of the Company’s voting stock or 10% or more of the total value of shares of

all classes of the Company’s stock;

• persons subject to special tax accounting rules as a result of any item of gross income with respect to the

ADSs being taken into account in an applicable financial statement;

• persons who acquire ADSs pursuant to the exercise of an employee stock option or otherwise as

compensation; or

• persons holding the ADSs in connection with a trade or business conducted outside the US.

THE SUMMARY OF US FEDERAL INCOME TAX CONSEQUENCES SET OUT BELOW IS FOR GENERAL

INFORMATION ONLY. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING

THE APPLICATION OF THE US FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL

AS THE STATE, LOCAL, NON-US AND OTHER TAX CONSEQUENCES TO THEM OF THE ACQUISITION,

OWNERSHIP AND DISPOSITION OF THE ADSS.

As used in this discussion, the term “US Holder” means a beneficial owner of the ADSs that is for US federal income

tax purposes:

• a citizen or individual resident of the US;

• a corporation (or other entity treated as a corporation) created or organized in or under the laws of the

US, any state thereof or the District of Columbia;

99

Table of Contents

• an estate, the income of which is subject to US federal income taxation regardless of its source; or

• a trust that (1) is subject to the primary supervision of a court within the US and the control of one or

more US persons for all substantial decisions of the trust or (2) has a valid election in effect under

applicable Treasury Regulations to be treated as a US person.

The US federal income tax treatment of a partner in an entity or arrangement treated as a partnership for US federal

income tax purposes that holds ADSs generally will depend on the status of the partner and the activities of the partnership.

Partnerships considering an investment in the ADSs and partners in such partnerships should consult their tax advisors

regarding the specific US federal income tax consequences to them of the acquisition, ownership and disposition of the

ADSs.

The discussion below assumes that the representations contained in the deposit agreement and any related agreement

are true and that the obligations in such agreements will be complied with in accordance with their terms.

ADSs

For US federal income tax purposes, US Holders of ADSs generally will be treated as the beneficial owners of the

underlying shares represented by the ADSs and an exchange of ADSs for the underlying shares generally will not be

subject to US federal income tax.

The US Treasury Department and the IRS have expressed concerns that US Holders of ADSs may be claiming foreign

tax credits in situations where an intermediary in the chain of ownership between the holder of an ADS and the issuer of

the security underlying the ADS has taken actions that are inconsistent with the US Holder of the ADS being treated as the

beneficial owner of the underlying security. Such actions (for example, a pre-release of an ADS by a depositary) also may

be inconsistent with the claiming of the reduced rate of tax applicable to certain dividends received by non-corporate US

Holders of ADSs, including individual US Holders. Accordingly, the availability of foreign tax credits or the reduced US

federal income tax rate for “qualified dividend income,” each discussed below, could be affected by actions taken by

intermediaries in the chain of ownership between the holder of an ADS and the Company, if as a result of such actions the

US Holder of an ADS is not properly treated as the beneficial owner of the underlying share.

Dividends and Other Distributions

Subject to the PFIC rules discussed below, the gross amount of any distribution made by the Company to a US Holder

with respect to the ADSs (including the amount of any taxes withheld therefrom) generally will be included in such

holder’s gross income as non-US source dividend income in the year actually or constructively received by the depository,

but only to the extent that the distribution is paid out of the Company’s current or accumulated earnings and profits (as

determined under US federal income tax principles). As a non-US company, the Company does not maintain calculations

of its earnings and profits under US federal income tax principles. Therefore, it is expected that any distributions generally

will be reported to US Holders as dividends. Any dividends that the Company pays will not be eligible for the dividends-

received deduction allowed to qualifying corporations under Section 243 of the Code.

With respect to certain non-corporate US Holders, including individual US Holders, dividends paid on the ADSs may

be eligible to be taxed at favorable rates applicable to “qualified dividend income,” provided that (1) the ADSs are readily

tradable on an established securities market in the US, (2) the Company is not a PFIC (as discussed below) for either its

taxable year in which the dividend is paid or the preceding taxable year and (3) certain minimum holding period and other

requirements are met.

Under a published IRS Notice, common or ordinary shares, or ADSs representing such shares, are considered to be

readily tradable on an established securities market in the US if they are listed on the Nasdaq Global Select Market. Our

ADSs are readily tradable on the Nasdaq Global Select Market. However, based on existing guidance, it is unclear whether

the shares will be considered to be readily tradable on an established securities market in the US, because only the ADSs,

and not the underlying shares, are listed on a securities market in the US. US Holders should consult their tax advisors

regarding the availability of the favorable rate applicable to qualified dividend income for any dividends the Company pays

with respect to the ADSs.

100

Table of Contents

The amount of any distribution paid in Danish kroner will be included in a US Holder’s income in an amount equal to

the US dollar value of such Danish kroner calculated by reference to the exchange rate in effect on the date the distribution

is actually or constructively received by the depository, regardless of whether the payment is in fact converted into US

dollars at that time. If the distribution is converted into US dollars on the date of receipt, a US Holder generally should not

be required to recognize foreign currency gain or loss in respect of the distribution. A US Holder may have foreign

currency gain or loss if the distribution is converted into, or exchanged for, US dollars after the date of receipt.

Any dividends the Company pays to US Holders generally will constitute non-US source “passive category” income

for US foreign tax credit limitation purposes. If any Danish taxes are withheld with respect to dividends paid to a US

Holder with respect to the ADSs, subject to certain conditions and limitations provided in the Code and the applicable

Treasury Regulations (including those introduced by Treasury Regulations that apply to foreign income taxes paid or

accrued in taxable years beginning on or after December 28, 2021), such taxes may be treated as non-US taxes eligible for

credit against such US Holder’s US federal income tax liability (to the extent not exceeding the withholding rate applicable

to the US Holder). A US Holder’s ability to use a foreign tax credit with respect to any such Danish taxes may not be

allowed unless such holder elects benefits under an applicable income tax treaty with respect to such tax. In lieu of

claiming a foreign tax credit, US Holders may, at their election, deduct creditable non-US taxes, including any Danish

taxes withheld from dividends on the ADSs, in computing their taxable income, subject to generally applicable limitations

under US federal income tax law. An election to deduct non-US taxes instead of claiming foreign tax credits applies to all

non-US taxes paid or accrued in the taxable year. If a refund of the tax withheld is available under the laws of Denmark or

under an applicable income tax treaty, the amount of tax withheld that is refundable will not be eligible for such credit

against a US Holder’s US federal income tax liability (and will not be eligible for the deduction against US federal taxable

income). If the dividends constitute qualified dividend income as discussed above, the amount of the dividend taken into

account for purposes of calculating the US foreign tax credit limitation generally will be limited to the gross amount of the

dividend, multiplied by the reduced rate applicable to the qualified dividend income, divided by the highest rate of tax

normally applicable to dividends.

The rules relating to the determination of the US foreign tax credit and the deduction of non-US taxes are complex,

and US Holders should consult their tax advisors to determine whether and to what extent a credit or deduction may be

available in their particular circumstances.

Taxable Dispositions of the ADSs

Subject to the PFIC rules discussed below, a US Holder generally will recognize taxable gain or loss on any sale,

exchange or other taxable disposition of an ADS in an amount equal to the difference between the sum of the fair market

value of any property and the amount of cash received in such disposition and the holder’s tax basis in the ADS. The US

Holder’s tax basis in the ADSs generally will equal the cost of the ADSs to the US Holder. The gain or loss generally will

be capital gain or loss, and generally will be a long-term capital gain or loss if the US Holder has held the ADS for more

than one year at the time of disposition. For certain non-corporate taxpayers (including individuals), long-term capital gains

are subject to tax at favorable rates. The deductibility of capital losses is subject to limitations.

Any gain or loss that a US Holder recognizes on a sale or other taxable disposition of an ADS generally will be treated

as US source income or loss for US foreign tax credit limitation purposes. US Holders should consult their tax advisors

regarding the proper treatment of any gain or loss in their particular circumstances, including the effects of any applicable

income tax treaties.

Passive Foreign Investment Company Considerations

Based on the current and anticipated value of our assets and the nature and composition of the Company’s income and

assets, the Company does not expect to be a PFIC for our current taxable year ending December 31, 2026, or in the

foreseeable future. However, PFIC status is based on an annual determination that cannot be made until the close of a

taxable year, involves extensive factual investigation, including ascertaining the fair market value of all of our assets on a

quarterly basis and the active or passive character of each item of income that we earn, and is subject to uncertainty in

several respects. Changes in the nature or composition of our income or assets, the structure of our operation or the value of

our assets may cause us to become a PFIC. The determination of the value of our assets may depend in part upon the value

of our goodwill not reflected on our balance sheet (which may depend upon the market value of the ADSs from time to

time, which may be volatile). Accordingly, we cannot assure you that we will not be a PFIC for our current taxable year

ending December 31, 2026, or for any future taxable year. If we are a PFIC for any year during which a US Holder holds

101

Table of Contents

the ADSs, we generally would continue to be treated as a PFIC with respect to that US Holder for all succeeding years

during which the US Holder holds the ADSs, even if we ceased to meet the threshold requirements for PFIC status in any

particular year, unless the US Holder has made a “deemed sale” election under the PFIC Rules when we cease to be a

PFIC.

A non-US corporation such as the Company will be treated as a PFIC for US federal income tax purposes for any

taxable year if, applying applicable look-through rules, either:

• at least 75% of its gross income for such year is “passive income” for purposes of the PFIC rules; or

• at least 50% of the value of its assets (generally, determined based on a quarterly average) during such

year is attributable to assets that produce or are held for the production of passive income.

For this purpose, passive income generally includes dividends, interest, royalties and rents other than certain royalties

and rents derived in the active conduct of a trade or business and not derived from a related person. The Company will be

treated as owning a proportionate share of the assets and earning a proportionate share of the income of any other

corporation in which we own, directly or indirectly, more than 25% by value of the stock.

For purposes of the income test, we believe that we are engaged in an active trade or business of discovering and

developing antibody therapeutics and that the royalties and milestone payments we receive from unrelated parties should be

treated as derived in the active conduct of a trade or business and not characterized as passive income. However, we have

no assurance that these anticipated milestone payments and royalties will be paid when expected. If any such payments are

delayed or not received then, depending on the amount of passive income we receive from other sources, the relative

percentage of our income that is passive could increase and potentially cause us to be classified as a PFIC. There can be no

assurances that we will not be classified as a PFIC for the current taxable year or for any future taxable year.

If we were a PFIC for any taxable year during which a US Holder holds ADSs, then, unless such US Holder makes a

“mark-to-market” election (as discussed below), such US Holder generally would be subject to special adverse tax rules

with respect to any “excess distribution” that it receives from the Company and any gain that it recognizes from a sale or

other disposition, including, in certain circumstances, a pledge, of ADSs. For this purpose, distributions that a US Holder

receives in a taxable year that are greater than 125% of the average annual distributions that it received during the shorter

of the three preceding taxable years or its holding period for the ADSs will be treated as an excess distribution. Under these

rules:

• the excess distribution or recognized gain would be allocated ratably over the US Holder’s holding

period for the ADSs;

• the amount of the excess distribution or recognized gain allocated to the taxable year of distribution or

gain, and to any taxable years in the US Holder’s holding period prior to the first taxable year in which

the Company was treated as a PFIC, would be treated as ordinary income; and

• the amount of the excess distribution or recognized gain allocated to each other taxable year would be

subject to the highest tax rate in effect for individuals or corporations, as applicable, for each such year

and the resulting tax will be subject to the interest charge generally applicable to underpayments of tax.

If the Company were a PFIC for any taxable year during which a US Holder holds ADSs and any of our non-US

subsidiaries or other corporate entities in which we own equity interests is also a PFIC, the US Holder would be treated as

owning a proportionate amount (by value) of the shares of each such non-US entity classified as a PFIC, each such entity

referred to as a lower-tier PFIC, for purposes of the application of these rules. US Holders should consult their own tax

advisor regarding the application of the PFIC rules to any of the Company’s lower-tier PFICs.

If the Company were a PFIC for any taxable year during which a US Holder holds ADSs, then in lieu of being subject

to the tax and interest-charge rules discussed above, the US Holder may make an election to include gain on the ADSs as

ordinary income under a mark-to-market method, provided that our ADSs constitute “marketable stock.” Marketable stock

is stock that is regularly traded on a qualified exchange or other market, as defined in applicable Treasury Regulations. The

Company expects that the ADSs, but not our shares, will be listed on the Nasdaq Global Select Market, which is a qualified

exchange or other market for these purposes.

102

Table of Contents

Consequently, if the ADSs are listed on the Nasdaq Global Select Market and are regularly traded, we expect that the

mark-to-market election would be available to US Holders of ADSs if the Company were to become a PFIC, but no

assurances are given in this regard.

Because a mark-to-market election cannot be made for any lower-tier PFICs that the Company may own (unless the

shares in such lower-tier PFIC are themselves treated as marketable stock), if the Company were a PFIC for any taxable

year, a US Holder that makes the mark-to-market election may continue to be subject to the tax and interest charges under

the general PFIC rules with respect to such US Holder’s indirect interest in any investments held by the Company that are

treated as an equity interest in a PFIC for US federal income tax purposes.

In certain circumstances, a shareholder in a PFIC may avoid the adverse tax and interest-charge regime described

above by making a “qualified electing fund” election to include in income its share of the corporation’s income on a current

basis. However, a US Holder may make a qualified electing fund election with respect to the ADSs only if the Company

agrees to furnish such US Holder annually with a PFIC annual information statement as specified in the applicable

Treasury Regulations. There is no assurance that we will provide such information that would enable a US Holder to make

a qualified electing fund election.

If a US Holder owns ADSs during any year in which the Company is a PFIC, such US Holder (including, potentially,

indirect holders) generally will be required to file an IRS Form 8621 with such holder’s US federal income tax return for

that year. US Holders should consult their own tax advisors regarding the application of the PFIC rules to their ownership

of the ADSs.

Information Reporting and Backup Withholding

Dividend payments with respect to the ADSs and proceeds from a sale, exchange, redemption or other taxable

disposition of the ADSs made within the US or through certain US related financial intermediaries may be subject to

information reporting to the IRS and possible US backup withholding. Backup withholding will not apply, however, to a

US Holder that furnishes a correct taxpayer identification number and makes any other required certification on IRS

Form W-9 or that is otherwise exempt from backup withholding. US Holders of the ADSs should consult their tax advisors

regarding the application of the US information reporting and backup withholding rules.

Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against such

US Holder’s US federal income tax liability, and such holder may obtain a refund of any excess amounts withheld under

the backup withholding rules by filing an appropriate claim for refund with the IRS and furnishing any required

information in a timely manner.

Certain US Holders may be required to comply with certain reporting requirements relating to the ADSs, including

filing IRS Form 8938, with respect to the holding of certain foreign financial assets, including stock of foreign issuers

(such as the Company), either directly or through certain foreign financial institutions, if the aggregate value of all such

assets exceeds US $50,000 on the last day of the tax year or US $75,000 at any time during the tax year. US Holders who

fail to report the required information could be subject to substantial penalties. US Holders should consult their own tax

advisors regarding the application of these rules to their ownership of the ADSs.

THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT

MAY BE IMPORTANT TO YOU. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS

REGARDING THE APPLICATION OF THE US FEDERAL TAX RULES TO THEIR PARTICULAR

CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-US AND OTHER TAX CONSEQUENCES TO THEM

OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF THE ADSS.

Material Danish Income Tax Considerations

The following is a summary of material Danish tax considerations relating to the ownership and disposition of ADSs.

The summary is for general information purposes only and does not constitute exhaustive tax or legal advice.

It is noted specifically that the summary does not address all possible tax consequences relating to the ownership and

disposition of ADSs. The summary does accordingly not apply to investors to whom special tax rules apply, and, therefore,

may not be relevant, for example, to investors subject to the Danish Tax on Pension Yields Act (i.e., pension savings),

103

Table of Contents

professional investors, certain institutional investors, insurance companies, pension companies, banks, stockbrokers and

investors with tax liability on return on pension investments. The summary does further not apply to non-Danish tax

resident investors that carry on business activities in Denmark through a permanent establishment, or to non-Danish tax

resident investors, who are resident in jurisdictions, which are considered non-cooperative tax jurisdictions by the EU.

In the context of the following section, “companies” refers to entities treated as separate taxable entities under

domestic tax laws of their jurisdiction of incorporation.

The summary is based solely on the tax laws of Denmark in effect on the date of this Annual Report on Form 20-F.

Danish tax laws may be subject to change, potentially with retroactive effect.

Potential investors in the ADSs are advised to consult their tax advisors regarding the applicable tax

consequences of ownership and disposition of the ADSs based on their particular circumstances.

Tax Treatment of ADSs Under Danish Tax Law

It is currently not clear under Danish tax legislation or case law how ADSs are to be treated for Danish tax purposes.

Recent administrative practice from the Danish tax authorities indicates that the ADSs may not be treated as shares for

Danish tax purposes, and that the ADS holder may not be treated as the direct owner of the shares underlying the ADSs and

accordingly not as the shareholder for Danish tax purposes. Thus, according to recent administrative practice, the Danish

tax authorities are of the opinion that the depositary bank may be the owner of the shares underlying the ADSs, and that the

qualification of whether the ADS holder or the depositary bank is the holder of the underlying shares for Danish tax

purposes depends on an assessment of the specific ADS program, with the main emphasis on the allocation of the

administrative rights attached to the shares, in particular the voting rights. Furthermore, the Danish tax authorities are of the

opinion that the ADS holder cannot be regarded as a holder of the underlying shares for Danish tax purposes to the extent

the number of ADS certificates held by the ADS holder represents a fraction of a share.

While it therefore is highly uncertain whether the ADS holder in respect of the ADSs is treated as the direct owner of

the shares underlying the ADSs and accordingly as the shareholder for Danish domestic tax law purposes, the summary in

the section immediately below assumes that the ADS holder for Danish tax purposes is treated as the direct owner of the

shares underlying the ADSs.

If, however, an ADS holder is found not to be the owner of the shares underlying the ADSs and accordingly not to be

treated as a shareholder for Danish tax purposes, then the ADSs will likely be taxed pursuant to the Danish tax rules on

taxation of financial contracts. The taxation of financial contracts differs from the taxation of shares in several ways, and,

among other differences, any Danish resident ADS holders will - if taxed under the rules on financial contracts - be subject

to a mark-to-market taxation, i.e., annual taxation on any unrealized gains accrued during the year. A high-level summary

of the tax treatment of financial contracts is laid out in a later section.

Taxation of ADS holders considered to be owners of the underlying shares

Danish Tax Resident Individuals

Sale of Shares

Capital gains from the sale of shares realized by Danish tax resident individuals are taxed as share income at a rate of

27% on the first DKK 79,400 (for cohabiting spouses, a total of DKK 158,800) and at a rate of 42% on share income

exceeding DKK 79,400 (for cohabiting spouses over DKK 158,800) (all 2026 amounts and thresholds). The threshold is

subject to annual adjustments and includes all share income included in the calculation (i.e., all capital gains on shares and

dividends derived by the individual or cohabiting spouses, respectively).

Gains and losses on the sale of shares are calculated as the difference between the purchase price and the sales price.

The purchase price is based on the average purchase price paid for the shares in the company ( i.e., not the purchase price

paid for each share).

104

Table of Contents

Losses on the sale of listed shares can only be offset against other share income deriving from listed shares ( i.e. ,

dividends and capital gains on the sale of listed shares) and subject to the Danish tax authorities having received certain

information concerning the ownership of the shares in due time. Unused losses will automatically be offset against a

cohabiting spouse’s share income deriving from listed shares and any additional losses can be carried forward and offset

against future share income deriving from listed shares.

Dividends

It is highly uncertain if the actual distribution of dividends to the ADS holder are considered dividends for Danish tax

purposes. However, if dividends paid to Danish tax resident individuals who are holders of ADSs are treated as dividends

for Danish tax purposes, then such dividends are included in the individual’s share income and taxed as such, as outlined

above. Dividends paid to Danish tax resident individuals are generally subject to withholding tax at the rate of 27%.

Non-Danish Tax Resident Individuals

Sale of Shares

Non-Danish tax resident individuals, including individuals tax resident in the US, are generally not taxed in Denmark

on gains realized on the sale of shares, subject to certain anti-avoidance rules (see below).

Dividends

Dividends paid on the shares underlying the ADSs to non-Danish tax resident individuals, including individuals tax

resident in the US, are generally subject to withholding tax at the rate of 27%. No additional tax should be imposed.

It is highly uncertain if the ADS holder is considered the holder of the shares underlying the ADSs. If the ADS holder

is considered to be the owner of the shares underlying the ADSs for Danish tax purposes and is the beneficial owner of the

dividends paid on the shares, then the ADS holder may in certain circumstances seek a refund of tax withheld on dividends

paid on the shares.

If this is the case, and the ADS holder is tax resident in a state with which Denmark has entered into a tax treaty and is

entitled to benefits under such tax treaty, the ADS holder may seek a refund from the Danish Tax Agency of the tax

withheld in excess of the applicable treaty rate (Danish tax treaties typically provide for a 15% tax rate). Denmark has

entered into tax treaties with dozens of countries, including the US and almost all EU member states. The treaty between

Denmark and the US generally provides for a 15% tax rate.

Similarly, if the ADS holder for Danish tax purposes is considered the owner of the underlying shares and the

beneficial owner of the dividends paid on the shares, Danish domestic tax law provides for a 15% tax rate, if the ADS

holder holds less than 10% of the nominal share capital in the company and is tax resident in a state that is obligated to

exchange information with Denmark under a tax treaty or an international agreement, convention or other administrative

agreement on assistance in tax matters. If the ADS holder is a tax resident outside the EU, it is an additional requirement

for application of the 15% tax rate that the ADS holder together with related shareholders holds less than 10% of the share

capital of the company.

If the depositary bank is considered the owner of the shares underlying the ADSs for Danish tax purposes, then the

depositary bank may potentially in certain circumstances seek a refund of tax withheld on dividends paid on the shares.

Any reduced tax rate according to an applicable tax treaty and/or Danish domestic tax law will not affect the

withholding rate (27%). In order to receive a refund (from 27% to e.g. , 15%), the shareholder must make a claim for such a

refund through certain certification procedures.

As a general rule, the refund shall be paid within six months following the Danish Tax Agency’s receipt of the refund

claim. If the refund is paid later than six months after the receipt of the claim, interest will in general be calculated on the

amount of the refund. The rate per month will be 0.2833% plus a premium (fixed annually). The six-month deadline is

suspended by the Danish Tax Agency, if the Tax Agency is unable to determine whether the taxpayer is entitled to a refund

based on the taxpayer’s affairs. If the deadline is suspended accordingly, computation of interest is also suspended.

105

Table of Contents

The Danish Tax Agency has published guidance on the documentation necessary for processing refund claims. The

guidance is available in English from the Danish tax authorities’ website, https://skat.dk/en-us/businesses/companies-

andfoundations/companies-and-foundations/declaring-and-paying-dividends-and-dividendtax/claiming-refund-of-danish-

dividend-tax. The information on, or information that can be accessed through, such website is not part of and should not

be incorporated by reference into this Annual Report on Form 20-F. We have included such website address as an inactive

textual reference only.

Danish Tax Resident Companies

Sale of Shares

For the purpose of taxation of sales of shares made by corporate shareholders (and dividends received by corporate

shareholders, see below), a distinction is made between:

“ Subsidiary Shares ,” which are generally defined as shares owned by a shareholder holding at least 10% of the share

capital of the issuing company;

“ Group Shares ,” which are generally defined as shares in a company in which the shareholder of the company and the

issuing company are subject to Danish joint taxation or satisfy the requirements for international joint taxation under

Danish law;

“ Tax-Exempt Portfolio Shares ,” which are generally defined as unlisted shares owned by a shareholder holding less

than 10% of the share capital of the issuing company; and

“ Taxable Portfolio Shares ,” which are defined as shares that do not qualify as Subsidiary Shares, Group Shares or

Tax-Exempt Portfolio Shares.

Gains and losses on disposal of Subsidiary Shares, Group Shares and Tax-Exempt Portfolio Shares realized by Danish

tax resident companies are generally not included in the taxable income of the shareholder, subject to certain anti-

avoidance rules (see below).

Capital gains on listed Taxable Portfolio Shares are taxable at the general Danish corporate tax rate of 22% and losses

on such shares are generally deductible. Gains and losses on listed Taxable Portfolio Shares are generally taxed under the

mark-to-market principle irrespective of realization.

Dividends

It is highly uncertain if the actual distribution of dividends to the ADS holder are considered dividends for Danish tax

purposes. However, if dividends paid to Danish tax resident companies who are holders of ADSs are treated as dividends

for Danish tax purposes, then the following should apply:

Dividends received on Subsidiary Shares, Group Shares, and Tax-Exempt Portfolio Shares are generally tax-exempt,

subject to certain anti-avoidance rules (see below).

Dividends received on Taxable Portfolio Shares are taxable at the general Danish corporate tax rate of 22% and tax is

generally withheld similarly at 22%.

Non-Danish Tax Resident Companies

Sale of Shares

Non-Danish tax resident companies, including companies tax resident in the US, are generally not taxed in Denmark

on gains realized on the sale of shares, subject to certain anti-avoidance rules (see below).

106

Table of Contents

Dividends

Dividends paid on the shares underlying the ADSs to non-Danish tax resident companies, including companies tax

resident in the US, are generally subject to withholding tax at the rate of 27%.

It is highly uncertain if the ADS holder is considered the holder of the shares underlying the ADSs. If the ADS holder

is considered to be the owner of the shares underlying the ADSs for Danish tax purposes and is the beneficial owner of the

dividends paid on the shares, then the ADS holder may in certain circumstances benefit from certain exemptions from

withholding tax on dividends or seek a refund of tax withheld on dividends paid on the shares.

If the ADS holder for Danish tax purposes is considered the holder of the shares underlying the ADSs and is

considered the beneficial owner of dividends paid on the shares, then the following exemptions apply if the shares held by

the ADS holder qualify as Subsidiary Shares or Group Shares: dividends received on Subsidiary Shares are exempt from

Danish withholding tax provided that taxation shall be waived or reduced under the Parent-Subsidiary Directive (2011/96/

EU) or under an applicable tax treaty. Similarly, dividends received on Group Shares, which are not Subsidiary Shares, are

exempt from Danish withholding tax if the shareholder is resident in the EU or the EEA and provided that taxation shall be

waived or reduced under the Parent-Subsidiary Directive (2011/96/EU) or under an applicable tax treaty had the shares

been Subsidiary Shares.

In other cases, dividends will generally be subject to tax at a rate of 22% effective for dividends distributed. However,

the withholding rate is 27%, meaning that foreign corporate shareholders receiving taxable dividends distributed from

Danish companies generally will be able to apply for a refund of at least 5% of the total dividend.

Further, if the ADS holder for Danish tax purposes is considered the holder of the shares underlying the ADSs, is

considered the beneficial owner of dividends paid on the shares, and is tax resident in a state with which Denmark has

entered into a tax treaty and is entitled to the benefits under such tax treaty, the ADS holder may seek a refund from the

Danish Tax Agency of the tax withheld in excess of the applicable treaty rate (Danish tax treaties typically provide for a

15% tax rate). Denmark has entered into tax treaties with dozens of countries, including the US and almost all EU member

states. The treaty between Denmark and the US generally provides for a 15% tax rate.

Similarly, in the event the ADS holder for Danish tax purposes is considered both the owner of the underlying shares

and the beneficial owner of the dividends paid on the shares, Danish domestic tax law provides for an applicable 15% tax

rate, if the ADS holder holds less than 10% of the share capital in the company and is tax resident in a state that is obligated

to exchange information with Denmark under a tax treaty or an international agreement, convention or other administrative

agreement on assistance in tax matters. If the ADS holder is a tax resident outside the EU, it is an additional requirement

for eligibility for the 15% tax rate that the ADS holder together with related shareholders (i) holds less than 10% of the

nominal share capital of the company (unless the ADS holder is tax resident in a country forming part of the EEA

(European Economic Area) and which has entered into a tax treaty with Denmark) and (ii) has no controlling interest over

the company (unless the ADS holder is tax resident in a country which has entered into a tax treaty with Denmark).

If the depositary bank is considered the owner of the shares underlying the ADSs for Danish tax purposes, then the

depositary bank may potentially in certain circumstances seek a refund of tax withheld on dividends paid on the shares.

Any reduced tax rate according to an applicable tax treaty (and/or the 15% tax rate provided for under Danish domestic

tax law) will not affect the withholding rate (27%). In order to receive a refund (from 27% to e.g. , 15%), the shareholder

must make a claim for such a refund through certain certification procedures.

As a general rule, the refund shall be paid within six months following the Danish Tax Agency’s receipt of the refund

claim. If the refund is paid later than six months after the receipt of the claim, interest will be calculated on the amount of

refund. The rate per month will be 0.2833% plus a premium fixed annually. The six-month deadline can be suspended by

the Danish Tax Agency, if the Tax Agency is unable to determine whether the taxpayer is entitled to a refund based on the

taxpayer’s affairs. If the deadline is suspended accordingly, computation of interest is also suspended.

The Danish Tax Agency has published guidance on the documentation necessary for processing refund claims. The

guidance is available in English from the Danish tax authorities’ website, https://skat.dk/en-us/businesses/companies-

andfoundations/companies-and-foundations/declaring-and-paying-dividends-and-dividendtax/claiming-refund-of-danish-

dividend-tax. The information on, or information that can be accessed through, such website is not part of and should not

107

Table of Contents

be incorporated by reference into this Annual Report on Form 20-F. We have included such website address as an inactive

textual reference only.

Taxation of ADS holders not considered to be owners of the underlying shares

Pursuant to Danish administrative practice, ADSs which do not constitute shares for tax purposes are instead likely

taxed as financial contracts, but there is some uncertainty in this respect. A high-level summary of the tax treatment of

financial contracts is laid out below.

Danish tax resident ADS holder individuals and companies

Gains and losses

Danish tax resident holders of financial contracts are generally taxed according to a mark-to-market principle in

respect of gains and losses on the financial contracts. The mark-to-market principle entails that unrealized gains and losses

on financial contracts are taxed annually regardless of whether the ADSs have been sold. The deductibility of losses may in

certain cases be restricted.

Dividends

If the ADS holders are not considered the shareholders for Danish tax purposes, any dividends received by the ADS

holders in respect of the ADSs will likely be taxable, and the ADS holders will likely not be able to obtain a refund of any

tax withholding on the dividend.

Non-Danish tax resident ADS holder individuals and companies

Gains and losses

Non-Danish tax resident individuals and companies, including individuals and companies tax resident in the US, are

generally not taxed in Denmark on gains realized on financial contracts, subject to certain anti-avoidance rules (see below).

Dividends

If the ADS holders are not considered the shareholders for Danish tax purposes, the ADS holders will likely not be

eligible for a refund of withholding tax on dividends. Communications from the Danish tax authorities indicate that the

depository bank in such cases in certain circumstances may be entitled to apply for a refund of Danish withholding tax on

dividends.

Danish Anti-Avoidance Rules

The below summary of Danish anti-avoidance rules is not exhaustive.

Payments may be subject to Danish withholding tax irrespective of the above, if the shareholder is not the beneficial

owner of the shares and dividend (e.g., if the shareholder reassigns the payments to a person or entity not itself entitled to

the above exemptions).

Further, Danish law has certain general anti-avoidance rules (“ GAAR ”), which focus on substance over form. Under

these rules the Danish tax authorities can set aside a setup, which, having been put into place for the main purpose or one of

the main purposes of obtaining a tax advantage that defeats the object or purpose of the applicable tax law, is not genuine

having regard to all relevant facts and circumstances. Subject to the conditions of the GAAR an investor might be denied

the benefits of the Parent-Subsidiary Directive (2011/96/EU) or a tax treaty, and Danish withholding tax of 27% will in

such cases be levied.

Finally, it should be noted that it is the shareholder who owns the share at the time of the general meeting where the

decision to distribute a dividend is passed to the shareholder, who is subject to Danish taxation on the dividend, and

thereby is entitled to make a tax reclaim if any.

108

Table of Contents

F. Dividends and Paying Agents

Not applicable.

G. Statement by Experts

Not applicable.

H. Documents on Display

Copies of this Annual Report on Form 20-F, as well as our Annual Report 2025 , which includes our Audited Financial

Statements, can be downloaded from the “Investors” page at www.genmab.com. The contents of our website are not

incorporated by reference into this Annual Report on Form 20-F. This Annual Report on Form 20-F is also filed and can be

viewed via EDGAR on www.sec.gov.

I. Subsidiary Information

Not applicable.

J. Annual Report to Security Holders

Our Annual Report 2025 has been attached as Exhibit 15.3 to this Annual Report on Form 20-F. Only those portions of

the Annual Report 2025 specifically incorporated by reference herein are deemed to be filed.

ITEM 11 QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISKS

For qualitative and quantitative disclosures about market risks including foreign currency risk, interest rate risk, and

credit risk, see Note 4.2 to our Audited Financial Statements included in our Annual Report 2025 .

ITEM 12 DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

A. Debt Securities

Not applicable.

B. Warrants and Rights

Not applicable.

C. Other Securities

Not applicable.

D. American Depositary Shares

As of July 17, 2025 Genmab's ADS program is administered by JPMorgan Chase Bank, N.A. The principal executive

office of the depositary is located at 383 Madison Avenue, Floor 11, New York, NY 10179. Below is a summary of fees

and expenses payable by ADS holders and of fees and payments by the depositary to us. Below is a summary of fees and

expenses payable by ADS holders and of fees and payments by the depositary to us. Please refer to Exhibit 2.3 hereto for a

summary of certain other material provisions of the amended and restated deposit agreement related to our ADS program.

For more complete information, holders should read the entire amended and restated deposit agreement and the form of

American Depositary Receipt incorporated by reference as Exhibits 2.1 and 2.2 hereto, respectively.

109

Table of Contents

Fees and Expenses

The depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against

deposits of shares, issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock

dividend or stock split declared by or issuances pursuant to a merger, exchange of securities or any other transaction or

event affecting the ADSs or deposited securities, and each person surrendering ADSs for withdrawal of deposited securities

or whose ADSs are cancelled or reduced for any other reason, a fee of up to U.S.$5.00 for each 100 ADSs (or portion

thereof) for each issued, delivered, reduced, cancelled or surrendered, or upon which a share distribution or elective

distribution is made or offered, as the case may be. The depositary may sell (by public or private sale) sufficient securities

and property received in respect of a share distribution, rights or other distribution prior to such deposit to pay such charge.

The following additional fees, charges and expenses will also be incurred by the ADS holders, the beneficial

owners, by any party depositing or withdrawing shares or by any party surrendering ADSs or to whom ADSs are issued

(including, without limitation, issuance pursuant to a stock dividend or stock split declared by us or an exchange of stock

regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable:

• a fee of up to $0.05 per ADS held for any cash distribution made, or for any elective cash/stock dividend offered,

pursuant to the deposit agreements;

• an aggregate fee of up to $0.05 per ADS per calendar year (or portion thereof) for services performed by the

depositary in administering the ADSs (which fee may be charged on a periodic basis during each calendar year

and will be assessed against ADS holders as of the record date or record dates set by the depositary during each

calendar year and will be payable in the manner described in the next succeeding provision);

• an amount for the reimbursement of such charges and expenses as are incurred by the depositary or any of its

agents (including, without limitation, the custodian, as well as charges and expenses incurred on behalf of ADS

holders in connection with compliance with foreign exchange control regulations or any law or regulation relating

to foreign investment) in connection with the servicing of the shares or other deposited securities, the sale of

securities (including, without limitation, deposited securities), the delivery of deposited securities or otherwise in

connection with the depositary’s or its custodian’s compliance with applicable law, rule or regulation (which

charges and expenses may be assessed on a proportionate basis against ADS holders as of the record date or dates

set by the depositary and will be payable at the sole discretion of the depositary by billing such ADS holders or by

deducting such charge or expense from one or more cash dividends or other cash distributions);

• a fee of up to $0.05 per ADS held for the direct or indirect distribution of securities (other than ADSs or rights to

purchase additional ADSs as described above) or the net cash proceeds from the public or private sale of any such

securities, regardless of whether any such distribution or sale is made by, for or received from, or (in each case) on

behalf of, the depositary, the Company or any third party (which fee may be assessed against ADS holders as of a

record date set by the depositary);

• stock transfer or other taxes and other governmental charges;

• a transaction fee per cancellation request (including any cancellation request made through SWIFT, facsimile

transmission or any other method of communication) as disclosed on the “Disclosures” page (or successor page)

of ADR.com and any applicable delivery expenses (which are payable by such persons or holders); and

• transfer or registration fees for the registration of transfer of deposited securities on any applicable register in

connection with the deposit or withdrawal of deposited securities.

To facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other

cash distributions and other corporate actions, the depositary may engage the foreign exchange desk within JPMorgan

Chase or its affiliates in order to enter into spot foreign exchange transactions to convert foreign currency into U.S. dollars

(“FX Transactions”). For certain currencies, FX Transactions are entered into with JPMorgan Chase or an affiliate, as the

case may be, acting in a principal capacity. For other currencies, FX Transactions are routed directly to and managed by an

unaffiliated local custodian (or other third-party local liquidity provider), and neither JPMorgan Chase nor any of its

affiliates is a party to such FX Transactions.

110

Table of Contents

The foreign exchange rate applied to an FX Transaction will be either (a) a published benchmark rate, or (b) a rate

determined by a third-party local liquidity provider, in each case plus or minus a spread, as applicable. The depositary will

disclose which foreign exchange rate and spread, if any, apply to such currency on the “Disclosures” page (or successor

page) of ADR.com. Such applicable foreign exchange rate and spread may (and neither the depositary, JPMorgan Chase

nor any of their affiliates is under any obligation to ensure that such rate does not) differ from rates and spreads at which

comparable transactions are entered into with other customers or the range of foreign exchange rates and spreads at which

JPMorgan Chase or any of its affiliates enters into foreign exchange transactions in the relevant currency pair on the date of

the FX Transaction. Additionally, the timing of execution of an FX Transaction varies according to local market dynamics,

which may include regulatory requirements, market hours and liquidity in the foreign exchange market or other factors.

Furthermore, JPMorgan Chase and its affiliates may manage the associated risks of their position in the market in a manner

they deem appropriate without regard to the impact of such activities on the depositary, us, ADS holders or beneficial

owners. The spread applied does not reflect any gains or losses that may be earned or incurred by JPMorgan Chase and its

affiliates as a result of risk management or other hedging related activity.

Notwithstanding the foregoing, to the extent Genmab provides U.S. dollars to the depositary, neither JPMorgan Chase

nor any of its affiliates will execute an FX Transaction as set forth herein. In such case, the depositary will distribute the

U.S. dollars received from us.

Further details relating to the applicable foreign exchange rate, the applicable spread and the execution of FX

Transactions will be provided by the depositary on ADR.com. Each holder and beneficial owner by holding or owning an

ADS or an interest therein, and Genmab, each acknowledge and agree that the terms applicable to FX Transactions

disclosed from time to time on ADR.com will apply to any FX Transaction executed pursuant to the deposit agreements.

Genmab will pay all other fees, charges and expenses of the depositary and any agent of the depositary (except the

custodian) pursuant to agreements from time to time between us and the depositary.

The right of the depositary to charge and receive payment of fees, charges and expenses survives the termination of the

deposit agreements, and will extend for those fees, charges and expenses incurred prior to the effectiveness of any

resignation or removal of the depositary.

The fees and charges described above may be amended from time to time by agreement between us and the depositary.

The depositary may make available to Genmab a set amount or a portion of the depositary fees charged in respect of

the ADS program or otherwise upon such terms and conditions as Genmab and the depositary may agree from time to time.

The depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or

surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for

making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of

distributable property to pay the fees.

The depositary may collect its annual fee for depositary services by deduction

PART II

ITEM 13 DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.

ITEM 14 MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF

PROCEEDS

None.

ITEM 15 CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

111

Table of Contents

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the

effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange

Act), as of the end of the period covered by this Annual Report on Form 20-F. Based on such evaluation, management, our

principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were

effective as of December 31, 2025 .

Report of Genmab Management on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as

defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is designed to provide reasonable

assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in

accordance with IFRS as issued by the IASB.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements

due to error or fraud. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that

controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or

procedures may deteriorate.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, assessed the

effectiveness of our internal control over financial reporting as of December 31, 2025 , using the criteria established in the

Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway

Commission (“ COSO ”). Based on this assessment our management concluded that, as of December 31, 2025 , Genmab’s

internal control over financial reporting was effective based on the COSO criteria. The effectiveness of the Company’s

internal control over financial reporting as of December 31, 2025 has been audited by Deloitte, Statsautoriseret

Revisionspartnerselskab, Denmark, an independent registered public accounting firm, as stated in their report which

appears on page 64 of this Annual Report on Form 20-F.

Excluded from our evaluation were internal controls over financial reporting at Merus, for which control was acquired

on December 12, 2025. The financial statements of this entity constitute 59.6% of total assets and less than 0.1% of

revenues as of and for the year ended December 31, 2025.

Changes in Internal Control over Financial Reporting

Except for changes related to debt, t here were no c hanges in our internal co ntrol over financial reporting (as defined in

Rule 13a-15(f) under the Exchange Act) during the period covered by this Annual Report on Form 20-F that have

materially affected, or is reasonably likely to materially affect, internal control over financial reporting.

ITEM 16A AUDIT COMMITTEE FINANCIAL EXPERTS

Our Audit and Finance Committee consists of members Rolf Hoffmann, Elizabeth O’Farrell, and Deirdre P. Connelly

and is chaired by Pernille Erenbjerg. Each member of the Audit and Finance Committee satisfies the independence

requirements of the corporate governance standards of the Nasdaq Stock Market. Due to their professional experience,

including their service in senior finance leadership positions and as audit committee chairs and members of other public

companies, both Pernille Erenbjerg and Elizabeth O’Farrell qualify as “audit committee financial experts,” as defined in

Nasdaq Rule 5605(c)(2)(A) and Item 407(d)(5)(ii) of Regulation S-K of the SEC , and as determined by our Board of

Directors.

ITEM 16B CODE OF ETHICS

We have adopted a written Code of Conduct, which articulates our commitment to conducting all aspects of our

business with integrity and includes 20 key ethical standards that guide our conduct. The Code of Conduct applies to all

Genmab employees, management, and members of our Board. This document is available on our website

(www.genmab.com). The contents of this website are not incorporated by reference into this Annual Report on Form 20-F.

112

Table of Contents

During 2025 , the Company did not amend its Code of Conduct or grant any waiver, including any implicit waiver,

from any provision of the Code of Conduct to any of its directors or employees. We expect that any amendments to the

current Code of Conduct, or any waivers of its requirements, will be disclosed on our website.

ITEM 16C PRINCIPAL ACCOUNTANT FEES AND SERVICES

For principal accountant fees and services, see Note 5.4 to our Audited Financial Statements included in our Annual

Report 2025 .

The audit opinion of Deloitte Statsautoriseret Revisionspartnerselskab (PCAOB no. 1294) is included in Item 18.

Audit Fees

Audit fees consist of fees billed for professional services rendered by the principal accountant for the audit of the

registrant’s annual financial statements or services that are normally provided by the accountant in connection with

statutory and regulatory filings or engagements for those fiscal years.

Audit-Related Fees

Audit-related fees consist of assurance and related services by the principal accountant that are reasonably related to

the performance of the audit or review of the registrant’s financial statements and are not reported under “Audit Fees”. Fees

for audit-related services include consultations concerning financial accounting reporting standards.

Tax Fees

Tax fees consist of fees billed for professional services rendered by the principal accountant for tax compliance, tax

advice, and tax planning, including tax fees billed for tax consultations.

All Other Fees

All other fees consist of products and services provided by the principal accountant, other than the services reported in

“Audit Fees,” “Audit-Related Fees” and “Tax Fees”.

Fees for other services comprise fees billed for other permitted services.

Pre-Approval Policies

The Audit Committee assesses and pre-approves all audit and non-audit services provided by the principal accountant.

ITEM 16D EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Not applicable.

ITEM 16E PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

In 2025 , Genmab conducted share repurchases under a single share buy-back program. The share buy-back program

announced on March 25, 2025 provided for the repurchase of up to 2,200,000 ordinary shares, and expired on July 10,

2025 (the “March Share Buy-Back Program”). Genmab made purchases of its ordinary shares under the March Share Buy-

Back Program to reduce capital and to honor our commitments under the RSU program . No shares remain to be

repurchased under the March Share Buy-Back Program. See “Item 6—Directors, Senior Management and Employees—B.

Compensation” for more details on the RSU and warrant programs.

113

Table of Contents

Period	Total Number of Shares Purchased	Average Price Paid per Share in DKK	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs
Share Repurchase Programs
March 26, 2025 - March 31, 2025	316,630	1,362.84	316,630	—
April 1, 2025 - April 30, 2025	1,152,244	1,269.71	1,152,244	—
May 1, 2025 - May 28, 2025	611,037	1,326.80	611,037	—
June 2, 2025 - June 26, 2025	120,089	1,324.59	120,089	—
Total	2,200,000		2,200,000	—

At Genmab’s Annual General Meeting on March 12, 2025, the Board of Directors was authorized to allow Genmab to

acquire treasury shares with a total nominal value of up to 10% of the share capital in the period until and including March

11, 2030 (the “2025 Authorization”) . The purchase price for the relevant shares may not deviate by more than 10% from

the price quoted on Nasdaq Copenhagen at the time of the acquisition. Such shares may only be acquired to the extent that

the Company’s total holding of treasury shares does not at any time exceed a nominal value of 10% of the share capital.

The authorization replaced existing previously provided authorizations to purchase treasury shares.

ITEM 16F CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

Not applicable.

ITEM 16G CORPORATE GOVERNANCE

The listing rules of the Nasdaq (the “ Nasdaq Listing Rules ”) provide that foreign private issuers may follow home

country practice in lieu of Nasdaq Global Select Market corporate governance standards, subject to certain exceptions and

except to the extent that such exemptions would be contrary to US federal securities laws. The home country practices we

follow in lieu of the Nasdaq Listing Rules are described below.

• We do not follow the quorum requirements of the Nasdaq Stock Market applicable to meetings of

shareholders. In accordance with Danish corporate law and generally accepted business practice, our articles

of association do not provide quorum requirements for general meetings of shareholders.

• We do not follow the requirements of the Nasdaq Stock Market regarding the provision of proxy statements

for general meetings of shareholders. Danish corporate law does not have a regulatory regime for the

solicitation of proxies. The solicitation of proxies is not a generally accepted business practice in Denmark,

although it has recently become more common for listed companies to do so. However, a shareholder may be

represented at a general meeting by proxy. Unless containing a provision to the contrary, instruments of proxy

will be deemed to be in force until revoked in writing by notification to the company. Rather than providing

proxy statements, we provide notice prior to convening a general meeting, including an agenda and other

relevant documents, to the Danish Business Authority and written notice to all registered shareholders who

have so requested.

• We do not follow the requirements of the Nasdaq Stock Market regarding shareholder approval for certain

issuances of securities under Nasdaq Listing Rule 5635. Pursuant to Danish corporate law and our articles of

association, our shareholders have authorized our Board to issue securities, including shares and warrants.

• We do not follow the requirement of the Nasdaq Stock Market that each member of the Compensation

Committee be independent as defined under Nasdaq Listing Rule 5605(a)(2). No such requirement exists

pursuant to Danish law. We do not have an independent Compensation Committee within the meaning of the

Nasdaq Listing Rules because we consider Anders Gersel Pedersen, a member of the Compensation

114

Table of Contents

Committee, to be a non-independent director solely by virtue of the length of his tenure on our Board,

following his election to the Board in 2003. We do not consider Dr. Pedersen’s tenure as material to his

ability to be independent from Executive Management in connection with his duties as a Compensation

Committee member. The charter of the Compensation Committee requires a majority of its members to meet

the independence requirements established by the Board and applicable laws, regulations, corporate

governance recommendations, and listing requirements (if any).We do not follow the requirement of the

Nasdaq Stock Market that we have independent director oversight of director nominations as prescribed by

Nasdaq Listing Rule 5605(e)(1). No such requirement exists pursuant to Danish law. We do not have

independent oversight of director nominations because we consider Anders Gersel Pedersen to be a non-

independent director solely by virtue of the length of his tenure on our Board, following his election to the

Board in 2003. We do not consider Dr. Pedersen’s tenure as material to his ability to be independent from

Executive Management in connection with his duties as a member of the Nominating and Corporate

Governance Committee. The charter of the Nominating and Corporate Governance Committee requires a

majority of its members to meet the independence requirements established by the Board and applicable laws,

regulations, corporate governance recommendations, and listing requirements (if any).

• We do not follow the requirement of the Nasdaq Stock Market that our independent directors must have

regularly scheduled meetings at which only independent directors are present. No such requirement exists

pursuant to Danish law. Our directors regularly meet in executive sessions without the participation of

management. However, our Employee Elected Directors, who are not independent within the meaning of the

Nasdaq Listing Rules, attend these executive sessions.

ITEM 16H MINE SAFETY DISCLOSURE

Not applicable.

ITEM 16I DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

ITEM 16J INSIDER TRADING POLICIES

We have adopted two insider trading policies, one of which governs the purchase, sale, and other transactions in our

securities by our Board of Directors, Executive Management and other permanent insiders and the other governs such

transactions by our employees, and employees of our directly and indirectly owned subsidiaries. These policies have been

reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any listing

standards applicable to us. Copies of our insider trading policies are attached as Exhibits 11.1 and 11.2 to this Annual

Report.

ITEM 16K CYBERSECURITY

Overview of Cybersecurity Program and Risk Management

Safeguarding the confidentiality, integrity, and availability of systems, data and applications as well as protecting trade

secrets and data privacy is an essential pillar in ensuring the business continuity of Genmab, and complying with regulatory

requirements, and maintaining the trust of our patients, employees, shareholders, partners, and other stakeholders. Genmab

maintains a comprehensive cybersecurity program based on the National Institute of Standards and Technology’s NIST

800 Special Publication Information Security standard (“ NIST Standard ”) for managing cybersecurity activities, including

formulation of global objectives of the cybersecurity program and risk identification and mitigation activities.

Genmab’s Information Security Department, led by the Global Head of Information Security and Digital Risk &

Compliance Management, is responsible for administering and annually updating our enterprise-wide information security

program. The program includes activities and projects in all six functions (govern, identify, protect, detect, respond,

recover) of the NIST standard with the goal of further improving Genmab’s security profile and adapting, where needed, to

changes in Genmab’s business strategy and threat environment. Input for the program comes from the annual attack and

115

Table of Contents

penetration test, periodic threat landscape and security maturity assessments, as well as requirements of applicable

cybersecurity regulations. The Information Security Department is also responsible for a number of global security

processes and services that Genmab undertakes, such as the following:

• proposing and administering information security policies and standards;

• security awareness training (including the administration of a third-party phishing learning platform, conducting

periodic global security awareness events and preparing other learning materials);

• security risk assessment of new and existing vendors, partners and other third parties with respect to whom a

security risk assessment is deemed appropriate;

• review of new contracts and assessment of the impact of new technologies on security;

• defining mandatory security controls and assessing solution security architecture of new or changed systems or

services;

• security incident detection and management;

• periodic operational security incident exercises, and vulnerability scanning.

We work with consultants and other third-party advisors to perform security services and conduct security assessments

and independent audits of the security and resilience of our systems and networks. We have also established a cyber

response task force consisting of leaders from Finance, Legal, Compliance, Communications, and Data, Digital & AI

(“ DD&AI ”) departments. The task force is responsible for cybersecurity crisis preparedness and the management of

cybersecurity crisis situations. This task force regularly leads scenario exercises, which include engagement of all levels of

management including members of Genmab’s Executive Committee, to assess Genmab’s resilience capabilities in the

event of a cybersecurity crisis.

We have integrated information security risk management into our overall risk management infrastructure through our

enterprise risk management program. The enterprise risk management program, which is overseen by our Global

Compliance & Risk Committee (“ GCRC ”), entails a formal process that seeks to identify, assess, mitigate and manage the

risks from both internal and external conditions that could significantly impact the Company and influence our business

strategy and performance.

Role of Management

The Global Head of Information Security and Digital Risk & Compliance Management is responsible for information

security within Genmab and reports to the Global Head of DD&AI . Our current Global Head of Information Security and

IT Risk & Compliance Management has more than 15 years of experience in leading global information and cyber security

departments and programs, and our current Global Head of DD&AI has more than 20 years of experience in leading,

managing and transforming analytics and technology departments, in each case for large, global organizations .

The Global Head of Information Security and Digital Risk & Compliance Management reports the status of the

Genmab information security program, security threats, incidents, and risks quarterly to the GCRC, chaired by Genmab’s

CEO and the Senior Vice President, Head of Global Compliance and Risk, and in which members of our Executive

Committee participate. The status of risk mitigation actions and newly identified risks are discussed during periodic

meetings of the DD&AI Risk Governance Board, consisting of members of the DD&AI Leadership Team and chaired by

the Global Head of DD&AI. Results of security assessments and periodic cyber threat landscape assessments may also be

integrated in strategic reports to Genmab’s relevant business leaders and the GCRC when appropriate.

Role of the Board of Directors

The Board of Directors oversees our approach to overall risk management. The board has delegated oversight of

information security strategy and risks to the Audit and Finance Committee. The Audit and Finance Committee is

responsible for reviewing Genmab’s information security strategy and program, including with respect to identification and

management of cybersecurity risks and threats. The Global Head of Information Security and Digital Risk & Compliance

116

Table of Contents

Management presents an update on the status of the Genmab information security strategy and program, including strategic

priorities, progress made in respect of those priorities and a review of cybersecurity incidents, risks, and threats to the Audit

and Finance Committee at least annually. A summary management report on the information security strategy, program,

incidents, risks and threats is presented to the Board of Directors periodically and is supplemented by discussions between

the Board of Directors and Audit and Finance Committee.

Cybersecurity Threats

For the year ended December 31, 2025 through the date of this annual report, there were no security incidents/breaches

leading to material risks from cybersecurity threats, that have materially affected or are reasonably likely to materially

affect the Company, including its business strategy, results of operations or financial condition.

PART III

ITEM 17 FINANCIAL STATEMENTS

See “Item 18—Financial Statements.”

ITEM 18 FINANCIAL STATEMENTS

The financial statements required by this item are incorporated herein by reference to pages 107-156 of our Annual

Report 2025 .

ITEM 19 EXHIBITS

a. Annual Report

The following pages from our Annual Report 2025 , filed together with this Form 20-F , as Exhibit 15.3, are

incorporated by reference into this Form 20-F. The content of websites, scientific articles and other sources referenced on

these pages are not incorporated by reference into this Annual Report on Form 20-F.

Page(s) incorporated by reference from our Annual Report 2025

Financial Review – pages 38-46

Consolidated Financial Statements for the Genmab Group – pages 107-156

Consolidated Statements of Comprehensive Income for the years ended December 31, 2025, 2024 and 2023 – page

107

Consolidated Balance Sheets as of December 31, 2025 and 2024 – page 108

Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 – page 109

Consolidated Statements of Changes in Equity for the years ended December 31, 2025, 2024 and 2023 – page 110

Notes to the Consolidated Financial Statements – pages 111-156

b. Exhibits

Exhibit Index

Exhibit No.	Description	Method of filing
1.1	English translation of Articles of Association of Genmab A/S, as currently in effect	Incorporated by reference to the Registrant’s Report furnished to the SEC on Form 6-K on February 3, 2025

117

Table of Contents

Exhibit No.	Description	Method of filing
2.1	Second Amended and Restated Deposit Agreement	Incorporated by reference to Exhibit (a) to the Registrant’s Form F-6 filed with the SEC on July 3, 2025
2.2	Form of American Depositary Receipt	Included in Exhibit 2.1, which is incorporated by reference to Exhibit (a) to the Registrant’s Form F-6 filed with the SEC on July 3, 2025
2.3	Indenture, dated as of December 3, 2025, among Genmab A/S, Genmab Finance LLC, the guarantors named therein and Wilmington Trust, National Association, as trustee	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
2.4	First Supplemental Indenture, dated as of January 28, 2026 among Genmab A/S, Genmab Finance LLC, the guarantors named therein and Wilmington Trust, National Association, as trustee	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
2.5	Indenture, dated as of December 3, 2025, among Genmab A/S, Genmab Finance LLC, the guarantors named therein, Wilmington Trust, National Association, as trustee and as notes collateral agent	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
2.6	First Supplemental Indenture, dated as of January 28, 2026, among Genmab A/S, Genmab Finance LLC, the guarantors named therein, Wilmington Trust, National Association, as trustee and as notes collateral agent	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
2.7	Description of Securities Registered under Section 12 of the Exchange Act	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
Agreement with J&J related to DARZALEX
4.1 †	License Agreement, dated as of August 30, 2012, by and between Janssen Biotech, Inc. and Genmab A/S	Incorporated by reference to Exhibit 10.1 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
4.2 †	Amendment Number 1 to the License Agreement, dated as of January 31, 2013, by and between Janssen Biotech, Inc. and Genmab A/S	Incorporated by reference to Exhibit 10.2 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
4.3 †	Amendment Number 2 to the License Agreement, dated as of October 10, 2013, by and between Janssen Biotech, Inc. and Genmab A/S	Incorporated by reference to Exhibit 10.3 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
Agreement with Novartis related to Kesimpta
4.6 †	Co-development and Collaboration Agreement, dated as of December 19, 2006, by and between Glaxo Group Limited and Genmab A/S	Incorporated by reference to Exhibit 10.5 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
4.7 †	Amendment Number 1 to the Co-development and Collaboration Agreement, dated as of June 30, 2008, by and between Glaxo Group Limited and Genmab A/S	Incorporated by reference to Exhibit 10.6 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
4.8 †	Amendment Number 2 to the Co-development and Collaboration Agreement, dated as of December 18, 2008, by and between Glaxo Group Limited and Genmab A/S	Incorporated by reference to Exhibit 10.7 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
4.9 †	Amendment Number 3 to the Co-development and Collaboration Agreement, dated as of July 1, 2010, by and between Glaxo Group Limited and Genmab A/S	Incorporated by reference to Exhibit 10.8 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019

118

Table of Contents

Exhibit No.	Description	Method of filing
4.10 †	Amendment Number 4 to the Co-development and Collaboration Agreement, dated as of December 20, 2010, by and between Glaxo Group Limited and Genmab A/S	Incorporated by reference to Exhibit 10.9 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
4.11 †	Novation Agreement, dated as of November 3, 2014, by and among Glaxo Group Limited, Novartis Pharma AG and Genmab A/S	Incorporated by reference to Exhibit 10.10 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
4.12 †	Amendment Number 5 to the Co-development and Collaboration Agreement, dated as of January 22, 2018, by and between Novartis Pharma AG and Genmab A/S	Incorporated by reference to Exhibit 10.11 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
Agreement with Medarex related to Medarex Technology
4.13 †	Amended and Restated Evaluation and Commercialization Agreement, dated as of July 12, 2012, by and among Bristol Myer Squibb Corporation, Medarex, Inc., GenPharm International, Inc. and Genmab A/S	Incorporated by reference to Exhibit 10.12 to the Registrant’s registration statement on Form F-1/A filed with the SEC on July 16, 2019
Agreement with AbbVie related to EPKINLY
4.14 †	Collaboration and License Agreement, dated as of June 10, 2020 by and between AbbVie Biotechnology Ltd. and Genmab A/S	Incorporated by reference to Exhibit 4.14 to the Registrant’s Annual Report on Form 20-F filed with the SEC on March 29, 2021
4.15 †	Amendment Number 1 to the Collaboration and License Agreement, dated as of November 8, 2022 by and between AbbVie Biotechnology Ltd. and Genmab A/S	Incorporated by reference to Exhibit 4.15 to the Registrant’s Annual Report on Form 20-F filed with the SEC on February 22, 2023
Credit Agreement
4.16	Credit agreement, dated as of December 12, 2025, among Genmab A/S, Genmab Finance LLC, the lenders and issuing banks from time to time party hereto and Morgan Stanley Senior Funding, Inc., as the administrative agent and collateral agent	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
8.1	List of Subsidiaries	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
11.1	Internal rules for the members of the Board of Directors and the Executive Management and other permanent insiders of Genmab A/S (CVR NO. 21032884) regarding the prevention of insider dealing, trading windows, unlawful disclosure of inside information, notification of transactions and guidelines for the company’s trade in its own securities	Incorporated by reference to Exhibit 11.1 to the Registrant's Annual Report on Form 20-F filed with the SEC on February 12, 2025
11.2	Internal Rules for the employees of Genmab A/S (CVR NO. 21032884) and its directly owned subsidiaries regarding the prevention of insider dealing, open trading windows and unlawful disclosure of inside information	Incorporated by reference to Exhibit 11.2 to the Registrant's Annual Report on Form 20-F filed with the SEC on February 12, 2025
12.1	Certification of the Principal Executive Officer	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
12.2	Certification of the Principal Financial Officer	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025

119

Table of Contents

Exhibit No.	Description	Method of filing
13.1	Certification of the Principal Executive Officer pursuant to 18 U.S.C. section 1350	Furnished together with this Annual Report on Form 20-F for the year ended December 31, 2025
13.2	Certification of the Principal Financial Officer pursuant to 18 U.S.C. section 1350	Furnished together with this Annual Report on Form 20-F for the year ended December 31, 2025
15.1	Consent of Independent Registered Public Accounting Firm	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
15.2	Consent of Independent Registered Public Accounting Firm	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
15.3	Genmab A/S statutory Annual Report 2025*	Filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
97	Genmab A/S Dodd-Frank Clawback Policy	Incorporated by reference to Exhibit 97 to the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC on February 14, 2024
EX-101.INS	Inline XBRL Instance Document	Incorporated by reference to Exhibit 101.INS to the Registrant’s report filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
EX-101.SCH	Inline XBRL Taxonomy Extension Schema Document	Incorporated by reference to Exhibit 101.SCH to the Registrant’s report filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
EX-101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	Incorporated by reference to Exhibit 101.CAL to the Registrant’s report filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
EX-101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	Incorporated by reference to Exhibit 101.DEF to the Registrant’s report filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
EX-101.LAB	Inline XBRL Taxonomy Extension Labels Linkbase Document	Incorporated by reference to Exhibit 101.LAB to the Registrant’s report filed together with this Annual Report on Form 20-F for the year ended December 31, 2025
EX-101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	Incorporated by reference to Exhibit 101.PRE to the Registrant’s report filed together with this Annual Report on Form 20-F for the year ended December 31, 2025

† Portions of this exhibit, marked by brackets, have been omitted pursuant to Instruction 4(a) to Exhibits to Form 20-F

because they are both (i) not material and (ii) include information of the type that we treat as private or confidential.

• Certain of the information included within Exhibit 15.3, which is provided pursuant to Rule 12b-23(a) of the Securities

Exchange Act of 1934, as amended, is incorporated by reference in this Form 20-F, as specified elsewhere in this Form

20-F. With the exception of the items and pages so specified, the Annual Report 2025 is not deemed to be filed as part

of this Annual Report on Form 20-F.

120

Table of Contents

SIGNATURES

The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused

and authorized the undersigned to sign this Annual Report on its behalf.

Genmab A/S
/s/ Jan G. van de Winkel
Name:	Jan G. van de Winkel
Title:	President and Chief Executive Officer

Dated: February 17, 2026

121

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of Genmab A/S

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying Consolidated Balance Sheets of Genmab A/S and its subsidiaries (the “Company”)

as of December 31, 2025 and 2024, the related Consolidated Statements of Comprehensive Income, Consolidated

Statements of Cash Flows and the Consolidated Statements of Changes in Equity, for each of the two years in the period

ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). We also have

audited the Company’s internal control over financial reporting as of December 31, 2025, based on criteria established in

Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway

Commission (COSO).

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position

of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two

years in the period ended December 31, 2025, in conformity with IFRS Accounting Standards as issued by the

International Accounting Standards Board (IASB). Also, in our opinion, the Company maintained, in all material respects,

effective internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control

— Integrated Framework (2013) issued by COSO.

As described in the Report of Genmab Management on Internal Control over Financial Reporting, management

excluded from its assessment the internal control over financial reporting at Merus N.V. (“Merus”), which was acquired on

December 12, 2025, and whose financial statements constitute 59.6% of total assets and less than 0.1% of revenues of the

consolidated financial statement amounts as of and for the year ended December 31, 2025. Accordingly, our audit did not

include the internal control over financial reporting at Merus.

Basis for Opinions

The Company’s management is responsible for these financial statements, for maintaining effective internal control

over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in

the accompanying Report of Genmab Management on Internal Control over Financial Reporting . Our responsibility is to

express an opinion on these financial statements and an opinion on the Company’s internal control over financial reporting

based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board

(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.

federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the

PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and

perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement,

whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material

respects.

Our audits of the financial statements included performing procedures to assess the risks of material misstatement of

the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such

procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

Our audits also included evaluating the accounting principles used and significant estimates made by management, as well

as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting

included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness

exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our

audits also included performing such other procedures as we considered necessary in the circumstances. We believe that

our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

122

Table of Contents

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding

the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with

generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and

procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the

transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded

as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and

that receipts and expenditures of the company are being made only in accordance with authorizations of management and

directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized

acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become

inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may

deteriorate.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current-period audit of the financial

statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts

or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or

complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial

statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate

opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Valuation of Acquired IPR&D Asset in the Merus N.V. Acquisition — Refer to Notes 3.1 and 5.5 to the financial

statements

Critical Audit Matter Description

The Company acquired Merus N.V. (“Merus”) for USD 8.017 billion on December 12, 2025. The Company accounted

for the acquisition as an asset acquisition based on an asset concentration test in accordance with IFRS 3 Business

Combinations , as substantially all of the fair value of the acquired assets is concentrated in a single identifiable asset.

Intangible assets acquired primarily included an in-process research and development intangible asset (“Acquired

IPR&D asset”). The Company allocated the cost price of the Acquired IPR&D asset using an income approach to estimate

the fair value at the acquisition date. The fair value determination of the Acquired IPR&D asset required the Company to

apply significant estimates and assumptions related to the forecasted future cash flows, such as probabilities of technical

and regulatory success, and the determination of the discount rates.

We identified the valuation of the Acquired IPR&D asset for the Merus acquisition as a critical audit matter because of

the high level of complexity and management judgement involved in determining the above outlined significant estimates

and assumptions used by the Company to determine the fair value of the asset. This required a high degree of auditor

judgement and an increased extent of effort when performing audit procedures to evaluate the reasonableness of

management’s estimates and assumptions.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the Company’s valuation of the Acquired IPR&D asset in the Merus acquisition

included the following, among others:

• We performed corroborative inquiries of key individuals from senior leadership, including research &

development, and personnel involved in forecasting the future cash flows in determining the appropriateness of

the probabilities of technical and regulatory success.

• We tested the effectiveness of controls relating to management's review of the significant estimates and

assumptions related to the forecasted future cash flows, including the determination of the probabilities of

technical and regulatory success and discount rates applied.

123

Table of Contents

• We evaluated the probabilities of technical and regulatory success against external medical studies and industry

benchmarks to determine if these were corroborative or contradictory to the probabilities of technical and

regulatory success applied by management.

• With the assistance of our valuation specialists, we evaluated the appropriateness of the valuation method and we

tested the source information and inputs applied in the determination of the discount rates, including comparison

to publicly available information of comparable companies, and tested the mathematical accuracy of the

calculation.

Revenue recognition of royalty revenue — Refer to Note 2.1 to the financial statements

Critical Audit Matter Description

The Company recognized royalty revenue, where revenue is recognized based on net sales by collaboration partners.

The Company uses net sales provided by its collaboration partners as an input to its calculation of the amount of royalty

revenue to recognize in each period. The preliminary net sales data provided by the collaboration partner may change once

final net sales data is available.

We identified the revenue recognition of royalty contracts for selected products as a critical audit matter because of the

significant estimation uncertainty related to the net sales data provided by collaboration partners. Specifically, the

collaboration partner’s estimate of net sales could change based on the final net sales impacting the royalty revenue

recognized in each period. This required a high degree of auditor judgement and an increased extent of effort when

performing audit procedures to evaluate the reliability of management’s estimates of the net sales. Further, the contracts

with the collaboration partners are complex and contain multiple clauses that directly impact revenue recognition, which

require an increased extent of audit effort to ensure accurate and complete revenue recognition.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the royalty revenue recognized based on the significant assumption of estimated net

sales provided by the collaboration partners and the complex and multiple clauses in the contracts included the following,

among others:

• We tested the effectiveness of controls relating to management’s review of the estimated net sales used in the

determination of royalty revenue recognition.

• We tested the overall reliability of the estimated net sales reported by the collaboration partners by assessing the

historical accuracy of the estimates.

• We tested the recognition of royalty revenue by reconciling to the contract terms, cash receipts and royalty reports

from collaboration partners or reported net sales.

• We obtained external confirmations from collaboration partners on the estimated and actual net sales amounts

reported.

/s/ Deloitte Statsautoriseret Revisionspartnerselskab

Copenhagen, Denmark

February 17, 2026

We have served as the Company's auditor since 2024.

124

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of Genmab A/S

Opinion on the Financial Statements

We have audited the consolidated statements of comprehensive income, statements of changes in equity and

statements of cash flows of Genmab A/S and its subsidiaries (the “Company”) for the year ended December 31, 2023,

including the related notes, as listed in the index appearing under Item 19 (collectively referred to as the “consolidated

financial statements”).

In our opinion, the consolidated financial statements present fairly, in all material respects, the results of operations

and cash flows of the Company for the year ended December 31, 2023 in conformity with IFRS Accounting Standards as

issued by the International Accounting Standards Board and IFRS Accounting Standards as adopted by the European

Union.

Change in Accounting Principle

As discussed in Note 1.1 to the consolidated financial statements, the Company changed the currency in which it

presents its financial statements in 2025 from Danish Kroner to U.S. Dollar.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to

express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting

firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be

independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and

regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of these consolidated financial statements in accordance with the standards of the PCAOB.

Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated

financial statements are free of material misstatement, whether due to error or fraud.

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial

statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included

examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our

audit also included evaluating the accounting principles used and significant estimates made by management, as well as

evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable

basis for our opinion.

/s/ PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab

Hellerup, Denmark

February 17, 2024, except for the revisions in Notes 1.4 and 4.5 (not presented herein) to the consolidated financial

statements appearing under Item 19 of the Company's 2024 annual report on Form 20-F, as to which the date is February

12, 2025, and the changes in presentation currency and reclassifications in Notes 1.1, 1.4, 4.2 and 4.5, as to which the date

is November 6, 2025.

We served as the Company's auditor from 2001 to 2024.